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Abstract
Abstract:
GLYCINE NITROSATION AND SIGNATURE MUTATIONS IN THE p53 
TUMOUR SUPPRESSOR GENE -  A MOLECULAR LINK BETWEEN DIET AND 
CANCERS OF THE GASTO-INTESTINAL TRACT
Genotoxic agents derived from diet may contribute to the total human burden of 
potentially carcinogenic DNA damage. For example, glycine is a simple primary 
amino acid and a commonly found dietary constituent in the red meat. The nitrosation 
of glycine would probably constitute a major source of alkylating agents, as glycine is 
one of the most abundant amino acids found in nature. It has been shown that O6- 
carboxymethyl-2'-deoxyguanosine, the major 0 6-guanine adduct of nitrosated glycine 
derivatives, is not repaired by 0 6-alkylguanine-DNA-alkyltransferase so could 
accumulate in the DNA of GI tract tissues as a promutagenic lesion. In DNA 
extracted from human gastric biopsies and white blood cells, using a sensitive 
Immunoblot assay, 0 6-CMdG adduct has been detected suggesting that the formation 
of carboxymethylating agents, possibly via nitrosation of glycine, does occur in man. 
Therefore genotoxic properties of the 0 6-carboxymethyl-2'-deoxyguanosine adduct 
were studied.
0 6-carboxymethyl-2'-deoxyguanosine adduct has been successfully synthesised and 
incorporated site specifically in to oligonucleotides. Nucleoside composition analysis 
of site specifically modified sequences confirmed the presence of O6- 
carboxymethylguanine adduct. The melting curves studies showed qualitative 
differences between base pair stabilities formed by 0 6-CMdG adduct with respect to 
0 6-MedG adduct and normal 2 ’-dG. 0 6-CMdG:T base pair was stable than O6- 
CMdG:C base pair suggesting that 0 6-CMdG adduct like 0 6-MedG might 
preferentially base pair with thymidine. However, quantitative studies on the melting 
temperatures of 0 6-CMdG adduct were not fully conclusive. Clearly further effort and 
experimentation is needed to substantiate the qualitative data.
The mutagenic potential of 0 6-carboxymethyl-2'-guanosine adduct was studied using 
Amplification Refractory Mutation System (ARMS) PCR technique. A shuttle vector 
was constructed by incorporating a single 0 6-CMdG adduct site specifically in to p53 
cDNA of plasmid, pLS76. The mutagenesis studies have indicated that O6- 
carboxymethyl-2'-deoxyguanosine adduct can induce both GC—>AT transition 
mutations and GC—>TA transversion mutations. Further studies are needed to focus 
on mutation specificity and frequency of 0 6-CMdG adduct. The mutagenesis studies 
on potassium diazoacetate, model compound of nitrosoglycine derivatives did not 
induce any functional mutations in the p53gene of embryonic fibroblast cells of 
Human p53 knock in (HUPKI) mouse. However, this is mainly due to problems 
associated with KDA stability rather than the toxicity of the compound.
The results presented in this thesis highlight some key aspects of methodology as well 
as the significance of mutagenecity of 0 6-CMdG adduct with respect to diet-related 
cancer risk.
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Chapter 1: Introduction
1.0 Introduction
DNA damage is an important cause of genetic disease. If the damage involves the 
genes that control cell growth, it can lead to the development of cancer. Of course, 
DNA damage may also result in cell death, which can have serious consequences for 
the organism of which the cell is a part, for example, loss of irreplaceable neurons in 
the brain. Accumulation of damaged DNA has also been considered to contribute to 
some of the features of aging. It is not surprising that a complex set of cellular 
surveillance and repair mechanisms have evolved to reverse the potentially 
deleterious damage that would otherwise destroy the precious blueprint for life. An 
increasing number of human hereditary diseases that are characterised by severe 
developmental problems and/or a predisposition to cancer have been found to be 
linked to deficiencies in DNA repair. The chemical events that led to DNA damage 
include hydrolysis, oxidation and electrophilic attack. These reactions are triggered by 
exposure of cells to exogenous chemicals (e.g. environmental agents, food 
constituents etc), or they can result from endogenous metabolic processes. Both 
exogenous carcinogens and endogenous biological processes are known to cause 
mutations. Classes of DNA damage include deletion, insertion, and base substitution 
(either transition or transversion). Transitions are base pair substitution mutations in 
which a pyrimidine replaces a pyrimidine (C—>T) or purine replaces a purine (A—>G). 
Transversions are base pair substitution mutations in which a purine replaces 
pyrimidine (T—>G) or a pyrimidine replaces a purine. (A—»C). Important sources, 
which generate point mutations spontaneously in human cells, include deamination of 
cytosine and 5-methylcytosine, DNA polymerase infidelity, depurination and 
oxidative damage by free radicals generated from biological processes. Apart from 
these processes, any abnormalities in the epigenetic mechanisms may cause
1
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deregulation of gene expression. For example, if methylation of CpG islands is 
disturbed due to deamination or depurination this can lead to GC—»AT transitions. A 
well studied mechanism by which chemical carcinogens and their ultimate 
carcinogenic metabolites cause mutations is by forming covalent adducts with the 
nucleotides in the DNA, increasing the possibilities of the errors during DNA 
replication. Very wide levels of 0 6-methyl-2'-deoxyguanosine (06-MedG) adduct 
have been detected in human DNA in several studies of various populations 
(Krytopoulos, 1998; Povey, 2000). This might be due to consequence of exposure to 
alkylating agents that are present in smoke or the diet or to unknown exogenous 
agents, endogenous processes also contribute to DNA alkylation (Mamett and 
Burcham, 1993; Hecht, 1999). Despite the indications that a single DNA adduct such 
as 0 6-MedG can be responsible for a wide variety of biological effects, the precise 
molecular mechanisms of recombination and toxicity remained to be defined, whilst 
that of point mutations is well established. The miscoding properties of 0 6-MedG had 
already been established in in vitro and in vivo polymerase fidelity studies (Loechler 
et al., 1984; Saffhill et al., 1985). Such mutations occurring in tumour suppressor 
genes can provide a selective advantage for clonal expansion of proneoplastic and 
neoplastic cells. Several lines of evidence support the relationship between 
carcinogenesis and alkylation damage-mediated G—>A transition mutations. One is 
the spectrum of tumour-associated mutations that are found in genes that are crucial 
for malignant transformation. These include the H-ras oncogene in which transition 
mutations have been reported in codons 12, 13 and 61 (Barch et al., 1991; Rumsby et 
al., 1991) and the TP53 tumour suppressor gene, where transitions are found in a 
number of locations (Ohgaki et al., 1992). These mutations are dependent on 
exposure to alkylating agents (Sukumar et al., 1983).
2
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markers o f  
dosimetry
markers o f  
effects
exposure
disease
internal exposure
biologically active dose
early biological response
macromolecular binding 
e.g. DMA adducts
altered structure/function
activated oncogenes 
inactivated suppressor genes
Figure 1.1: Biomonitoring o f exposure to genotoxic compounds. The formation and prevalence ofDNA 
adducts is dependent on a multitude o f events such as absorption o f the genotoxic compound, its 
distribution to different tissues, and if  necessary> its metabolic activation to reactive intermediates. In 
general formation of DNA adducts reflect on individual susceptibility to genotoxic agents as well as 
differences in DNA repair (Courtesy of Gottschalk et al, 2006)
Exposure assessment can be carried out at different stages in the process that can lead 
to the development of tumour as illustrated in Figure 1.1. In the search for a common 
theme underlying the broad range of cancers, p53 has enjoyed a great deal of attention 
as the most frequently mutated gene in many types of tumours.
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1.1 Insights in to p53 Tumour Suppressor Gene
1.1.1 p53, A Tumour Suppressor Gene
P53 is a nuclear protein that regulates gene expression. It is located on chromosome 
17pl3.1. It lies at the heart of stress pathways leading to human carcinogenesis. Any 
alteration in p53 gene function provides a selective advantage of clonal expansion of 
proneoplastic and neoplastic cells. It plays a pivotal role in protection against the 
development of cancer. It is thought to prevent accumulation of genomic alterations 
by hindering cell proliferation under genomic stress. The two principal functions of 
p53 are induction of cell cycle arrest and the activation of apoptotic cell death. 
Keeping p53 function under control is vital for normal cells (Kubbutat and Vousden, 
1998).
1.1.2 Structure of p53
The p53 gene consists of 11 exons, of which exons from 2-11 code for a protein of 
393 amino acids. The p53 protein can be divided in to three domains; they are as 
follows [Figure 1.2]
1. N-terminal transactivation domain
2. Core domain- sequence specific DNA binding activity
3. C-terminal oligomerisation domain.
More recently, a proline rich domain has been identified between the transactivation 
domain and sequence specific DNA binding domain. This region is important for 
some p53 activities that require interaction with SH-3 domain containing proteins. 
The amino acid sequence of p53 contains five regions (1-V) that are highly conserved 
among different species (Kubbutat and Vousden, 1998).
4
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T ransactivation 
Domain 
MDM2 Binding
245
248 2 7 3
2 4 9  282
IV V
Proline-rich region 
(Binds SH3-domains)
393
NLS NLS NLS
Basic Region 
Tetramerisation
Figure 1.2: Primary structure o f  p53 tumour suppressor protein: The amino acid sequence o f p53
protein consists offive regions (l-V) that are highly conserved among different species, indicating that 
it has an important role in the function o f  regulation o f  the protein. Several residues (marked by 
numbers) within these conserved boxes are often mutated in humans. These mutations destroy the 
sequence-specific DNA binding activity o f p53, suggesting that this function is critical for suppression. 
P53 is a phospho protein and several in vivo phosphoiylation sites have been mapped with red boxes. 
NLS indicates the position o f  the nuclear localisation signals (Kubbutat and Vousden, 1998).
1.1.3 Functions of p53
Recent studies investigating the mechanisms underlying the biological activity of the 
p53 indicate that this protein is involved in regulation of gene expression, DNA 
synthesis and repair, genomic plasticity, and programmed cell death. It regulates gene 
expression by acting as a transcription factor and mediates many of its downstream 
effects by activation or repression of target genes. Numerous p53 target genes that 
have been implicated to act, as a down stream effectors are cyclin dependent kinase 
inhibitor, p21Wafl/Cipl which induces cell cycle arrest. It activates ribonucleotide
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reductase, named p53R2 is associated with DNA repair. It also activates expression of 
many genes that mediate mitochondrial and death receptor induced pathways [Figure 
1.3] (Almog and Rotter, 1997; Ryan et al., 2001).
Tubulrvdyn&in network
Transcriptional MDM2 
acttvafion .
Figure 1.3: A model depicting some o f the mechanisms that may regulate subcellular localisation, 
stability and transcriptional activity o f  p53 suppressor protein (Ryan et al., 2001).
It induces apoptotic proteins localised to mitochondria such as Bax, NOXA, PUMA 
and p53AIPl that trigger cytochrome c release and activation of Apaf-l/caspase-9 
apoptosome. The expression of many death receptors such as Fas and Killer DR5, and 
the death domain containing protein, PIDD is under the control of p53. It also induces 
expression of PERP, a potential mediator of apoptosis that belongs to PMP-22/gas3 
family of proteins that are localised to the endoplasmic reticulum (ER) and Golgi. 
Many other studies have implicated that it also has a role in embryogenesis, gene
6
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targeting, spermatogenesis and angiogenesis. Its transactivation activity is required for 
cell differentiation (Ryan et al., 2001).
1.1.4 Regulation of p53 Stability
The key regulator of p53 is the MDM2 protein, which can inhibit both p53 
transcriptional activity and targeting p53 for ubiquitination. MDM2 can function as 
E3 ligase, the final component of the enzyme cascade that results in the conjugation 
of ubiquitin to proteins, targeting them for degradation by proteosome. MDM2 
ubiquitinates both p53 and itself, contributing to the rapid turnover of both proteins. 
As MDM2 is a transcriptional target of p53, an auto regulatory feedback loop is 
generated in which increased p53 activity leads to increased expression of its own 
negative regulator. P53 function depends on nuclear localization, and both nuclear 
import, nuclear export of p53 is dependent on its interaction with the microtubule 
network, and dynein, a molecular motor indicating that p53 is actively transported 
towards the nucleus, where nuclear localisation signals within the carboxy terminus of 
p53 allow efficient nuclear import. p53 also contains efficient nuclear export signal 
within its carboxy terminus [Figure 1.3] (Ryan et al., 2001).
1.1.5 Post-translational modification of P53/MDM2 -  Regulating, Stabilisation 
and Activation of p53 protein
It is crucial to stabilise p53 for a cell experiencing genomic stress in order to maintain 
homeostasis. The importance of this process is underscored by a variety of process 
with which cell disrupts MDM2 in response to stress. These mechanisms include 
post-translational modifications of both p53 and MDM2, subcellular redistribution, 
inhibition of MDM2 activity and direct repression of MdM2 transcription. Post-
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translational modifications of p53 play an important role in both stabilisation and 
activation of the p53. Phosphorylation of Ser20 by checkpoint kinases, Chkl and 
Chk2 in response to ionising radiation is important in abrogating p53-Mdm2 
interaction (Chehab et al., 2000; Hirao et al., 2000), (Sheih et al., 2000). 
Phosphorylation of Thr81 by Jun amino-terminal kinase can lead to p53 stabilisation 
(Buschmann et al., 2001). Acetylation of p53 may also contribute to p53 stabilisation. 
The inhibition of cellular deacetylases leads to longer half-life of endogenous p53 (Ito 
et al, 2001). Mdm2 can inhibit p53 acetylation mediated either by CREB binding 
protein (CBP) or by highly related p300 protein (Kobet et al., 2000). P53 is
ubiquitinated and acetylated on similar sites at the carboxy terminus suggesting that 
these modifications compete for the same residues. This suggests a possible link 
between acetylation and stabilisation (Rodriguez et al., 2000). MDM2 can be 
modified post-translationally to prevent p53-Mdm2 interaction. It becomes 
hypophosphorylated in conserved region 11 after DNA damage as well as in response 
to ionising radiation resulting in p53 stabilisation (Blattner et al., 2002).
Ubiquitination represents an essential activity of MdM2 for 
regulating the amount of p53 protein availability. It acts as an E3 ligase for p53 by 
linking E2-congugated ubiquitin molecule to it via an isopeptide bond in the nucleus 
(Zhang and Yiong, 2001). This is shuttled in to cytoplasm either directly or indirectly 
by MDM2 and then recognised by the 26S proteosome for further degradation 
(Gottiffedi and Prives, 2001; Michael and Voren, 2002; Yousden and Woude, 
2000). Suppressor gene 101 (TSG101) and c-Abl both have a negative effect on p53 
ubiquitination (Li et al., 2001; Sionov et al., 2001). Apart from post-translational 
modifications such as phosphorylation, ubiquitination and acetylation, several 
proteins like INGlb, pRb, and MdmX inhibit p53-MdM2 interaction by directly
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binding to p53 or MdM2 (Hsieh et al., 2001; Kamijo et al., 1998; Leung et al., 2002; 
Sharp et al., 1999). Oncogenes such as Myc and El A are thought to activate p53 
through a pl9 alternative reading frame (pi9 ^ ^  (Seavey et al., 1999; Tolbert et al.,
2002). The predominant regulator of MdM2 is p i9 ^ ^  a protein derived from the 
INK4a/ARF locus. This is located in nucleoli, where it promotes p53 accumulation by 
binding to and sequestering MdM2 (Sherr, 1998).
P53 stabilisation may also occur through MdM2-independent 
mechanisms. Caplainl, (3-catenin and JNK have been shown to stabilise p53 in MdM2 
-null cell lines (Damalas et al., 1999; Fuchs et al., 1998; Kubbutat and Vousden, 
1997). Protein Sin3a was shown to bind to p53 on the promoters of genes targeted for 
repression in response to DNA damage. This interaction stabilises p53 independent 
of MdM2 extended promoter association (Zilfou et al., 2001). Reduced nicotinamide 
adenine dinucleotide (NADH) quinone oxidoreductase 1 (NQOl) stabilises p53 by an 
MdM2 and ubiquitin independent mechanism. NQOl is a unique oxidative stress 
specific pathway for p53 stabilisation (Asher et al., 2001; Asher et al., 2002).
Apart from p53 stabilisation, transcriptional activation of p53 
is essential for initiating an early response to genotoxic stress. P53 regulates 
transcription of many down stream targets. However, the initial activation of its 
function as a transcription factor is the key for its ability to drive particular 
downstream pathways. Many residues at both the amino and carboxy terminus of p53 
are phosphorylated in response to genotoxic stress. Phosphorylation of Ser46 is 
important in regulating UV induced apoptosis through the activation of gene p53AIPl. 
p53DINPl is also seems to be regulating Ser46 phosphorylation in response to 
genotoxic stress (Oda, 2000). Homeodomain-interacting protein kinase-2 (HIPK2) 
specifically phosphorylates Ser46 in response to UV radiation and distinctively drives
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an apoptotic response (D’Orazi et al., 2002; Hoffmann et al., 2002). Ser392 at 
carboxy terminus is phosphorylated in response to UV radiation by complex 
containing CK2, hSptl6  and SSRP1 (Keller et al., 2001).
A unique combination of phosphorylated residues could serve 
as a framework for further post-translational modifications. There is evidence to link 
the importance of post-translational modifications with p53 transcriptional activation 
in response to genotoxic stress. Pinl, a propyl isomerase, binds to p53 and stimulates 
its transcriptional activity. This is due to conformational changes induced by Pin 1 
(Zacchi et al., 2002; Zheng et al., 2002). Acetylation was shown to be an important 
modification of histones that correlated with increased transcriptional activity. 
CBP/p300, a protein with histone acetyl transferase activity is a co-activator of p53 
and regulates its transcriptional as well as biological function in vivo. The functional 
consequences of acetylation are diverse and include DNA binding, enhancement of 
stability, and changes in protein-protein interactions (Avantaggiati et al., 1997; Gu et 
al., 1997; Lill et al., 1997). P53 is particularly acetylated at multiple lysine residues 
(Lys370, Lys371, Lys 372, Lys381 and Lys382) of the carboxy-terminal regulatory 
domain by CBP/p300 and, to a lesser extent, Lys320 by p300/CBP associated factor 
(PCAF). These acetylation sites are particularly important for ubiquitination and 
subsequent degradation of p53 by Mdm2 (Appella and Anderson, 2001).
1.1.6 Alterations of p53 -  Carcinogen finger prints
P53 was found to be inactivated in almost 50% of human cancers (Hainut et al., 2000). 
The occurrence of missense mutations, deletions, or nonsense mutations of the gene 
prevents the protein from oligomerising and forming tetrameric complexes that can 
bind specific DNA sequences (Hussain and Harris, 1998). The frequency of p53
10
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somatic mutations in sporadic human cancers varies 2 0 % to 60% among types and 
can be over 80% in histological subtypes. These mutations were also found to be 
inherited in the families with a predisposition to multiple cancers such as in the Li- 
Fraumeni syndrome (Malkin, 1994). 87% of the p53 somatic mutations are missense 
mutations that lead to amino acid substitutions in proteins thus altering protein 
conformation. Most of the mutations (90%) identified to date have been observed in 
DNA binding domain and mainly effect amino acids of highly conserved regions 
(Hainut et al., 2000). The studies of the nature of p53 mutations and their distribution 
along the coding sequence have allowed the identification of specific mutation 
spectrum, revealing clues to the mechanisms of mutations. Some of these ‘mutagen 
fingerprints’ are well characterised and have been linked to exposure to various 
environmental mutagens and endogenous biological factors using epidemiological and 
experimental evidence. Well characterised and extensively documented examples are
(1) the association of GC—>TA transversions in lung cancer with tobacco smoke. (2) 
the link between dietary exposure to aflatoxin B and GC—>TA transversions at codon 
249 (Arg—>Ser) in hepatocellular carcinomas (HCC) and (3) the strong correlation 
between CC—>TT tandem dipyrimidine transition mutations in skin cancer and 
exposure to sunlight (Greenblatt et al., 1994; Hainaut and Holstein, 2000; Hollstein et 
al., 1998; Hussain and Harris, 1999).
Lung cancers have been strongly associated with tobacco 
smoking (Phillips, 1996). Residues most frequently mutated in the p53 gene of lung 
from smoking include codons 154, 156, 157, 158, 159, 237, 245, 248 and 273. 
Mutations consist predominantly of GC—>TA transversions (Hernandez -Boussard 
and Hainut, 1998; Pfeifer and Denissenko, 1998; Smith et al., 2000). Codon 157 was 
considered hotspot specific for lung cancer. However, many studies reported that 157
11
Chapter 1: Introduction
is equally important in lung and non-lung cancers (Rodin and Rodin, 2000). 
Mutations found in codon 248 and 273 are Quiet common in other human 
malignancies except for the fact that the mutations found at these codons are 
exclusively GC—>AT transitions than GC—>TA transversions observed in lung cancer. 
Polycyclic aromatic hydrocarbons such as benzo[a]pyrene are the mutagens found in 
cigarette smoke. It was reported that p53 hotspot mutation sites correlated with the 
preferential adduct formation sites after exposure of human bronchial epithelial cells 
to the tobacco smoke metabolite benzo[a]pyrene diol epoxide (Denissenko et al., 
1996).
The high prevalence of G—>T transversions affecting the third 
nucleotide of codon 249 in heptaocellular carcinoma (HCC) has been distinctively 
associated with aflatoxin B exposure (Hsu et al., 1991). P53 mutation spectra obtained 
from HCC subjects from different regions of the world have been reported to vary 
widely (Montesano et al., 1997). In areas of high aflatoxin B exposure such as Qidong 
(China) and Mozambique, the frequency of GC—>TA mutations in particular at codon 
249 clearly dominates the spectrum (~ 90%). In contrast, the HCC related p53 
mutation spectrum data from European countries and USA with little or no exposure 
to aflatoxin B have low prevalence of GC—»TA mutations (~10%). Similar 
associations have been established between UV irradiation and development of 
human skin cancer using experimental and epidemiological evidence. Mutations 
found in p53 gene of non-melanoma skin cancer (NMSC) subjects exhibited a high 
frequency of C—>T transitions, including tandem CC—>TT mutations according to 
IARC p53 database. The mutations correlate with mutagenic effects of UV light via 
photoproducts such as cyclobutane pyrimidine dimers, which if not repaired, result in 
CC—>TT tandem mutations (Brash et al., 1996; Greenblatt et al., 1994).
12
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Gastro-intestinal cancer is the second most common cancer in 
the world. Current models suggest that human gastric carcinogenesis is a multistep 
and multifactorial process accompanied by an accumulation of multiple genetic 
alterations. The most common genetic alteration in gastric cancer involves the p53 
gene. p53 alterations represent an early event in the intestinal type and a late event 
related to progression in the diffuse type gastric cancer. It is interesting to note that 
GC—>AT transitions are common mutations in p53 and are specifically induced by 
alkylating agents, A-nitroso compounds (NOC), which are involved in the 
pathogenesis of gastro-intestinal cancer (Fedriga et al., 2000). The endogenous 
formation of NOC’s derives from the interaction of amino compounds such as amino 
acids and nitrosating agents such as nitrates and nitrites. Many epidemiological case- 
control studies have supported this hypothesis, which showed that a major risk for 
stomach cancer is present in meat, nitrite and nitrate - rich diet. Alkylating NOC's are 
suspected of directly causing GC—»AT transitions of the p53 gene and of mediating 
non-CpG site mutations, where the NO mediated deamination of 5-methylcytosine to 
give thymine may be important. This DNA methylation by alkylating NOC’s causing 
GC—>AT transition is also consistent with the role of alkylation of O6- position of 2- 
deoxyguanosine (Fedriga et al., 2000). It was reported that NO induces mutations in 
human cells. The p53 mutations observed in colon cancer could be induced by NO- 
related damage of thymine while those reported in liver and lung cancer could be 
induced by NO via depurination (Nguyen et al., 1992).
Hence, it would be interesting to discuss (1) the mechanisms of 
reaction of alkylating agents with DNA and relevance of specific alkyl adducts in 
induction of mutations. (2) The type of NOC’s and the mechanisms by which NOC 
compounds are formed endogenously. (3) The different sources through which
13
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humans are exposed to NOC. (4) The etiological role of NOC in the incidence of 
gastric-intestinal cancers? In this, various epidemiological studies, which have shown 
NOC is responsible for gastric and other human cancers will be discussed.
14
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1.2 Reaction of Alkylating Agents with DNA
Alkylating agents react with the nucleophilic nitrogen and oxygen centres in DNA 
and at the oxygen atoms of the phosphate intemucleotide linkage. They are at least 12 
sites in DNA that can be targeted by alkylating agents [Table 1.1]. The specificity of 
reactions at different centres depend on factors such as the nucleophilicity of the DNA 
site, reactivity of the electrophilic species as well as steric effects i.e. accessibility.
Snl mechanism: e.g. meihyldiazonium ion
Slow
-
RY ----- -----► RT + Y“
Fast
R+ + X" ---------- ► RX
Sn2 mechanism: e.g. methylmethanesulphonate ion (MMS)
X i + 3 i i y X— R— Y" i>-+XA
Figure 1.4: Snl and Sn2 types of nucleophilic substitutions. RY- alkylating agent/ electrophile (R ~ 
alkyl group, Y - leaving group) R+- (electrophile) carbocation, X ' -  nucleophilic site in DNA, RX -  
alkylated product, MMS -  methyl methanesulphonate
Ring nitrogen’s such as N3 and N7 of adenine and guanine are the most nucleophilic 
sites in DNA whereas the exocyclic base oxygens are less nucleophilic centres 
(Beranek, 1990; Saffhill et al., 1985). Each alkylating agent produces a different 
spectrum of adducts and can react via either Snl or Sn2 mechanisms [Figure 1.4].
15
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Nucleophilic substitution involving the Sn2 pathway is a bimolecular reaction, which 
is highly dependent on steric accessibility. During this type of substitution a transition 
complex is formed which results from the attack of electrophile on the nucleophilic 
centre of DNA. An alkylated product is formed upon the release of leaving group 
(Ehrenberg and Osterman-Golkar, 1980). In contrast, Snl reactions are unimolecular 
and follow in general first order kinetics. The rate of reaction is dependent on the 
formation of a reactive electrophilic intermediate called carbocation. The carbocation 
subsequently reacts with nucleophilic site in DNA thereby forming a covalently 
bonded DNA adduct (Beranek, (1990).
Type of DNA base Alkylation Site
Adenine Nl-N3-
N7-
Guanine N3-N7-
O6-
Cytosine N3-
o 2- 1
Thymine N3- 1 O2-
o 4- I
Intern ucleo tide 
Phosphate Chains Phosphotriesters
Table 1.1: Alkylation sites in DNA
Less reactive, weak electrophiles such as methylmethanesulphonate (MMS) usually 
react via Sn2 mechanisms resulting predominantly in alkylation of DNA sites with 
relatively high nucleophilicity. Hence, high amount of adducts are formed mainly at 
nitrogen centres with very little reaction at oxygen sites.
16
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Adduct
Percentage of Total Alkylation by
MNU ENU MNNG MMS DMS
Nl-alkyladenine 0.7-1.3 0.2-0.3 1 .0 1.9-3.8 1.0-3.0
N3-alkvladenine 8.0-9.0 2.8-5.6 1 2 .0 10.4-11.3 15.0-18.0
N7-alkyladenine 0 .8 -2 .0 0.3-0.6 - 1 .8 2 .0
N3-alkylguanine 0 .6 -1 .9 0 .6 -1 .6 - 0 .6 1.1-1.3
N7-alkylguanine 65.0-70.0 i 11.0-11.5 67.0 81.0-83.0 71.0-76.0
0 6-alkylguanine 5.9-8.2 7.8-9,5 7.0 0.3 0.2-0.3
N3-alkyIcytosine 0.06-0.6 0 .2 -0 .6 2 .0 <0 .1 <2 .2
0 2-alkylcytosine 0 .1 2.7-2.8 - n.d. n.d.
N3-aIkylthymine 0.1-0.3 0 .8 _ 0 .1 _
O -alkylthymine 0.1-0.3 7.4-7.8 - n.d. -
0 4-alkyIcytosine 0.1-0.7 1.0-2.5 - n.d. -
Phosphotriesters 12.0-17.0 55.0-57.0 - 0 .8 -
Table 1.2: In vitro alkylation patterns o f DNA expressed as a percentage o f  total alkylation [Beranek 
(1990)]. MNU- N-methyl-N-nitrosourea, ENU- N-ethyi-N-nitrosourea, MNNG- N'-methyl-N'-nitro.N- 
nitrosoguanidine, MMS -  methyl methanesulphonate, DMS -  dimethylsulphate, n.d. not detected or 
below limits o f  detection, dash indicates data not reported
In contrast, highly reactive electrophiles such as methyldiazonium ion tend to react 
via Snl mechanism. Irrespective of the nucleophilicity of DNA sites, highly reactive 
electrophiles generate a broad spectrum of adducts with alkylation occurring at 
nitrogen and oxygen sites [Table 1.2]. Alkylating agents such as N-methyl-N- 
nitrosourea (NMU), N-ethyl-N'-nitrosourea (ENU) and N-methyl-N'-nitro-N- 
nitrosoguanidine (MNNG) follow Snl mechanism whereas MMS and DMS 
(dimethymethanesulphonate) follow the Sn2 reaction pathway [Beranek (1990)]. 
However, there is some evidence that the apparent Snl mechanisms followed by 
alkyldiazonium ion have some Sn2 character in them. This is due to the highly
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reactive nature of the alkyldiazonium ion, which has an extremely stable leaving 
group -  nitrogen.
These reactions can also be explained based on Swain-Scott 
relationship describing the reactivity of the alkylating agent with nucleophiles (Swain 
and Scott, 1953). Reagents with a low Swain-Scott constant tend to react extensively 
with less nucleophilic centres (e.g. O6- position of guanine). In contrast, alkylating 
agents such as MMS with a higher constant tend to react with the more nucleophilic 
centres (e.g. N7 of guanine) (Vogel and Nivard, 1994). In fact, Snl and Sn2 
mechanisms represent extremes for DNA alkylating agents. There is evidence that the 
methyldiazonium ion CHsN2+ reacts with via the Sn2 (and not Snl) pathway. This ion 
is, however, so reactive that it shows little discrimination between the nitrogen and 
oxygen centres in DNA (Loechler, 1994). The degree, to which DNA is alkylated and 
the relative quantity of the various adducts formed depend upon the type of alkylating 
agent and the nature of alkyl groups. The potential to react with oxygen atoms 
enhances the relative mutagenicity and carcinogenicity of various alkylating agents 
(Saffhill, 1984), thus explaining the increased mutagenicity reported for N-nitroso 
compounds compared to alkylmethylsulphonates and N-nitroso-N-ethylurea 
compared to its methyl analogue.
1.2.1 Relevance of Certain Alkyl DNA adducts to Mutation Induction
The DNA adducts formed at different sites of DNA are not equally mutagenic. It is 
necessary to distinguish between sites that are generally more susceptible to 
alkylation and those that that are biologically more significant. In general, DNA 
adducts at sites involving hydrogen bonding (such as exocyclic oxygen atoms) are 
more likely to induce mutations and to result in misincorporation during DNA
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replication than those centres, which are not involved, such as N3 and N7 of guanine 
and adenine. N7-alkylguanine is the predominant adduct formed by alkylating agents, 
but the mutagenic, carcinogenic and cytotoxic potential of this adduct is considered to 
be of minor importance (Pieper, 1998). Interestingly N3 and N7-alkylpurines readily 
depurinate due to the labile nature of the glycosidic bond there by resulting in the 
formation of biologically significant apurinic sites (Pieper, 1998; Saffhill et al., 1985). 
Depurination of N3-methyladenine, N3- and N7- methylguanine is further facilitated 
by DNA glycosylases (Loeb, 1986). Apurinic sites lead to the preferential 
misincorporation of adenine residues opposite to these lesions during DNA replication 
resulting in GC—>TA and AT—»TA transversion mutations in the case of N7- 
methylguanine and N3-methyladenine respectively (Loeb, 1986).
DNA adducts formed at oxygen sites such as 0 6- of guanine
2 4 •  2and O - and O - of thymine and O - of cytosine are more likely to be promutagenic 
than those formed at nitrogen centres (Saffhill et al., 1985; Singer, 1986; Singer and 
Essigman, 1991). 0 4-methylthymine and 0 6-methylguanine are the major 
promutagenic lesions formed by alkylating agents. Many in vitro and in vivo studies 
on 0 4-methylthymine demonstrated that this adduct mispairs with guanine during 
replication [Figure 1.5]. This stable mispair induces AT—>GC transition mutations 
(Preston et al., 1986). This mutation is consistent with the mutagenic and carcinogenic 
potential of alkylating agents that form 0 4-methylthymine adducts. Although 0 A- 
methylthymine adduct is formed to a lesser extent than O6-methylguanine, the 
contribution of this adduct to the mutagenesis of alkylating agents is still of interest 
(Singer, 1986).
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Thymine: 0 6-methylguanine Thymine:Of'-methylguaninc
CH,
Thymine:Adenine 0 4-metfaylthymine:Giiaiiine
Figure 1.5: (f-methylguanine and Cf -methylthymine form stable mispairs with thymine and guanine 
respectively.
The mutagenic potential of 0 6-alkylguanine adducts was first suggested by Loveless 
in 1969 (Loveless, 1969). Many studies demonstrated the relationship between 
persistence of 0 6-alkylguanine adducts and alkylation induced mutagenesis (Frei et 
al., 1978; Goth and Rajewsky, 1974; Loveless, 1969; Richardson and Richardson, 
1990; Samson and Caims, 1977; Swann and Magee, 1968). The mispairing of O6- 
methylguanine with thymine during DNA replication results exclusively in GC—>AT 
transition mutations [Figure 1.5] (Loechler et al., 1984). Because of the specific 
mutagenic properties of NMU (G—>A transitions) it has been possible to examine 
whether oncogenes can be the target of chemical carcinogens. It was demonstrated 
that ras oncogenes present in NMU induced mammary carcinomas in rats are 
activated by GC—>AT transitions. This observation strongly supports the concept that
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these mutations are caused by NMU directed methylation of the O6- position of the 2'- 
deoxyguanosine (Zarbl et al., 1985). This type of mutation is also common in human 
colorectal cancer cases expressing ras mutations (Bos, 1989).
1.2.2 Sequence specificity and DNA Repair of O-Alkylated Bases
Apart from nature of the alkylating agents, DNA adduct formation is also influenced 
by the sequence context of the DNA, as the reaction of electrophiles with nucleophilic 
sites in DNA can be affected by bases neighbouring the target base (Richardson and 
Richardson, 1990). A strong preference for GC—»AT transition mutations at sites 
preceded 5’ by a purine base (5'-PuG-3') by Snl agents that act via an alkyldiazonium 
ion was observed in E.coli. However, this preference was not observed for Sn2 
alkylating agents such as alkyl sulphates and alkyl alkanesulphonates (Glickman et 
al., 1987). The GC—>AT transition induction is nine and five times at G preceded 5' 
by guanine or adenine respectively than those preceded by pyrimidine base (5'-PyG - 
3') (Bums et al., 1987). This sequence preference was explained by an influence of 
flanking base pairs on the molecular electrostatic potential of the Opposition in 
guanine. This preference for 5'-PuG-3' over 5'-PyG-3' was supported by the observed 
alterations in the H-ras oncogene following NMU treatment (Zarbl, 1985). These 
observations were also extended to AT—>GC transitions. Mutations induced by ENU 
via 0 4-alkylthymine occur primarily at 5'-PuT-3' sites. This suggests that the 
distribution of mutations by this adduct is influenced by the same base context that 
influences 0 6-alkylguanine directed mutations (Bums et al., 1988; Dolan et al., 1988). 
Many DNA repair studies demonstrated that 0 6-alkylguanine and 0 4-alkylthymine 
adducts flanked by a GC base pair are less efficiently removed by excision repair
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mechanisms than those flanked by AT base-pair (Bums et al., 1988; Horsfall et al.,
1990).
DNA repair capability varies with the type of species, cell and 
organ, explaining in part the sensitivity of certain cells and organs to tumourigenesis. 
There are three main repair mechanisms existing for adducts generated by alkylating 
agents: (1) direct reversal of the modification by removal of only the altered group (2 ) 
Oxidative delakylation (3) base/nucleotide excision repair (Singer and Hang., 1997). 
The DNA adducts formed at the O6- position of the guanine are predominantly 
repaired by an alkyltransferase protein, <96-alkylguanine-DNA-alkyltransferase 
(ATase). This repair enzyme catalyses the transfer of alkyl group to the sulfhydryl 
group present on the cysteine residue within protein it self. The DNA sequence is 
therefore repaired in a single step. The cysteine acceptor site of the repair enzyme is 
not regenerated in this process (Kyrtopoulos, 1998; Lindahl, 1982; Pegg, 2000). 
Hence, the limiting factor for this repair process is the amount of repair enzyme, O6- 
alkylguanine-DNA-alkyltransferase present. The amount of this repair enzyme 
present is tissue and organ specific. Therefore, the tissues with less amount of this 
enzyme activity are more likely to form tumours (Karran and Lindahl, 1985; Pegg, 
1984). The alkylated form of this enzyme is unstable in mammalian cells and
degrades rapidly (Pegg and Byers, 1992). Currently there is no evidence of repair
•  * 2enzymes from eukaryotic sources that are able to remove O-alkylpyrimidines i.e., O -
and 0 4-alkylthymine and 0 2-alkylcytosine efficiently (Singer, 1986). However, the 
E.coli AGT protein has been reported to repair 0 4-alkylthymine very efficiently using 
the same acceptor site as for the repair of 0 6-methylguanine, whereas the human 
ATase enzyme appears to be very poor in its function (Pegg, 2000).
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Organisms have evolved a variety of mechanisms to repair 
alkylation damage. Recently, it was discovered that a family of proteins called the alk 
proteins could directly repair some of the alkylation DNA base damage. E.coli upon 
receiving a methyl group from the damaged DNA turns on transcriptional activator 
Ada protein, which in turn activates its own expression and that of alkA, alkB and 
aidB genes. The upregulated Ada is a bifunctional protein, which uses N-terminal 
Cys38 residue to remove methyl group from Sp-methyl-phosphotriester and C- 
terminal Cys321 residue to remove a methyl adduct from both 0 6-methylguanine and 
0 4-methylthymine (Mishina and He, 2006). alkA is a glycosylase that cleaves 
methylated bases from DNA and performs first step of well-known base excision 
repair of base lesions. 3-methyladenine is an abundant alkylated lesion generated by 
both Snl and Sn2 alkylating agents is preferentially repaired by alkA protein. It is a 
strongly cytotoxic base because its methyl group protrudes in to the minor groove of 
DNA double helix, where it can block DNA replication and transcription. alkA 
protein has broad specificity. It also releases minor products such as O2- 
methylcytosine, O -methylthymine generated by Snl agents as well as 8 - 
methylguanine lesion generated by methyl radicals. alkA also liberates altered 
adenines such as ethenoadenine generated as a consequence of DNA exposure to lipid 
peroxidation products, hypoxanthine and uracil generated by active oxygen 
(Sedgwick and Lindhal, 2002). alkB protein utilizes a mononuclear non-heme iron
(II) and a-ketoglutarate as cofactor and cosubstrate. These proteins activate dioxygen 
and oxidise methyl group. The resulting oxidised product decomposes spontaneously 
in aqueous solution to give formaldehyde and the repaired base. E.coli alkB performs
• • • • 1 3an unprecedented oxidative dealkylation repair of N -methyl-adenine and N -methyl­
cytosine. It is now known that alkB gene is conserved from bacteria to human. The
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first human homologue now called ABH1 is 52% similar and 23% identical to E.coli 
alkB. However, the purified gene product of ABH1 showed no activity like alkB. Two 
other homologues ABH2 and ABH3 were shown to function like alkB and could 
complement E.coli mutant phenotype. Both the products showed repair activities for
1 3  1N -methyl-adenine and N -methyl-cytosine. It has been shown that ABH2 prefers N - 
methyl-adenine and ABH3 prefers N -methyl-cytosine (Mishina et al., 2006; Mishina 
and He, 2006).
Even though, the simplest pathway is direct DNA repair, most 
types of DNA damage are recognised and fixed by complex repair mechanisms such 
as excision repair and recombination. Base excision repair targets are mispaired, 
deaminated, alkylated, oxidised and otherwise modified bases. Highly specific 
enzymes called DNA-N-glycosylase that hydrolyses the N-glycoside bond between 
the sugar-phosphate backbone and damaged residues leaving an abasic site implement 
through base excision repair. DNA glycosylases differ in substrate specificity and 
function. Most of them recognise a broad range of substrates, others are highly 
specific. Some glycosylases may possess AP lyase activity. In mammals after 
damaged DNA has been excised, two alternate repair pathways are employed. In the 
case of short patch repair, a 5-AP endonuclease and deoxyribophosphodiesterase 
introduced a single nucleotide gap to the damaged strand, which is then reconstituted 
with DNA polymerase p and DNA ligase III. In the case of long patch repair, DNA 
segments 2-13 bases long are replaced around the AP site. DNA is resynthesised with 
polymerases 5, 8 or p. The synthesis is associated with creating a flap of “old” DNA, 
which is further removed by DNAse. DNA ligase completes the process of reinstating 
the phosphodiester bond. Alkylated bases commonly repaired by DNA-N-
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glycosylases are 3-methyladenine, 7-methyladenine and 3-methylguanine (Vasilenko 
and Nevinsky, 2003).
Nucleotide excision repair system repairs damage in 
transcribed genes, therefore, it is often referred to as transcription-coupled repair 
(TCR). However, NER repairs damage regardless of its locations in the genome and 
current phase of cell cycle. Primary substrates of this type of repair are UV light- 
induced pyrimidine dimers, as well as chemical adducts and interstrand DNA cross­
links. In E. coli, the NER pathway involves three enzymes UvrA, UvrB and UvrC. 
Eukaryotes from yeast to human do not have UvrABC homologues but, nevertheless, 
NER mechanisms in pro and eukaryotes are strikingly similar. In human, mutations in 
NER pathway genes are associated with disorders. Among them is Xeroderma 
Pigmentosum (XP). Mutations in any of the seven genes (XPA-XPG) eventuate in 
severe skin sensitivity to UV exposure (Vasilenko and Nevinsky, 2003).
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1.3 What are NOC?
NOC stands for 7V-nitroso compounds, a class of carcinogens that have attracted much 
interest since N- nitrosodimethylamine (NDMA) was found to be a liver carcinogen in 
rats by Magee and Barnes in the mid 1950’s (Magee and Bames, 1967)]. They are 
many types of nitroso compounds existing, but from carcinogenic point of view 
nitrosamines, nitrosamides and nitrosoureas are important. TV-nitrosamides and N- 
nitrosoamines are stable components derived from parent nitrogen precursors by 
replacement of a proton by the nitroso group [Figure 1.6] (Shuker, 1988).
H NO
+ NO X
R1^  CH2-R VT  CH2-R
R’=H Primary amine Primary nitrosamine (unstable)
R'= alkyl Secondary amine dialkylnitrosamines (metabolism required)
R’= acyl amide nitrosamides (spontaneous decomposition)
Figure 1.6: Summary of the main N-nitrosation pathways giving rise to N-nitroso compounds (Shuker, 
2000).
Humans are exposed to preformed NOC as well as to 
endogenously formed NOC. The in vivo formation of NOC can occur by three 
different ways, they are as follows.
1. Acid-catalysed
2. Enzymatic reactions mediated by bacteria, virus and parasites
3. Inflammation
NO mediated
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? h 3 X
;0
di
O x ^
/ = N  ^
Spontaneous
s '
R-N+= N  +
enzymatic R R
NH2
N
Figure L7: 77ze main sites o f alkylation in DNA by N-nitroso compounds (Shuker, 2000).
Consequently, endogenous nitrosation may occur at various sites of the body such as 
the oral cavity, stomach, urinary bladder, lungs, and other sites of infection and 
inflammation. Indirect evidence for endogenous nitrosation comes from in vitro 
systems where background levels of DNA alkylation appear to be related to 
nitrosation of amino acids (Sedgwick, 1997). NOC form reactive DNA-alkylating 
agents upon spontaneous decomposition (diazoalkanes, nitrosoureas, nitrosoamides 
and related compounds) or after oxidation (dialkylnitrosamines). The intermediate, 
probably an alkyl-diazonium ion, reacts with all of the nucleophilic centres in DNA 
[Figure 1.7] (Singer and Gumberger, 1983). Most interesting are 0 6-alkylguanine and 
0 4-alkylthymine, since these are promutagenic modifications leading to mis- 
incorporation of opposing bases on DNA replication (Singer and Essigmann, 1991). 
There have been a number of reports associating elevated levels of this 0 6-methyl
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adduct with increased risk of cancer (The Eurogast study Group, 1994; Umbenhauer 
et al., 1985).
Umbenhauer (Umbenhauer et al., 1985) had used 
radioimmuno assay techniques to detect 0 6-MedG and 0 6-ethyl-2'-deoxyguanosine 
(0 6-EtdG) in human tissues by using monoclonal antibodies against the adducts. Their 
analysis comprised 37 human tissue specimens derived from patients of People 
Republic of China, who underwent surgery for cancer of the oesophagus. Twelve 
tissues samples obtained from hospitals in Europe were used as controls. Seventeen 
of the samples obtained from china showed a level of 0 6-MedG ranging from 15 -50 
fmol/mg. Ten of the samples showed higher levels up to 160 fmol/mg and the 
remaining samples were below the level of detection. The tissue samples from Europe 
showed levels below 45 fmol/mg 0 6-MedG adduct of which seven being below the 
limit of detection. 0 6-EtdG was not detected in any of the above samples. The activity 
of 0 6-alkylguanine-DNA-alkyltransferase in tissue samples from china ranged from 
190 -  326 fmol of 0 6-MedG removed from mg of protein.
1.3.1 Mechanisms of Endogenous Nitrosation
1.3.1.1 Acid Catalysed Nitrosation
Nitrosation of amines and amides to form carcinogenic N-nitroso compounds were 
studied in detail by Ridd in 1961 (Ridd, 1961). To affect nitrosation, nitrite must be 
acidified to form nitrous acid (HNO2). Since, this reaction requires acidification, it 
occurs in vivo mainly in the acidic stomach. This dimerizes with loss of water to form 
N2 0 3 , which reacts with amines to form NOC. Nitrous acid can also be protonated to 
form H2N0 2 +, which preferentially reacts with amides to form nitrosoamides (Mirvish, 
1995).
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Reactions:
Nitrosation of Secondary amines
NaNOz + BT 
2HN02 
N2O3 + HNR1R2 
Nitrosation of Amides
HNO2 + H* 
H2N 02++ RNHCOR'
■+■ HN02 +NaH
>  N 2 O 3  +  H 2 0
>  (NO)x NRiR2 + HN02
h 2n o 2+
-► RN(NO)COR’ + H20  + H*
It has also been shown that nitrosation also occurs at both 
neutral and basic pH in the presence of NO* and 0 2. Challis and Kyrtopolous (1978) 
demonstrated that N2O3 and N2O4 formed from NO* and 0 2 rapidly nitrosate amines, 
both at neutral and basic pH. The mechanism of nitrosation at neutral and basic 
conditions is nucleophilic attack on the nitrosyl nitrogen ofO  = N -  0 -  N = 0  
(N2O3) by the free amine (Challis and Kyrtopolous, 1978).
Reactions
Formation of Nitrosating agents
2NO" + 0 2 -----
2N02 <------- ► N2O4 -----
NO' + N 02‘ 4  ► N20 3
>  2NOz
N 02‘ +NO3 +2H+ 
-► 2N02' + 2H+
Nitrosation of a secondary amine
N2O3 + R2NH -------------- ► R2N----- n  = o  + h n o 2
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Nitrosation at neutral and basic conditions can also be catalysed by carbonyl 
compounds. The catalytic effect depends upon the structure of carbonyl compounds. 
Keefer and Roller (1973) demonstrated for the first time that the secondary amines 
were easily nitrosated by nitrite ion in alkaline formaldehyde solution (Keefer and 
Roller, 1973). However, nitrosation at neutral and basic pH is not significant with 
respect to endogenous nitrosation, since N2O3 was thought to be formed primarily in 
acidic stomach (Liu and Hotchkiss, 1995).
1.3.1.2 NO - Mediated Endogenous Nitrosation
Several human cancers have been associated with chronic bacterial, viral and parasitic 
infections. NO* levels are elevated in these infections. Long-term exposure to elevated 
NO* in cells could have potential genotoxic effects on hosts. They are at least three 
mechanisms by which intracellular elevated NO* could exert genotoxic effects after 
reacting with O2. These include
1. Formation of carcinogenic TV-nitroso compounds
2. Direct deamination of DNA bases
3. Oxidation of DNA after formation of peroxynitrite and hydroxy radicals (Liu and 
Hotchkiss, 1995).
NO is synthesised from L-Arg through the L-Arg-NO* 
pathway by NO* synthase (NOS) with NADPH (Marietta, 1988; Marietta, 1993; 
Stuehr et al., 1989) and oxygen as co-substrates (Kwone et al., 1990; Leone et al.,
1991). The enzyme has many features in common with P-450 enzymes. Three 
different forms of NOS are found existing, they are as follows
1. eNOS (present in the endothelium of blood vessels)
2. nNOS (present in neurons)
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3. iNOS (present in immune system cells and hepatocytes) (Liu and Hotchkiss, 
(1995).
*  2N02*
*- N 02' + N 0 3 + 2H+
-►2N02' + 2H+
B. Nitrosation of a secondary amine
N2O3 + R2NH  ► R2N N = O + h n o 2
C. Deamination of primary amine
n 2o 3 + r - n h 2  >. r ++ n 2 + n o 2 + h 2o
D. Hydroxy radical production
NO* + 0 2* ________ ^ ONOO'
ONOO + IT  ________ ► ONOOH
ONOOH ------------ ► HO- + N 02‘
O I
Both eNOS and nNOS are constitutive and Ca /Calmodulin dependent. Agonists
such as acetylcholine and bradykinin that elevate intracellular Ca2+ alter the
conformation of calmodulin, which binds to NOS inducing NO synthesis from L-Arg 
(Liu and Hotchkiss, 1995). iNOS is an inducible Ca2+/calmodulin independent 
flavoprotein in which tetrahydrobiopterin acts as a cofactor (Stuehr et al., 1991; Tayeh 
and Marietta, 1989).
A. Formation of Nitrosating agents
2NO* + 0 2 —
2N02* <------- ► N20 4 —
NO* + N 02* «----- ► N2Os
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Because NO* has an unpaired electron it is highly reactive in the gas phase with 
oxygen to form nitrosating agents (Liu and Hotchkiss, 1995). NO* reacts with 
molecular oxygen (O2) to produce NO2*, which exists in equilibrium with the 
nitrosating agents N2O3 and N2O4 (Marietta, 1988). This occurs at both gaseous and 
aqueous phase, but it is first order reaction in the former (Wink, 1993) and second 
order reaction in the latter (Stamler et al., 1992). The formation of nitrosating agents 
N2O3 and N2O4 are favoured in solution compared to gaseous phase and the reaction 
is likely to be slow at physiological concentrations (Furchgott and Vanhoutte, 1989). 
Both N2O3 and N2O4 are capable of reacting with water to yield NO2’ and NO3'. NO3’ 
is the urinary excretory end product of NO (Liu and Hotchkiss, 1995).
There is substantial evidence that NO* synthesis and 
endogenous nitrosation are elevated because of acute inflammation and chronic 
infection (Bartsch et al., 1989; Hotchkiss et al., 1992). In 1987, it was reported that 
bacterial urinary tract infections in humans cause increased urinary excretion of 
nitrosoamino acid and nitrosamines (Ohshima et al., 1987). Tricker reported that 
patients having bladder cancer due to infection with schistosoma haematobium 
infection and patients with urinary diversions excreted more NO2’ and NO3" and N- 
nitroso aminoacids (Tricker et al., 1989a; Tricker et al., 1989b). It was found that 
bacteria can catalyse nitrosation. This activity is linked to nitrate reductase in non- 
denitrifiers and to nitrite reductase in denitrifiers (Suziki and Mituoka, 1984).
Humans infected with liver flukes have an elevated risk of 
cholangiocarcinoma. Srianujata observed that subjects with cholangiocarcinoma have 
elevated urinary NO3' levels (Srianujata et al., 1987). A human study with controlled 
low NO3' diet showed that subjects with O.viverini liver fluke infections had 
increased amounts of salivary NO2' and urinary and plasma NO3' . Ohshima found
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that hamsters infected with the above liver fluke excreted the increased amounts of 
N 03’ and N-nitrosoamino acid in urine (Ohshima and Bartsch, 1994). Woodchucks 
chronically infected with WHV have shown increased synthesis and excretion of N 03‘ 
and 7V-nitrosodimethylamine (NMDA). Treatment of WHV infected animals with
E.coli LPS demonstrated 15 fold increase in N 03" excretion (Liu et al., 1991). The 
same results have been obtained from human studies in which subjects have chronic 
active hepatitis (Ohshima and Bartsch, 1994). Workers at the University of Pittsburgh 
have showed that hepatocytes formed NO* when treated with immunostimulants 
(Billiar et al., 1990a; Billiar et al., 1990b).
It has been shown that in cirrhosis patients there has been an 
increased background formation of A-nitroso amino acid (Bartsch et al., 1989)]. Liu et 
al., (1992) have demonstrated elevated NO* formation in vitro, in vitro and in vivo 
data suggest that elevation of NO* synthesis may be a general and primary response to 
infections and inflammation (Liu and Hotchkiss, 1995).
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1.4 Exposures to NOC
1.4.1 Tobacco products
Cigarette smoking causes 30% of all cancers in the USA and Western Europe. There 
are 55 carcinogens in cigarette smoke that have been evaluated by the International 
Agency for Research on Cancer. Tobacco specific nitrosamines such as N- 
nitrosonomicotine (NNN) and 4-(methylnitrosamino)-l-(3-pyridyl)-l-butanone 
(NNK) and polyaromatic hydrocarbons (PAH) contribute to the induction of cancer of 
the lung, oesophagus, pancreas, nasal and oral mucosa. The levels of NNK and PAHs 
in cigarette smoke are similar (Hoffmann and Hecht, 1990). However, NNK is the 
only compound that can induces lung tumours in all three rodent models, rats, mice 
and hamsters. The organospecificity of NNK for the lung is remarkable. It induces 
adenoma and adenocarcinoma, independent of the route of administration. It 
metabolises via a-hydroxylation to form intermediates that alkylate DNA bases with 
methyl and pyridyloxobutyl groups (Hecht, 1998). Hydroxylation of a-methylene 
carbon of NNK generates an unstable a-hydroxynitrosamine that spontaneously 
decomposes to methanediazohydroxide, which reacts with DNA to form methyl 
adducts such as 0 6-MedG and N7-MedG (Hecht, 1998). The similar pathway also 
generates diazonium ion is a pyridyloxobutylating agent. It reacts with DNA bases to 
form pyridyloxobutyl adducts (Hecht, 1998; Thomson et al., 2003; Wang et al., 2003). 
The quantitative studies on the pyridyloxobutyl adducts formed by the NNK reported 
that the most abundant adduct formed by NNK is 4-hydroxy-1-(3-pyridyl)-l-butanone 
(Sturla et al., 2005). Although, both a-hydroxylation pathways of NNK lead to the 
formation of DNA adducts and important to the tumorigenecity of NNK, a 
preponderance of experimental data in mice implicates a-methylene hydroxylation 
and subsequent formation of 0 6-methylguanine as crucial factors for NNK
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tumorigenecity (Jalas et al., 2003; Peterson et al, 2001). NNN induces oesophageal 
and nasal tumours in rats and is likely to play an important role in tobacco-related 
oesophageal cancer in smokers. (Hecht, 1998; Hoffman and Hecht, 1990). The 
association of snuff dipping with nasal cancer is due to NNN because the NNN and its 
NNN-N-oxide induce nasal squamous carcinoma in rats. NNN is metabolically 
activated by hydroxylation at 2' position causing the opening of ring. This result in 
formation of mutagenic pyridyloxobutyled-DNA adducts by NNN. O6 - 
pyridyloxobutyl-dG is one of the products of this pathway was found to be highly 
mutagenic in both bacterial and mammalian cells (Pauly et al., 2002; Wang et al., 
2003). Analysis of human lung DNA demonstrated that levels of pyridyloxobutylated 
DNA are higher in lung cancer patients than in controls (Schlobe et al., 2002). Oral 
cancer is associated with chewing tobacco in USA and chewing quids along with 
betel nuts and tobacco in India (Mirvish, 1995). Among the PAHs, benzo(a)pyrene 
(Bap) is the most extensively studied compound, and its ability to induce lung 
tumours upon local administration and inhalation is well documented (Thyssen et al., 
1981; Wolterbeek et al., 1981). When administered systematically, it causes lung 
tumours in mice, but not in rats (Culp et al., 1998). The major metabolic pathway of 
activation for BAP is conversion to its 7,8-diol-9,10-epoxides (BPDE), one of the four
• •  • •  9enantiomers is highly carcinogenic and reacts with DNA to form adducts with N  of 
deoxyguanosine (Hecht, 1996; Hecht, 1998). Carcinogenic PAHs such as 
Benzo(a)pyrene, 7, 12b-dimethylbenz(a)anthracene and dibenzo(a)pyrene have been 
shown to be metabolically activated by two major mechanisms, one electron oxidation 
to form radical cation intermediates and monooxygenation to form bay region diol 
epoxides. The adducts formed by these mechanisms can be either stable or 
depurinating (Todorovic et al., 2005). BaP is metabolically activated via a three-step
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process. First, cytochromes P450 catalyze the formation of (7R,&S)-epoxy-7,8- 
dihydrobenzo[<z]pyrene(BaP-7,8 -oxide). This is converted to (7R,&R)-dihydroxy-7,8- 
dihydrobenzo[a]pyrene (BaP-7,8 -diol), catalyzed by epoxide hydrolase. BaP-7,8 -diol 
then undergoes another oxidation step, catalyzed by cytochromes P450 and other 
enzymes, producing mainly (7R,&S)-dihydroxy-(9*S',/0R)-epoxy-7,8,9,lO- 
tetrahydrobenzo[a]pyrene (BPDE). Among the four possible 7,8-diol-9,10-epoxide 
isomers of BaP, BPDE is formed to the greatest extent in mammalian systems 
examined to date, and has high tumorigenic activity in murine models. BPDE reacts 
with DNA producing a major adduct at the N2 position of deoxyguanosine (BPDE- 
A2-dG). Convincing evidence clearly documents the presence of this adducts in target 
tissues of animals treated with BaP. The mutagenicity of BPDE-A2-dG and its effects 
on DNA conformation have also been conclusively demonstrated (Boysen and Hecht,
2003).
1.4.2 Nitrite Cured Meat
Consumption of nitrite preserved meat and fish has been associated with childhood 
leukaemia and brain cancer, two of the most common cancers in children. Many 
studies have linked this childhood leukaemia and brain cancer with the consumption 
of hotdogs by pregnant mothers. Fried bacon formerly contains up to lOOppb of 
nitrosamines chiefly N-nitrosopyrrolidine (NPYR) and N-nitrosodimethylamine 
(DMN). Similar studies have indicated during frying and drying process of bacon, 
dehydration of creatine results in the formation of creatinine, which easily undergoes 
nitrosation to form methylurea (Mirvish, 1995). Hot dog consumption by children was 
linked with childhood leukaemia, with odd ratios of 9.5 and 95% confidence interval 
of 1.6-58 for >12 hot dogs/mo (Peterson et al., 1994). The levels of NOC measured in
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the gastrointestinal tracts of Sprague-Dawley rats fed with semipurified diet, 180g 
beef-pork hot dogs mixed with 820g diet or 180g sauteed beef mixed with 820g diet 
showed a 16-fold increase from stomach to proximal small intestine and 1.7 fold 
increase from distal colon to faeces. In addition, Swiss mice fed with semipurified 
diet, 180g beef-pork hot dogs mixed with 820g diet or 180g sauteed beef mixed with 
820g diet have produced fecal NOC outputs of 3.5 -  7.0 (hotdogs) and 2.0 -2.9 (beef) 
times with respect to control groups. Overall, the results support the hypothesis that 
colonic NOC’s are a cause of colon cancer (Mirvish, 2002; Mirvish, 2003). The 
consumption of nitrite cured meat by pregnant women was linked with brain cancer in 
their children in nine control studies (Bunin, 1998). A meta-analysis was performed 
examining the possible association of maternal intake of cured meat during pregnancy 
and risk of paediatric brain tumours. Analyzing child brain tumour risk by type of 
cured meat ingested showed that hot dog consumption increased child brain tumour 
risk by 33%, with a similar increase shown by frequent ingestion of sausage by 44% 
(Huncharek and Kupelnick, 2004). Despite the apparent risk, meat remains a 
nutritionally important component of most western diets (Truswell, 2001). Processed 
meat was also associated with a higher risk for type 2 diabetes, with a relative risk of 
1.46 and a 95% confidence interval of 1.14-1.86 for consumption > 5times/wk 
compared with less than once per month (Van Dam et al., 2002).
1.4.3 Alcohols and Beverages
Until 1979, beer contained about 5ppb of DMN. This is due to the reactions between 
tertiary amines hordenine and gramine in malted barley with nitrogen oxide present in 
natural gas kilns in which malted barley was dried. After 1980 DMN content was 
lowered by reducing flame temperature, by adding elemental sulphur to the flames or
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by indirect heating of the malted barley (Mirvish, 1995). 1-Methylpyrene, a 
hepatocarcinogen, is metabolised via 1 -hydroxymethapyrene (HMP) to a reactive 
sulphuric acid ester. These esters form either DNA adducts or conjugated with 
glutathione to form Methylpyrenyl mercapturic acid. It was reported that bioactivation 
of HMP in rats treated with 4-Methylpyrazole (alcohol dehydrogenase inhibitor), 
disulfiram (aldehyde dehydrogenase inhibitor) or ethanol (a substrate of alcohol 
dehydrogenases) caused increase in the levels of hepatic DNA adducts by 28, 3.8 and 
15-fold, respectively (Ma et al., 2002). The effect of ethanol and acetaldehyde 
treatment on the removal of benzo(a)pyrene diol epoxide (BPDE)-DNA adducts in the 
immortalised human mammary epithelial cell line MCF-10F was examined. Cells 
treated with 15 and 25mM ethanol resulted in significantly higher half-life of BPDE- 
DNA adducts/Units DNA compared to controls. There is no particular trend observed 
for cells treated with 2.5 and 5.0pM acetaldehyde with respect to controls. In addition, 
cells treated with 25mM ethanol exhibited a 2-fold increase in 8 -oxo-deoxyguanosine 
adducts compared to controls (Singletary, 2004). Alcoholic beverage consumption is 
causally related to an increased risk of cancer of the upper gastro-intestinal tract. 
Acetalehyde causes sister chromatid exchanges and chromosomal aberrations in 
human cells. The best studied DNA adduct is N[2]-ethyl-2'-deoxyguanosine, which is 
increased in liver DNA obtained from ethanol treated rodents and white blood cells 
obtained from human alcohol abusers. However, carcinogenic relevance of this adduct 
is unclear. Recently it was reported that l,N[2]-propano-2'-deoxyguanosine can also 
be formed from acetaldehyde in genotoxic and mutagenic effects of crotanaldehyde. 
This adduct can exist in two forms: a ring closed form or a ring opened aldehyde 
form. Ring-closed from is mutagenic. The aldehyde form can participate in the 
formation of secondary lesions, including DNA-protein cross-links and DNA
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interstrand cross-links, which explain many of the genotoxic effects of the 
acetaldehyde (Brooks and Theravathu, 2005) (Brooks and Theruvathu, 2006).
1.4.4 Drugs
A considerable fraction of drugs are theoretically nitrosable due to the presence of 
secondary or tertiary amines or N-substituted amines, amides or other groups which 
by reacting with nitrite in the gastric environment. When these drugs are administered 
chronically, high gastric levels of these drugs can occur and easily undergo nitrosation 
to give carcinogenic NOC. The yield of NOC not only depends on chemical structure 
of the drug but also on the drug-nitrite molar ratio, pH, temperature and reaction time. 
In many cases, the drug-nitrite interaction product is, in a foreseeable way, an already 
known NOC; for example, the NOC formed by several drugs is A- 
nitrosodimethylamine and A-nitrosodiethylamine. For other drugs, the reaction of the 
secondary amino group with nitrite yields the expected A-nitroso derivative; e.g., A- 
nitrosomethamphetamine, A-nitrosoephedrine, A-nitrosopropanolol and other A- 
nitroso P-blockers. Sometimes the reaction products formation is much more 
complex. I  ARC classifies A-nitrosodimethylamine, A-nitrosodiethylamine, A-methyl- 
A-nitrosourea and A-ethyl-A-nitrosourea as probably carcinogenic to human. Many 
drugs like chlordiazepoxide, a tranquilliser, antihistamines like methapyrilene, 
chlorpheniramine and diphenhydramine, alcohol deterrent disufiram and the antibiotic 
oxytetracycline react with nitrite to give N-nitrosodiethylamine (DEN) and DMN. 
The tertiary amine analgesic, aminopyrine, is readily nitrosated to give DMN because 
of its unusual enamine structure. Piperazine is a cyclic secondary diamine, which 
undergoes nitrosation to form carcinogens, mono and dinitrosopiperazine (MNP and 
DNP) (Mirvish, 1995; Brambilla and Martelli, 2007). 3'-Azido-3'-deoxythymidine
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(AZT, Zidovudine) has been effectively used for HIV infection treatment. It inhibits 
virus reproduction through virus reverse transcriptase inhibition. However, the side 
effects of this anti-retroviral drug might be cumulative, particularly in its effects on 
the patients DNA. As a nucleoside analogue AZT might incorporate in to hosts DNA, 
and then form DNA adducts. This may result in potential long-term risks of 
mutagenesis in AIDS patients who received therapy (Huang et al., 2004).
1.4.5 Industrial Exposure
Workers in certain industries are exposed to carcinogenic nitrosoamines. Workers in 
rubber industry are exposed to nitrosoamines such as DMN, DEN and N- 
nitrosomorpholine (NMOR), which are formed during vulcanisation process. There is 
an association between working in the rubber industry and cancer of the bladder, 
stomach, lung and leukaemia. The relationship between exposure to high 
concentrations of nitrosamines and cancer mortality among a cohort of rubber 
workers was examined. It was reported that nitrosamine exposure was significantly 
associated with increased mortality from cancers of the oesophagus and of the oral 
acvity and pharynx. A non-significant trend of increasing mortality was found for 
cancer of the prostrate and brain. No association was found between exposure to 
notrosamines and stomach cancer (Straif et al., 2000). Occupational nitrosamine 
exposure from a rubber vehicle seal curing operation were compared with peripheral
n
blood concentrations of two nitrosamines related DNA adducts N -methylguanine and 
0 6-methylguanine. No significant association was found between nitrosamine
7 •exposure and N -methylguanine. However, a positive association between 
nitrosamine exposure and 0 6-methylguanine adducts was found, linking nitrosamine 
exposure one-step closer to human cancers (Reh et al., 2000). (1-
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Chloroethenyl)oxirane is a major mutagenic metabolite of chloroprene, an important 
large-scale petrochemical used in the manufacture of synthetic rubbers. It is reactive 
towards DNA forming wide variety of mutagenic DNA adducts such as N7-(3-chloro- 
2-hydroxy-3-buten-1 -yl)-2'-deoxyguanosine, N1 -(3-chloro-2-hydroxy-3 -buten-1 -yl)- 
2'-deoxyadenosine, N6-(3-chloro-2-hydroxy-3-buten-l-yl)-2'-deoxyadenosine N3-(3- 
chloro-2-hydroxy-3 -buten-1 -yl)-2'-deoxyuridine and N3 -(3 -chloro-2-hydroxy-3 -
buten-l-yl)-2'-deoxythymidine (Munter et al., 2002), (Munter et al., 2006). 1,3 -  
Butadiene is a high production volume chemical used in chemical industry. It is also 
ubiquitous environmental pollutant found in urban air, tobacco and car exhausts. It is 
metabolised to butadiene monoexpoxide and diepoxy butane and butadiene 
diolepoxide. These epoxides are genotoxic and alkylate DNA both in vitro and in vivo 
mainly at N7 position of guanine (Koivisto et al., 1999; Selzer and Elferra, 1999). 
Workers from leather tanneries are exposed to DMN, which is formed from DMSO 
used to remove hair (depilate) from the skins. Metal industries use metal working 
fluids contain N-nitrosodiethanolamine (NDELA) added as a rust retarder. NDELA 
penetrates the skin and lung so that people are exposed to it by direct contact and 
inhalation (Mirvish, 1995). Levels of 8-hydroxy-2'-deoxyguanosine in DNA of white 
blood cells of workers exposed to asbestos fibres were examined in Germany. For 
patients suffering from respiratory cancer, cancer of the gastrointestinal tract, 
mouth/pharynx/larynx and urogenital tract the mean DNA adduct levels is 
significantly higher (Marczynski et al., 2000). Chromium is corrosive, cytotoxic and 
carcinogenic for humans and can induce acute and chronic lung tissue toxicity. 
Chromium causes biochemical changes in the airways causing oxidative stress via 
hydrogen peroxide and Malondialdehyde (Caglieri et al., 2006)
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1.5 NOC -  A Risk Factor for Gastro-Intestinal Cancers -  The Role of 
Consumption of Protein Diet
Despite of a large store of accumulated knowledge about the modes of action of N- 
nitroso compounds (NOC), there was still a great uncertainty about the role of NOC 
in human cancer. For many years, it was thought that the main route of exposure to 
NOC was from external sources. Endogenous synthesis of NOC in animals was 
initially reported by Sander and Burkle in 1969 (Sander and Burkle, 1969), and in 
humans by Ohshima and Bartsch in 1981 (Ohshima and Bartsch, 1981). This opened 
up the possibility of completely different and possible major source of NOC. Since 
then evidence has accumulated suggesting that body fluids, particularly, gastric juice 
do contain NOC and that certain pathologies (e.g., chronic inflammation or bacterial 
overgrowths) increase the levels of NOC (Shuker, 2000).
An etiological model proposed by Correa in 1975 proposed a 
role for NOC in gastric cancer. It proposes that irritants and nutritional deficiencies 
contribute to the development of atrophic gastritis. This leads to the increase in gastric 
pH thus promoting bacterial growth. These bacteria promote the reduction of nitrate 
(from food and endogenous sources) to nitrite. In the absence of antioxidants (such as 
vitamin C and E, which inhibit nitrosation), this nitrite is available to combine with 
compounds from drugs and food to form NOC. Exposure of gastric mucosa to small 
doses of NOC over a prolonged period is postulated to be a key event in the 
carcinogenic process (Correa, 1992; Susan and Correa, 1989).
Experimental data from many epidemiological studies give 
supporting evidence for the above hypothesis. Bartsch et al used the N-nitrosoproline 
(NPRO) test to test Correa's model in subjects with pancreatic cancer. NPRO is an 
unusual nitrosamine in that it is resistant to metabolic activation and is excreted
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unchanged in the urine. Furthermore, its precursor L-proline, a natural amino acid, is 
capable of being efficiently nitrosated under mildly acidic conditions where as more 
basic dialkylamines are protonated and are less reactive. Later it was reported that 
NPRO levels were high in subjects who lived in high cancer risk areas of the world 
(Bartsch et al., 1988; Bartsch et al., 1988; Bartsch et al., 1992).
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Figure 1.8: The graph showing levels o f  total N-nitroso compounds (NOC) in fasting gastric juice at a 
wide range o f pH values (Xu and Reed, 1993).
Earlier studies have reported the presence of background levels of NPRO in human 
urine and in elegant series of animal experiments with stable isotope labelled NPRO 
and nitrite. Humans are exposed to nitrate from exogenous sources (food and water) 
and endogenous sources (nitrate is the end product of the in vivo enzymatic formation 
of oxides of nitrogen). Chronic diseases or infections such as hepatitis can produce 
elevated levels of nitrate. Both endogenously formed and environmentally derived 
nitrate are found in saliva and gastric fluid, where they can be reduced to nitrite.
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Human exposure to exogenous and endogenous nitrate results in the formation of N- 
nitroso compounds in both stomach and other sites (Hotchkiss et al., 1985). 
Hotchkiss and colleagues showed that urinary NPRO was derived from both 
exogenous and endogenous sources as well as the mixed intermediate routes 
(Perciballi et al., 1989).
Further support for the Correa elaboration of hypothesis and the 
role of NOC in gastric cancer has led to the quantifying of NOC levels in the dynamic 
system of gastric contents by several groups. A well conducted and extensive series of 
observations by Xu and Reed demonstrated that total NOC concentrations varied as a 
function of intragastric pH with maximal values being found at either end of the scale 
from pH~2 to pH~ 8  [Figure 1.8]. It has been shown that precursor nitrogenous 
compounds can be converted in to NOC under acidic conditions (via a nitrous 
mediated pathway) or at neutral or mildly alkaline conditions (via gaseous oxides of 
nitrogen of bacterial and from other sources). A significant relationship between NOC 
and intragstric pH was found in the high pH range 5.00 -  8.42 (r = 0.218, P < 0.01). 
However, in the low pH 1.13 -  4.99 there was no significant relationship between 
NOC and intragastric pH (r = -0.067, P > 0.05). Increased NOC concentrations were 
observed in samples at both low and high pH ranges. Mean NOC concentrations in 
gastric juice samples at pH 1.13 -  2.99 and 6.00 -  8.42 were significantly higher than 
those at pH 3.00 -  5.99 and those at pH 6.00 - 8.42 were also significantly higher than 
the NOC levels at pH 1.13 -2.99 (Xu and Reed, 1993).
H.pylori infection is very common, but only a small proportion 
of people infected with the bacterium develop gastric cancer. Such infection is 
therefore not sufficient, in itself, to cause gastric cancer. One possible explanation is 
that the infection induces predisposing pathological changes in the gastric mucosa,
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Figure 1.9 An integrated model of gastric carcinogensis. Two vertical atrows indicate the two causal 
pathways leading to diffuse and intestinal-type gastric cancers. The effects of diet and drinking water 
quality are shown by dotted arrows with (-) and dotted lines for protective effects and solid arrows and 
(+) for hazardous effects (Yamaguchi and Kakizoe, 2001).
such as atrophic gastritis and intestinal metaplasia, which in turn increase the risk of 
gastric cancer. In attempts to integrate the role of NOC, dietary factors and H.pylori 
infection in gastric carcinogenesis, the first issue to be addressed is why the relative 
risk for H.pylori infection is similar in gastric cancers of the diffuse and intestinal 
types. The epidemiological features of the two forms are quiet different; the intestinal 
type is believed to comprise the epidemic component of gastric cancer, whereas the 
risk of the diffuse type is stable across country and region. In addition, the risk of the
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intestinal type, but not diffuse type, is related to chronic atrophic gastritis and 
metaplasia. The reasons for these differences are unknown. An integrated model was 
proposed by Yamaguchi and Kakizoe (Yamaguchi and Kakizoe, 2001) offering some 
possible explanations for the above inconsistencies [Figure 1.9].
One shared characteristic feature of diffuse and intestinal types 
as regards the effect of H.pylori infection is the enhancement of inflammatory 
responses, including epithelial-cell proliferation, infiltration of neutrophil and 
macrophages, and oxidative DNA damage. One possible explanation is that the 
inflammatory response directly increases the risk of developing the diffuse type of 
cancer, and the same response increases the risk of chronic atrophic gastritis and 
intestinal metaplasia in patients who ultimately develop intestinal-type gastric cancer. 
The fact that the incidence of diffuse-type gastric cancer does not differ by region 
suggests that the genetic susceptibility has a role in this type, as shown by the 
previously mentioned polymorphisms in the interleukin lgene cluster (El-Omar, 
2000). In the intestinal type of gastric cancer, environmental factors other than
H.pylori infection seem to play a part in the carcinogenic process. These factors may 
facilitate the development of atrophic gastritis and intestinal metaplasia, or 
alternatively they may increase endogenous nitrosation as result of ingestion of larger 
amounts of nitrate, nitrite, or secondary amines. The equal sex distribution of the 
diffuse type seems to reflect the equal sex distribution of H-pylori infection, whereas, 
the male dominance of the intestinal type could reflect the sex differences in some of 
the other factors. Exposure of N-nitroso compounds, which causes genetic events 
leading to cancer, probably facilitates advancement of chronic atrophic gastritis and 
intestinal metaplasia of adulthood. By contrast, in the diffuse type, genetic events 
probably occur at an earlier stage in the life, along with H.pylori infection. This
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difference in timing of genetic events may explain the older age at onset of intestinal 
type. Two protective actions of fresh fruits and vegetables are likely: as antioxidants 
to protect the gastric epithelium from inflammatory responses caused by H.pylori, and 
as nitrite scavengers to prevent endogenous nitrosation leading to the carcinogenic N- 
nitroso compounds in the gastric lumen (Yamaguchi and Kakizoe, 2001).
High gastric cancer mortality in ftigian province, China has 
been associated with consumption of certain salted fermented fish products. The 
major mutagen in these products is related to the nitrosation of methionine was 
demonstrated by Weisburger and colleagues (Chen, et al., 1995). China, with one of 
the world’s highest rate of gastric cancers has yielded clues to the environmental 
determinants of this tumour. A pilot study involving assays of urine and gastric juice 
of 60 individuals in a screening program showed higher levels of N-nitrosoproline and 
of cis- and £ra«s-A-nitroso-2-methylthiazolidine-4-carboxylic acid among persons 
with gastric dysplasia than in normal controls or those with chronic atrophic gastritis 
(Chen et al., (1995). Sandhu et al., (Sandhu et al., 2001) reviewed 13 prospective 
cohort studies and stated that the risk of colorectal cancer was increased by 1 2  - 
17%/100g of red meat consumed per day and by 49%/25g of processed meat 
consumed per day. Most of the processed meat was probably preserved with nitrite.
TV-nitroso compounds undergo a-hydroxylation by CYP2E1 
enzyme to form DNA adducts. The gene coding for this is polymorphic and thus may 
constitute a susceptibility factor for colorectal cancer. In a study conducted in Hawaii, 
it was found that subjects with one type of CYP2E1 variant were found to be at 60% 
increased risk (95% confidence interval, 1.1-2.5) for rectal cancer. The above subjects 
who were predicted to have been exposed levels of nitrosamines, based on their high 
intake of red meat or processed meat were at a markedly greater increased risk (2 -fold
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for red meat and 3-fold for processed meat) for rectal cancer (Marchand et al., 2002). 
Red meat that has been cooked to the degree termed well done’ is a positive risk 
factor for colorectal cancer. Under high pyrolytic temperatures, heterocyclic amines 
and benzopyrene molecules can form inside and on surface of red meat. A major 
source of benzopyrene is red meat exposed to a naked flame, as occurs during the 
barbecuing process. In a study it was observed a 6% risk of large adenoma per 
lOng/day consumption of BP. Consistent with this finding an incremental increase of 
lOg of barbecued red meat per day was associated with 29% increased risk of large 
adenoma (Gunter et al., 2005).
Endogenous TV-nitrosation was specifically linked to ingestion 
of haem rather than inorganic iron or protein and may account for increased risk 
associated with red meat consumption in colorectal cancer. In this study, it was found 
that subjects fed with red meat have significantly greater levels of NOC with respect 
to those on low meat diet. They also observed that 8 -mg supplement of haem iron also 
increased fecal NOC compared wih low meat diet (Cross et al., 2003). In another 
study, the formation of TV-nitroso compounds in upper GI tract was assessed in 27 
ileostomists. These subjects were fed with diets containing no meat, or 240g red meat 
or 240g processed meat in a randomly cross over intervention design studies. The 
observations from the above studies indicated increased formation of TV-nitroso 
compounds with red meat and processed meat consumption with respect to no meat 
diet. These studies have also observed that A-nitroso compounds were formed only in 
the presence of nitrosated haemoglobin, at pH 6 .8  but not in the absence of nitrosated 
haemoglobin. These findings demonstrate that haem may facilitate the formation of 
NOC in the absence of colonic flora in the upper GI tract (Lunn et al., 2006).
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The finding that high intake of red meat but not of chicken or 
fish might be associated with increased colon cancer risk was first reported in 
prospective studies of willett et al. in 1990. The evidence of an inverse relationship 
between colon cancer risk and fish intake is less consistent than the evidence of a 
positive association with red meat. The European Prospective Investigation in to 
Cancer and Nutrition (EPIC) studies on large western european population that 
includes half a million subjects from 1 0  european countries examined whether the 
associations exists between intakes of red and processed meat, of poultry, and of fish 
and colorectal cancer risk. EPIC studies have used a proportional hazards model 
adjusted for age, sex, energy (fat and non-fat sources) height, weight, work-related 
physical activity, smoking status, dietary fibre and folate, and alcohol consumption. 
They reported in this population study, that the absolute risk of development of 
colorectal cancer within ten years for a study subject aged 50 years was 1.73% for the 
highest category of red meat intake and 1.28% for the lowest category of intake and 
was 1.81% for subjects in the lowest category of fish intake and 1.28% for subjects in 
highest category of fish intake (Norat et al., 2005). The above results are further 
confirmed by randomised cross over design studies on human subjects fed with red 
meat, high red meat, high fibre and vegetarian diets. The exfoliated colonocytes 
recovered from human stool obtained from subjects on red and processed meat diet 
and vegetarian diet were measured for apparent total NOC. The level of NOC specific 
0 6-alkylguanine adducts, 0 6"MedG and <96"CMdG were significantly higher for the 
subjects on high red meat diet. Luminal NOC arising from red meat diet form 
alkylating DNA adducts in colonic cells, if not repaired, this may explain the 
association between red and processed meat and colorectal cancer (Lewin et al., 
2006).
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1.6 Nitrosation of Glycine and Other Amino acids - A Potential Source of 
Alkylating agents
Despite a continuous decline in the overall incidence, gastric cancer still remains a 
common cancer in both sexes. Many epidemiological studies unravelled a plethora of 
possible etiological factors responsible for gastric cancer. Our concern is mostly on 
protein-rich diet, exposure to nitrate, and nitrite precursors in dietary constituents. 
Consumption of nitrite and dietary nitrogen containing compounds may result in the 
formation of nitrosamides and nitrosamines under the acidic conditions of the 
stomach. The latter compounds can form adducts with DNA and are carcinogenic 
leading to a potential risk for human gastrointestinal cancer.
Glycine, a simplest a-amino acid is among the most abundant 
amino acids in dietary proteins. Free glycine occurs in biological fluids at millimolar 
concentrations (Komorowska et al., 1981). It was reported in 1904 that nitrosation of 
glycine esters give rise to stable diazoacetic esters (Curtius, 1904). The formation of 
the salts of diazoacetic acid, were reported in 1908 (Muller, 1908). Apart from 
kinetics studies on decomposition, the potential toxicity and carcinogenicity of this 
simple compound have not been tested (Kreevoy and Konasewich, 1970). The 
resurgence of interest in chemistry and biology of diazo and N-nitrosopeptides was 
reviewed in 1989 (Challis, 1989). It was reported that diazo and N-nitrosopeptides are 
consistently mutagenic in many test systems and several are potent carcinogens in 
animal models (Anderson and Blowers, 1994).
Current models for analysis of total NOC do not permit 
identification of individual compounds. Hence there have been no studies to date 
directed at evaluating the possible contribution of these compounds to human
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Figure 1.10: Mechanism o f nitrosation o f glycine and subsequent formation of Cf-MedG and O’- 
CMdG. Nitrosation of glycine gives rise to alkylating agents which carboxymethylate and methylate 
DNA. Diazoacetic acid is fanned as a common intermediate
exposure. Further more DNA alkylation products of even simple nitrosated peptides 
are likely to be very complex. They are 20 different possible dipeptides for N-terminal 
glycine alone and the number of possible dipeptides of different amino acids increases 
arithmetically. Therefore, for the sheers reasons of practicality, in the first instance it 
was focussed on nitrosation of simple amino acids. Many studies reporting that 
nitrosoglycine derivatives react with nitric oxide to form diazonium ion, which reacts 
at nucleophilic Opposition of 2'-deoxyguanosine to give rise to pre-mutagenic 
adducts 0 6-MedG and 0 6-CMdG will be discussed in detail in next section [Figure
1.10] (Shuker, 2000).
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1.6.1 0 6-carboxymethylguanine -  A potential premutagenic lesion produced by 
nitrosoglycine derivatives
In several studies of DNA damage by nitrosated glycine derivatives the expected
n
formation of carboxymethyl adducts N  -carboxymethyl-2'-deoxyguanosine [7- 
CMdG], A^-carboxymethyl-2-deoxyguanosine [3-CMdG] and 0 5-carboxymethyl-2'- 
deoxyguanosine [0 6-CMdG] was observed (Harrison et al., 1997; Shuker et al., 1987; 
Zurlo et al., 1982). Simple nitrosated bile acid conjugate N-nitrosoglycocholic acid 
reacts with DNA to give rise to 0 6-CMdG and 0 6-MedG. The latter has already been 
established as a toxic, promutagenic lesion and is repaired by DNA repair enzyme, 
O6- alkylguanine-DNA-alkyltransferase (ATase). Calf thymus DNA treated with 14C- 
NOGC was hydrolysed by acid treatment and analysed by radio chromatographic 
HPLC. 7-CMdG, 3-CMdG and 0 6-CMdG adducts were detected. The 14C labelled 
NOGC treated DNA was incubated with Atase from both prokaryotic and eukaryotic 
sources along with H -NMU labelled DNA. It was found that Atase got inactivated 
proportionally with the increasing concentrations of 14C-NOGC, which was 
determined by its inability to transfer methyl groups from H -  MNU. This was 
determined by measuring radioactivity transferred to Atase by both scintillation 
counting and radio-chromatographic HPLC (Shuker and Margison, 1997).
When 14C-NOGC-treated calf thymus DNA hydrolysates were 
analysed by HPLC with fluorescence detection, a substantial peak of 0 6-MedG was 
also detected along with 0 6-CMdG. Interestingly O6- CMdG alone was found, but not 
0 6-MedG when calf thymus DNA incubated with excess Atase. This suggests that 
14C-NOGC treated calf-thymus DNA also formed <96-MedG adduct, which under the 
conditions of incubation with Atase got completely repaired, but not 0 6-CMdG. It 
was concluded from these observations that both methylation and carboxymethylation
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Reaction of Nitrosoglvcine derivatives with DNA to form Carboxvmethvl 
diazonium ion
Figure 1..11: Various types of diazoacetic acid and N-nitroglycine derivatives. Both diazoacetic acid 
and N-nitrosoglycine derivatives give rise to a common reactive, potent alkylating intetmediate, the 
carboxymethydiazonium ion. APNG [N-(N’-acetyl-L-propyl)-N-nitrosoglycine], N-nitrosoglycocholic 
acid is a carcinogen and mutagenic derivative of the naturally occurring bile acid conjugate of 
glycocholic acid (Harrison, et al, 1999).
diazoacetic acid derivatives N-nitrosoglycine derivatives
\  “ “  ‘
H OK* o
Potassium diazoacetate APNG
N-Nitrosoglycocholic acid
r
II
I I I
N
Carboxymethyldiazonium ion
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is a general property of nitrosoglycine derivatives suggesting <96-CMdG is a useful 
biomarker of this pathway (Shuker and Margison, 1997).
Calf-thymus DNA has been treated with various nitrosated 
glycine derivatives such as potassium diazoacetate (KDA), N-acetyl-L-prolyl-TV- 
nitrosoglycine (APNG), azaserine (AS) at varying concentrations and with a single 
concentration of mesyloxyacetic acid (MAA) to reconfirm the above results [Figure
1.11]. An assay for quantification of both 0 6-CMdG and 0 6-MedG adducts was 
developed, which involves affinity purification followed by HPLC/fluorescence 
analysis. The calf thymus DNA treated with nitroso-glycine derivatives was acid 
hydrolysed and both adducts are separated using immunoaffinity columns. The acid 
hydrolysates were directly analysed by HPLC. The results indicated that concomitant 
methylation and carboxymethylation is the general property of N-carboxymethyl-N- 
nitrosocompounds (APNG) as well as of diazoacetic acid derivatives. Different 
compounds yield different amounts of both adducts ruling out the possibility of single 
common intermediate such as carboxymethyl diazonium ion (Harrison et al., 1999).
The reported works described above have established that 
nitrosated glycine derivatives are potential DNA alkylating agents. Another 
interesting finding was that the major 0 6-guanine adduct of nitrosated glycine 
derivatives, O -CMdG is not repaired by O -alkylguanine alkyl transferase and is 
likely to accumulate in the DNA of human gastro-intestinal tract. The formation of the 
characteristic 0 6-carboxymethyl adducts by nitrosated glycine derivatives offers an 
approach to evaluate their overall contribution to the overall burden of diet related 
NOC exposures. For example 7-CMG is excreted unchanged in urine and could be 
used as a non-invasive marker (Harrison et al., 1999).
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Previous in vitro studies with a range of nitrosated glycine 
derivatives had established that the ratio of O -CMdG to O -MedG ranged from 10:1 
to 40:1 (Harrison et al., 1999). It has been suggested that such compounds are 
responsible for back ground levels of DNA methylation. The ratio of formation of O6- 
CMdG to 06-MedG appears to be 100:1 in human subjects and this would be 
consistent with the hypothesis that nitrosated glycine derivatives may be the source of 
damage (Shuker, 2000). Further support for this hypothesis comes from the 
volunteers, who are on protein intake, has demonstrated increased levels of total NOC 
(Bingham et al., 1996). A number of epidemiological studies have linked protein 
intake with increased risk of GI tract.
The role of dietary glycine in forming 0 6-alkylguanine 
adducts at physiological relevant concentrations was further investigated. The amount 
of diazoacetate anion formed when glycine (lOpM -  50mM) reacted with nitric oxide 
was observed using HPLC assay. The amount of the ion formed was measured using 
colorimetric measurement of nitrite. Diazoacetate anion formation depended linearly 
on glycine concentration. It was reported that at physiological concentrations of 
glycine and nitric oxide, the diazoacetate anion is not detectable. Solutions of 
nitrosated glycine reacted with 2-deoxyguanosine and and calf-thymus DNA gave 
0 6-CMdG adducts, and at high concentrations of glycine and nitric oxide, 0 6-MedG 
adducts were observed. Studies with synthetic diazoacetate anion indicated that 
concentrations < 14pM did not give detectable 0 6-alkylguanine adducts. However 
0 6-CMdG adducts were detected in Human Blood samples obtained from three 
volunteers consuming a standardized high meat diet using Immunoslot Blot assay 
(Cupid et al., 2004).
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1.7 Objectives of the Thesis
Glycine is a simple primary amino acid and is among the most abundant amino acids 
found in dietary proteins. Nitrosated glycine derivatives react with DNA to give rise 
to several adducts including 0 6-carboxymethyl-2'-deoxyguanine adducts. Random 
mutagenesis studies on our routinely used laboratory model of A-nitrosoglycine 
derivative, potassium diazoacetate (KDA) using p53 yeast expression system 
indicated that this mutagen can induce transition mutations (C-T transitions) in the 
p53 Tumour suppressor gene via 0 6-carboxymethyl-2'-deoxyguanine adducts 
(Gottschalg et al., 2006). These mutations were also observed in p53 gene obtained 
from the tissues of colon cancer patients. There is some indirect evidence that this is 
related to endogenous nitrosation of glycine. It was also previously reported that this 
adduct is not repaired by repair enzyme 0 6-alkylguanine-DNA-alkyltransferase. In 
this context, it would be particularly interesting to study the physical, chemical and 
biological properties of 0 6-carboxymethyl-2'-deoxyguanine adduct. The objectives of 
the studies reported in this project are outlined below.
• Synthesis and Characterisation of oligonucleotides containing 0 6-alkylguanine 
adducts.
• Adduct site-specific mutagenesis studies on 0 6-alkylguanine adducts using 
amplification refractory mutation system -  polymerase chain reaction (ARMS- 
PCR) assays.
• Carcinogen specific mutagenesis studies on TV-nitrosoglycine derivative, 
potassium diazoacetate using HUPKI (Human p53 Knock-In) mouse 
embryonic fibroblast cell lines.
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2.0 Materials and Methods
2.1 Materials
2.1.1 Reagents - Synthesis of fl6-carboxvmethvlguanine phosphoramidite
The starting material 2’-deoxyguanosine [Catalogue No:05-0910-24] was obtained 
from CRUACHEM Ltd, Todd campus, West of Scotland Science Park Acre Road, 
Glasgow, G20, QUA, Scotland.
2.1.2 Reagents Obtained from Acros Organics
Product Name Catalogue No
Acetic anhydride 14949 0010
N, N-dimethyl formamide 11622 0025
4-dimethylaminopyridine 99% 14827 0053
2-mesitylenesulfonyl chloride 99% 12559 0250
Methanol extra dry with molecular sieves 36439 1000
Phenylacetic acid 98% 13028 0050
Phenylacetyl chloride 13030 1000
Pyridine extra dry with molecular sieves 36442 1000
Pyridine 13178 0010
T etrahydrofuran 34845 1000
Triethylamine 99.5% 13791 0010
2.1.3 Reagents obtained from Sigma-Aldrich Company
Product Name 
Acetonitrile Anhydrous 99.8% 
Dichloromethane Anhydrous 99.8%
Catalogue No 
27,100-4 
27,099-7
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2 -cyanoethyl-A,A-diisopropylchloro
phosphoramidite
Dichloromethane, anhydrous 99.8%
N,N, -diisopropylethylamine
l,8-diazabicyclo-(5.4.0)undec-7-ene
4,4-dimethoxytrityl chloride 95%
Ethyl diazoacetate
Methylglycolate
30,230-9
27,099-7
387649-100
13,900-9
10,001-3
E-22201
32,526-0
2.1.4 Laboratory Solvents obtained from Fischer Scientific
Acetonitrile, Chloroform, Dichloromethane, Diethyl ether, Ethyl acetate, Hexane, 
Methanol, n-pentane,
2.1.5 Reagents for DNA synthesis obtained from Glen Research products
2.15.1 Monomers used for DNA synthesis:
All the phosphoramidites used were ultra-mild p-cyanoethyl (CE) phosphoramidites 
Product Name Catalogue No
Pac-dA-CE phophoramidite 10-1601-05E
Ac-dc-CE phosphoramidite 10-1015-05E
iPr-Pac-dG-CE Phosphoramidite 10-1621-05E
dT-CE Phosphoramidite 10-1030-05E
O -Me-dG-phosphoramidite 10-1070-02E
2.1.5.2 Solvents/Reagents used for DNA synthesis:
Product Name
Activator 
(0.45M Tetrazole sublimed in 
Acetonitrile)
Catalogue No 
30-3102-52E
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Anhydrous Wash 40-4050-53E
Diluent (acetonitrile anhydrous) 40-4050-50E
Cap Mix A 40-4212-52E
(9:1- THF/Acetic anhydride)
Cap Mix B 40-4212-52E
(0.02M 1-methylimidazole in THF/Pyridine/KhO)
Oxidising Solution 40-4132-52E
(0.02M h  in THF/Pyridine/F^O
Deblocking Mixture 40-4140-69E
(3% Trichloroacetic acid in Dichloromethane)
2.1.5.3 DNA supports Used for DNA synthesis;
Product Name Catalogue No
Pac-dA 20-2801-41
Ac-dC 20-2215-41
iPr-Pac-dG 20-2821-41
500A° CPG dT 20-2230-41
2.1.6 HPLC systems used for Characterization of Oligonucleotides
• Waters™ 2690 Separations Module equipped with Waters™ 996 Photodiode 
Array detector & Waters™ 474 scanning Florescence Detector.
• Waters™ 616 pump equipped with Waters™ 996 Photodiode Array detector 
& Waters™ 474 scanning Florescence Detector.
• Dionex BIOLC system equipped with a DIONEX variable wavelength 
detector.
2.1.6.1 HPLC and FPLC Columns Used:
• Waters™ XTerra® MS Ci8 (2.5pm, 4.6*50 mm) column on HPLC for 
purification analysis on longer oligonucleotides.
• Waters™ XTerra® MS Ci8 (3.5pm, 2.1x150 mm) column on HPLC for 
Fluorescence assays on base modified oligonucleotides.
• Pharmacia Mono Q HR 5/5 ion exchange column (Amersham Biosciences, 
Uppsala, Sweden, SE-75184)] on FPLC for Preparative purification of 
Oligonucleotides.
• Atlantis (5pm, 4.5x25mm) Ci8 column on HPLC for nucleoside composition 
analysis on pentamers.
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Phenomenex, Syngery 4|um, Hydro-RP 80A (2.00x150mm) column on HPLC 
for fluorescence assays on modified DNA to detect the presence of modified 
bases.
2.1.7 Other Purification Kits used for DNA Purification:
Product Name Company Catalogue No
NENSORB™ PREP 
Ci8 Sep-Pak Reverse-Phase 
Cartridges
Perkin Elmer Life Sciences 
Waters™ Corporation
NLP-028
2.1.8 Enzymes used in this Research Proiect:
Product Name Company Catalogue No
Alkaline phosphatase Sigma-Aldrich P-5521
Nuclease PI US Biological N7000
Amplitaq Gold® DNA polymerase 
With 10X PCR Gold buffer & 
25mM ofMgCl2 Solution
Applied Biosystems 4311814
Quick-Stick™ Ligase BIOLINE BIO-27027
Restriction enzymes used for Restriction Fragment analysis are obtained from
New England Biolabs (UK) Ltd
Acl 1, Age 1, Apo 1, BbvC 1, Bmr 1, Bsa 1, Bst E l l ,  Bsu 36 1, Bts 1, Cla 1, Ear 1, 
EcoR 1, EcoR VNae 1, Nar 1, Pci 1, Sac 1, Sea 1,
2.1.9 Molecular Biology Kits and DNA ladders used in this Research Proiect:
Product Name Company Catalogue No
QIAquick™ Gel purification Kit QIAGEN 28704
QIAfilter™ Plasmid Midi Kit (25) QIAGEN 12143
QIAEXII® Gel Extraction Kit QIAGEN 2 0 0 2 1
NOVABLUE Competent cells Novagen 69825-4
Hyperladder IV, quantitative BIOLINE BIO-33029
Tridye 1KB DNA Ladder NewEngland Biolabs (UK) Ltd N3272S
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All the common laboratory chemicals used for adduct specific mutagenesis 
experiments including materials used for preparing gels such as Agaraose, 
polyacrylamide with A,A-methylenebisacrylamide, LB-Agar and LB-medium, Tris 
Base -  108g, Boric Acid -  55g, EDTA (pH 8.0) - 40pl, 10% APS and antibiotic 
penicillin were supplied by Dept of Pathology, University of Leeds, Leeds, UK.
All the common laboratory chemicals used for KDA 
mutagenesis studies such as Potassium hydroxide, chemicals used for cell culture such 
as DMEM Medium, 10% FCS, Trypsin, Trypan Blue dye and chemicals routinely 
used for DNA extraction such as 50mMTris-HCl, pH-8.0, 50mM EDTA, 1% Sodium 
dodecyl sulphate (SDS), lOmMNaCl, 20mg/ml proteinase K, Phenol, chloroform, 
Isopropanol, 70%ethanol, 3M sodium acetate pH - 5.2 were supplied by Dept of 
Genetic Alterations in Carcinogenesis, German Cancer Research Centre, Heidelberg, 
Germany.
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2.2 Methods Applied for Synthesis and Characterisation of Oligonucleotides 
Containing 2*-deoxyguanosine, O6 - methyl-2’-deoxyguanosme and O6-
carboxymethyl-2f-deoxyguanosine
2.2.1 Synthesis and Characterisation of 5f-0-(4,4-dimethoxytriphenylmethyl)- 
7V2-phenylacetyl-06-methoxycarbonylmethyl-2f-deoxyguanosine-3’-0-(2- 
cyanoethyl-A/,A/-diisopropylamino)-phosphoramidite using NMR and LC-MS
The method, which was used to synthesise 0 6-CMdG is primarily based on the work 
done by Gaffney et al., (Gaffney and Jones, 1982). This is an unambiguous route 
involving the introduction of methyl glycolate at O6 position of 2 -deoxyguanosione 
by displacing an arylsulphonate group. In a modification developed by Xu (Xu, 
2000), the 3' and 5'-OH groups were protected using acetyl groups instead of 
methoxyacetyl groups previously used by Harrison et al., (Harrison et al., 1997). The 
pivotal part of the synthesis, involving the introduction of methylglycolate moiety at 
O6 position of 2'-deoxyguanosine is similar in both methods. In the conventional 
synthesis, an isobutyryl group was used to protect exocyclic amino group. However, it
9 f ihas been documented that acyl groups protecting N  -position of O -substituted 2'- 
deoxyguanosine were resistant to removal by ammonia than unsubstituted 2 '- 
deoxyguanosine (Borow-Borowski and Chambers, 1987; Li and Swann, 1989; Smith 
et al., 1990). Therefore, phenylacetyl group, which is base labile, was used to protect 
the exocyclic 2-amino group of 2'-deoxyguanosine. This is because we cannot use 
ammonia for deprotection, since it converts ester at O6-position in to amide group. 
0.4M triethylamine/methanol was used for deprotection of 3' and 5'-OH groups, 
because it is chemically specific and there is a less risk for removal of phenylacetyl 
group.
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Compounds 1 - 7  were synthesised and characterised using 
NMR and LC-MS methods, according to reported procedure (Xu, 2000). Compounds 
1-6 were characterised using proton (1H) chemical shifts and compound 7 was 
characterised using 31P chemical shifts on NMR instrument with 300 MHz magnetic 
field from JOEL (JNM-LA 300) at the labs of chemistry, The Open University, 
Milton Keynes, UK. The chemical shifts were assigned by NMR technician Mr 
Gordon Howell and research assistant Mr. Praveen Patel at the Dept of Chemistry, 
The Open University, Milton Keynes, UK. lOmg of each compound was dissolved in 
DMSO-d6 solvent to characterise *H and 31P chemical shifts. The chemical shifts 
observed were in accordance with the Literature (Xu, 2000).
Compounds 1 - 6  were characterised on VG Micromass 
Quattro Triple Quadrupole LC-MS spectrometer. All the compounds were 
characterised by mass Spectrometry technician Mr Graham Jeffs, at the Dept of 
Chemistry, The Open University, Milton Keynes, UK. The eluant system used for 
characterisation was 50/50 acetonitrile/0.02 NH4AC (pH 5.4). Since, the samples were 
injected directly from the autosampler therefore no column was used. Compounds 
were 1 - 6  were characterised using positive ion mode LC-MS. The recorded m/z data 
was in agreement with the literature (Xu, 2000).
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2.2.1.1 Synthesis of 3’, 5’-diacetyl-2’-deoxyguanosine (compound 1)
6 g (2 1  mmol) of 2 -deoxyguanosine was dissolved in 6 8  ml pyridine and 108 ml of 
DMF in a round bottomed flask. Acetic anhydride (12.5ml) was added slowly drop by 
drop to the reaction mixture at room temperature [Figure 2.1]. The reaction was 
monitored for 48hrs using TLC (chloroform and methanol (10/90) solvent system) (Li 
and Swann, 1989).
(1)
Figure 2-1: The protection o f 3'and 5’ hydroxyl groups of sugar moiety by acetyl groups using acetic 
anhydride reagent.
Since this reaction takes a long time to go for completion, DMAP was added as a 
catalyst to increase the rate of the reaction at the room temperature. The reaction was 
finished in just 2-3hrs. Pyridine was removed under vacuum and the product was 
recrystallised from 95% ethanol (7.4g) Yield: 93%. UV Xmax 254nm !H NMR data (in 
DMSO-d6): 2.04 (3H, s, acetyl at 5'), 2.09 (3H, s, acetyl at 3'), 2.44-2.98 (2H, m, 2'-H 
and 2"-H), 4.17-4.32 ( 3H, m, 4'-H and 5'-H), 5.33 (1H, d, 3'-H), 6 . 15 (1H, dd, l'-H), 
6.56 (2H, s, 2-NH2), 7.90 (1H, s, 8 '-H) and 10.66 (1H, s, N-H). MS m/z: [2MH+] 
found at 702.12, (MH+) found at 351.32, (MH+ - Sugar fragment) found at 151.77.
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2.2.1.2 Protection of Exocyclic 2f-Amino group by Phenylacetylation (compound 
2)
Phenylacetylation of the exocyclic amino group was carried out using phenylacetyl 
chloride. Comparatively better yields of phenylacetylated product can be achieved 
with phenylacetic anhydride than chloride. Phenylacetyl chloride is highly reactive 
forming many side products, which makes separation difficult and gives low yields. 
However, phenylacetic anhydride is unstable and the protection was done using 
phenylacetyl chloride. The advantage of using phenylacetyl moiety for protecting 
exocyclic amino group is that it remains stable during deprotection of acetyl groups 
by triethylamine in methanol.
2.2.1.2.1 Synthesis of Phenylacetic anhydride
Phenylacetic anhydride was prepared by the reaction between phenylacetyl chloride 
and sodium salt of phenylacetic acid. Phenylacetic acid (13.6g, 0.1M) was added to a 
stirred aqueous solution of sodium hydroxide (0.1M in 15ml) to prepare sodium salt 
of phenyl acetic acid. 5 drops of pyridine was added followed by slow addition of 
phenylacetyl chloride (15.46 g, 0.1M).
Reactions:
C6H5CH2COOH + NaOH -----------► C6H5CH2COONa + H20
C6H5CH2COONa + C6H5CH2COCl -----------► (C6H5C0)20  + NaCl
Finally, the reaction mixture was washed with water to remove NaCl. Since, NaCl is 
an inorganic salt it can be easily removed by washing with water. However, 
phenylacetic anhydride is highly unstable and hydrolyses on contact with water. 
Hence, similar reaction was repeated using total non-aqueous phase. Sodium salt of
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phenylacetic acid was dissolved in ethyl acetate solvent to which phenylacetyl 
chloride was added. After the completion of reaction, the desired product was 
precipitated in ether solvent. This procedure does not give acceptable yields.
2.2.1.2.2 Protection of Exocyclic 2’-Amino group of 2’-deoxyguanosine with 
Phenylacetic anhydride
5g (14.2nmol) of 3',5'-diacetyl-2'-deoxyguanosine was dried by evaporation of a 
pyridine solution (30ml). Phenylacetic anhydride (20g, 85mmol) in pyridine (70ml) 
was then added and the solution stirred (120° C, 30min) (Li and Swann, 1989). 
Pyridine was evaporated and the reaction mixture was dissolved in 100ml of 
chloroform and washed with 100ml of sodium bicarbonate thrice. The organic layer 
was dried (MgS0 4 ) and is evaporated under reduced pressure to a thick gum. The 
gummy residue was applied to silica gel and desired product was purified by 
methanol/chloroform (10/90) solvent system.
(1) (2)
Figure2.2: The protection o f exocyclic 2 -amino group of 2-deoxyguanosine sugar moiety by 
phenylacetyl group using phenylacetyl chloride reagen t.
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2.2.1.2.3 Protection of Exocyclic 2f-Amino group of 2’-deoxyguanosine using 
Phenylacetyl chloride
3', 5 - diacetyl-2'-deoxyguanosine (4g, 11.3mmol) was dissolved in pyridine (30ml) 
and evaporated. Pyridine (50ml) was added and the reaction was stirred at room 
temperature. Phenylacetyl chloride is highly reactive and induces exothermic reaction 
when reacted with amine. Hence, the reaction system was kept cooled by keeping it 
stirring in an ice-bath. Phenylacetyl chloride (10ml, 55.36mmol) was added slowly 
drop by drop. The reaction was monitored using TLC with methanol/chloroform 
(5/95) solvent system. The reaction mixture was left overnight and additional amount 
of phenylacetyl chloride (l-2ml) was added to complete the reaction [Figure 2.2]. 
Pyridine was evaporated and the reaction mixture was dissolved in 100ml of 
chloroform and washed with 100ml of sodium bicarbonate thrice. The organic layer 
was dried (MgSC>4) and is evaporated under reduced pressure to a thick gum. This 
gummy residue was applied to silica gel and desired product was purified by 
methanol/chloroform (10/90) solvent system. The desired product containing fractions 
were pooled together, evaporated and dried to form yellowish powder (3g) Yield: 
46%. UV Xmax 259nm ]H NMR data (in DMSO-ds): 2.02 (3H, s, acetyl at 5'), 2.08 
(3H, s, acetyl at 3'), 2.54 -2.96 (2H, m, 2'-H and 2"-H), 3.80 (2H, s, CH2 of 
phenylacetyl), 4.14-4.47 ( 3H m, 4'-H and 5’-H), 5.31 (1H, d, 3'-H), 6.22 ( 1H, dd, I'­
ll), 7.23-7.34 (5H, m, of C6H5), 8.24 (1H, s, 8 '-H), and 11.94 ( 1H, s, N2-H, ex). MS 
m/z: (MH+) found at 470.40, (MH+ - sugar fragment) found at 269.56 [MH+- Sugar 
Fragment - PAC] -  151.53
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2.2.1.3 Mesitylenesulphonylation of Opposition of /V2-phenylacetyl-3',5?-diacetyl- 
2’-deoxyguanosine (compound 3)
3',5'-diacetyl-A^2-phenylacetyl-2'-deoxyguanosine (3g, 6.4mmol) was dissolved in 
DCM (100ml), to which TEA (3ml), DMAP (30mg) and mesitylenesulphonyl 
chloride (1.5g, 6 .8 mmol) were added sequentially. Reaction was monitored using 
TLC with methanol/chloroform (10/90) solvent system. After 30 min about two- 
thirds of the starting material (Rt-0.5) was converted in to a new spot with Rt - 0.8. 
Then additional amount of mesitylenesulphonyl chloride (0.5g) was added and the 
solution left stirred for another two hours to complete the reaction [Figure 2.3]. The 
solvent was evaporated under the vacuum and applied to a silica gel column and 
eluted with chloroform. The fractions containing the product were pooled together 
and concentrated to a small volume for recrystallisation. However, this compound 
was found to be quite unstable and gave poor yields on isolation. Hence, it was not 
isolated by column during subsequent experiments and used with out purification in 
the subsequent step (Xu, 2000).
(2) (3)
Figure 2.3: Addition o f mesitylenesulphonyl group at O6 position of 2 '-deoxyguanosine using 
mesitylenesulphonyl chloride reagent.
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The crystals formed were washed with diethyl ether, collected by filtration, and dried 
to give crystals of 3.9g (yield: 93%). UV Vax = 279nm. *H NMR data (in DMSO-d6): 
1.98 (3H, s, acetyl at 5'), 2.20 (3H, s, CH3 at 4-position of mesitylenesulphonyl), 2.06 
( 3H, s, acetyl at 3'), 2.54 ( 6 H, s, 2 XCH3 at 2 and 6  positions of mesitylenesulphonyl), 
2.89-2.98 (2H, m, 2'-H and 2"- H) 3.82 (2H, s, CH2 of phenylacetyl), 4.24-4.36 (3H, 
m, 4'-H and 5'-H), 5.40 (1H, d, 3'-H), 6.30 (1H, t, l'-H), 6.38 (2H, s, 2' and 5' 
positions of mesitylenesulphonyl) 7.19-7.36 (5H, m, 5H of phenylacetyl) 8.02 ( 1H, s, 
8 -H) and 10.78 (1H, s,N2-H ex)
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2.2.1.4 Synthesis of 3’,5’-diacetyl-iV2-phenylacetyl-06-methoxycarbonylmethyl-2’- 
deoxyguanosine (compound 4)
3',5'-diacetyl-A^2-phenylacetyl-(96-mesitylenesulphonyl-2'-deoxyguanosine (2.9g, 
4.46mmol) was dissolved in dried acetonitrile (20ml), to which quinuclidine (0.77g, 6  
mmol) was added. The solution was kept stirred at room temperature. After 30 
Minutes TLC (10/90, methanol/chloroform) had showed that all of the starting 
material is converted in to a new spot with its Rt being near zero. Then 
methylglycolate (2 ml, 25mmol) and 1, 8 -diazabicyclo (5,4,0) undec-7-ene (DBU) 
(0.6 ml, 3.9 mmol) were added sequentially. After 2 hrs, about quarter of the starting 
material was converted in to a new spot with Rt around 0.8. Then additional amount 
of methylglycolate (0.5ml) and DBU (0.3ml) were added and the solution was left 
stirred overnight [Figure 2.4]. S
AcO.
NH-PAc
AcO.
NH-PAc
OAc OAc
(3) (4)
Figure 2.4: Substitution o f (f-position of 2 -deoxyguanosine with methoxycarbonylmethyl group by 
displacing mesitylenesulphonyl group with quinuclidine followed by methylglycolate.
After the completion of reaction, solvent was evaporated under the vacuum and the 
residue was dissolved in ethyl acetate (1 0 0 ml) and washed with saturated aqueous
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solution of sodium chloride thrice (3x100ml). The organic layer was dried over 
sodium sulphate, concentrated and applied to silica gel to elute with chloroform, 
collected and dried to give compound 4 (in foam, 1.9g, yield: 75%). UV Vax = 
267nm. !H NMR data (in DMSO-de): 2.00 (3H, s, acetyl at 5'), 2.06 (3H, s, acetyl at 
3'), 2.47-2.95 (2H, m, 2'-H and 2"-H), 3.64 (3H, s, OCH3), 3.94 (2H, s, CH2 of 
phenylacetyl), 4.25-4.41 (3H, m, 4f-H and 5'-H), 4.98 (2H, s, CH2 of O6- CH2), 5.37 
(1H, m, 3-H), 6.35 (1H, t, l'-H), 7.19-7.33 (5H, m, C6H5), 7.92 (1H, s, 8 '-H), 10. 6 8  
(1H, s, N2-H, ex). MS m/z: (MH+) found at 542.44, (MH+-sugar fragment) found at 
342.24, (MH+-sugar ffagment-Pac group) found at 224.03. C2sH29 0 9  N5 requires 
542.1887.
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2.2.1.5 Synthesis of -phenylacetyl-0 -methoxycarbonymethyl-2’-
deoxyguanosine (compound 5)
9 f\3',5'-diacetyl-./V -phenylacetyl-0 -methoxycarbonylmethyl-2'-deoxyguanosine (1.7g, 
3.15mmol) was dissolved in 25 ml of 0.4M triethylamine in methanol. Deprotection 
of protecting groups was monitored using TLC (10/90) methanol/ chloroform solvent 
system. The acetyl groups of the starting material were removed gradually to from
three new spots. Spots with Rt - 0.7 and Rt- 0.5 represent 3* and 5'- deacetylated
2 6products and spot with Rt- 0.35 represents N  -phenylacetyl-0 - 
methoxycarbonylmethyl-2'-deoxyguanosine (5). The reaction mixture was left stirred 
overnight to let the reaction go for completion to form desired compound N  - 
phenylacetyl-06-methoxycarbonylmethyl-2'-deoxyguanosine (5) with Rt- 0.35. 
Solvent was evaporated under the vacuum and the solid residue left was co­
evaporated with absolute alcohol once and toluene twice to give white foam 
(compound 5) [Figure 2.5].
OCHUCOOCH
>
NH—PAc
HO
OH H
NH— PAc
AcO.
OAc H
(4) (5)
Figure 2.5: The deprotection of 3’ and 5' hydroxyl groups of 2-deoxyguanosine using triethylamine in 
methanol reagent.
The residue was recrystallized from methanol to give white crystals of compound 5 
about 950mg. Yield: 62.5%. UV = 269nm. 'H NMR data (in DMSO-d6): 2.23-
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2.74 (2H, m, 2'-H and 2"-H), 3.57 (2H, m, 5'-H), 3.64 (3H, s, OCH3), 3.79 (2H, s, CH2 
of Phenylacetyl), 3.84 (1H, m, 4'-H), 4.40 (1H, m, 3'-H), 4.89 (1H, t, 5 '-OH), 5.17, 
(2H, s, CH2 of 0 6-CH2), 5.30 (1H, d, 3'-OH), 6.32 (1H, t, l ’-H), 7.19-7.34 (5H, m, 
C6H5), 8.48 (1H, s, 8 '-H), 10.64 (1H, s, N2-H). MS m/z: (MH4) found at 458.30, 
(MH+-sugar fragment) found at 342.61, (MH+-sugar fragment-Pac group) found at 
224.05. C2 iH240 7 N5 requires 458.1676.
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2.2.1.6 Synthesis of 5f-0-(4,4f-dimethoxytriphenylmethyl)-/V2-phenylacetyl-06- 
methoxycarbonylmethyl-2’-deoxyguanosine (compound 6)
N  -phenylacetyl-0 -methoxycarbonylmethyl-2'-deoxyguanosine (450mg, 0.98M) was 
dissolved in anhydrous pyridine (1 0 ml) and the solution was cooled in an ice bath. 
DMAP (lOmg) and DMT-C1 (340mg, 0.001M) were added sequentially. Reaction 
was monitored on TLC using ethyl ether and then (10/90) methanol / chloroform 
solvent system. After completion of the reaction, pyridine was evaporated under the 
vacuum and the concentrated residue was applied to silica gel to purify the compound 
with methanol/chloroform (10/90) solvent system. Since, DMT group is sensitive to 
the acidic nature of silica, the basic conditions on the column were maintained by 
adding a few drops of pyridine to eluting solvent. The fractions were pooled together, 
evaporated and the resulting residue was precipitated from ice-cold pentane [Figure 
2 .6].
o c h 2c o o c hOCHUCOOCH
DMT—O
(5) (6)
Figure 2.6: The addition of 4',4’- dimeihoxytriphenylmethyl (DMT) group on 5 -OH position o f 2'- 
deoxyguanosine is essential for inter-nucleotide chain formation during automated DNA synthesis.
The precipitate was the dried to give a slightly yellowish powder (450mg). Yield: 
65%. *H NMR data (in DMSO-d6): 2.30-2.85 (2H, m, 2'-H and 2"-H), 3.07 (2H,m, 5'- 
H and 5"-H), 3.65 ( 3H, s, OCH3), 3.69 (6 H, s, 4,4-OCH3 of DMT), 3.77 (2H, s, CH2
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of phenylacetyl), 3.94 (1H, m, 4'-H), 4.45 (1M, m, 3'-H), 5.18 (2H, s, CH2 of O6- 
CH2), 5.30 (1H, d, 3'-OH), 6.35 (1H, t, l'-H), 7.13-7.32 (18H, m, 5H of phenylacetyl 
and 13H of DMT), 8.36 (1H, s, 8 ’-H), 10.60 (N2-H, ex). MS m/z: (MH+) found at 
759.54, (MH+ - DMT) found at 302.24.
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2.2.1.7 Synthesis of 5f-0-(4,4’-dimethoxytriphenyImethyl)-iV2-phenylacetyl-06 
methoxycarbonylmethyl-2'-deoxyguanosme-3'-0-(2-cyanoethyl-AyV- 
diisopropylamino)-phosphoramidite (compound 7)
DMT—O
OCH2COOCH3
N NH—PAc
h 5 h Ah
-►
DMT—(X
O
o c h 2c o o c h 3
X
N NH—PAc
/ P \  ^ \ ^ C N  
(i-Pr)2"N O
(6) ( 7 )
O C E j C O O C H i O C H , C O O
N
H O
<11 
N  N  N — P A c  
H
0.5M NaOH 
 ►
H O
N
< 1 1
n^ n^ nh2
N
V F
4j I ,V \A A A A A /V \A A A A A /\A A A A A A A A A A /\A A A A A / * 3
DNA with compound 7
Bo h *1
J I / V W W W W W W V '> /W V W V W W W W V W , 3
DNA with 0 6-CMdG Phosphoramidite
Figure 2.7: The addition of 3’-0-(2-cyanoethyl-N,N-diisopropylamino)-phosphoramidite at 3'-OH 
position o f 2'-deoxyguanosine is essential for inter-nucleotide chain formation during automated DNA 
synthesis. Compound 7 is directly incorporated in to an oligonucleotide sequence and deprotected with 
0.5M NaOH solution to obtain final sequence with 0 6-CMdG adduct.
2 65 O-(4,4'-dimethoxytriphenylmethyl)-TV" -phenylacetyl-0 -methoxycarbonylmethyl- 
2'-deoxyguanosine was dissolved in dried THF (5ml) and diisopropylethylamine 
(0.6ml) was added to the reaction mixture. Under constant stirring 0.2ml of 2-
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cyanoethyl-iY,7V-diisopropylchloro phosphoramidite was added. The mixture was 
stirred for half an hour at room temperature by which period starting material was 
converted to two higher Rt products as checked by TLC 
(dichloromethane/ethylacetate/diisopropylethylamine) in the ratio 75:25:2. Both the 
products are stereo isomers of the compound 7. The mixture was diluted with 30ml of 
ethyl acetate and washed with saturated NaHCC>3 (3><30ml). The organic phase was 
dried over sodium sulphate and evaporated to a small volume, then co-evaporated 
with toluene to an oily residue. The residue was purified by chromatography on silica 
gel eluting both the products with
dichloromethane/ethylacetate/diisopropylethylamine in the ratio (75:25:2). The 
fractions containing both the desired products were combined, evaporated and 
precipitated with ice-cold pentane and freeze dried with benzene to give a white 
powder (120mg) [Figure 2.7]. Compound 7 is the precursor of 0 6-carboxymethyl-2'- 
deoxyguanosine phosphoramidite. Initially the compound 7 was directly incorporated 
in to the oligonucleotide sequence. Then final sequence containing compound 7 was 
deprotected with 0.5M NaOH to remove functional protecting groups to form O6-
o 1
carboxymethyl-2-deoxyguanosine phosphoramidite. Yield: 46%. P NMR data (in 
DMSO-de): 151.15 and 151.20
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2.2.2 Synthesis of Oligonucleotides containing Normal 2f-deoxyguanosine, O6 - 
methyl-2’-deoxyguanosine and 0 6-carboxymethyl-2'-deoxyguanosine using 
Expedite™ 8908 instruments
Merrifield (Merrifield, 1963) and Letsinger (Letsinger et al., 1964) originally 
developed the concept of solid phase synthesis simultaneously for peptide synthesis. 
Later this idea is adapted for oligonucleotide synthesis by Letsinger (Letsinger and 
Mahadevan, 1966). This concept has four basic aspects, which are as follows
1. The oligonucleotide is synthesised while attached covalently to a solid support.
2. Excess soluble protected nucleotides and coupling reagent can drive a reaction 
near to completion.
3. The reaction is carried out in a single reaction vessel to diminish mechanical 
losses due to solid support manipulation, allowing synthesis with minute 
quantities of starting materials.
4. Heterogeneous reactions are standardised, and these procedures are easily 
automated.
p-cyanoethyl phosphoramidite chemistry is the method of choice in DNA synthesis. 
This method provides the following advantages.
1. High coupling efficiency
2. Reduced side reactions, which maintain high biological activity
Each DNA synthesis cycle is composed of four steps with intervening wash steps to 
remove excess of reagents and reaction by products.
The steps involved in each synthesis cycle are as follows
1. Deblocking
2. Coupling
3. Capping
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4. Oxidation
5. Capping
Following the final capping step, all the steps are repeated again, until chain
elongation is completed (Xu, 2002).
1. Deblocking: The monomers, which will be used on Expedite systems for DNA 
synthesis, consists of 5-OH protecting group, DMT (4,4-dimethoxytrityl group) 
on the sugar moiety. This step involves cleavage of 5’-OH protecting 
dimethoxytrityl group, which can be confirmed by observing orange colour liquid 
flowing through trityl waste. The intensity of the colour indicates the quality of 
the reaction, which is essential for good coupling yield.
2. Coupling: This step involves coupling of incoming phosphoramidite monomer to 
the monomer on the solid support. They cannot simply couple to each other. This 
involves activation by tetrazole (proton abstractor), a weak acid. Free 5'-OH acts 
as a nucleophile by donating proton to the dialkyl amino group, forming a reactive 
intermediate.
3. Capping: The coupling reaction is not quantitative in a finite period. A small 
percentage of truncated sequences will always be produced at the end. If these 
truncated sequences are allowed to react further, it will be difficult to isolate 
product from sequence mixture. This problem is overcome by acetylating free OH 
groups. Acetic anhydride is used as a capping reagent to acetylate free OH groups, 
there by preventing failure sequences to react further.
4. Oxidation: The newly formed phosphite intemucleotide linkage is highly 
unstable and susceptible to both acidic and basic conditions. This trivalent 
phosphite group is oxidised to pentavalent phosphate group. Iodine is used as mild
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oxidant in basic tetrahydrofuran solution with water as the oxygen donor. This 
reaction is extremely fast.
Oligonucleotides Sequences Synthesised for Physical and Biochemical studies
(a) Nucleoside Composition Analysis:
I . 51 AGGCT 3’ (Standard Pentamer)
2 .5 ’ AGXCT 3’(X= 0 6-methylguanine)
3. 5‘ AGYCT 3,(Y=06-carboxymethylguanine)
(b) Sequences for Melting point (tm) Analysis:
4 .5 ’ CGC GAG CTT GCG 3’ (t„- Standard Sequence)
5 .5 ’ CGC GAG CTC GCG 3* (t*- Standard Sequence)
6. 5’ CGC XAG CTT GCG 3’ (X= 0 6-Methylguanine)
7 .5 ’ CGC XAG CTC GCG 3* (X= 0 6-Methylguanine)
8. 5’ CGC YAG CTT GCG 3* (Y= 0 6-Carboxymethylguanine)
9 .5 ’ CGC YAG CTC GCG 3' (Y= 0 6-Carboxymethylguanine)
(c) Sequences used for Mutagenesis Studies:
10.5’ TCA GCA TCT TAT CCG AGT GGA AGG A 3’ (Standard 25mer)
II.5* AAT TTC CTT CCA CTC GGA TAA GAT GC 3’ (Standard 26mer)
12. 5' TCA GCA TCT TAT CCX AGT GGA AGG A 3’ (X= 0 6-Methylguanine)
13. 5’ AAT TTC CTT CCA CTC XGA TAA GAT GC 3’ (X= 0 6-Methylguanine)
14. 5’ TCA GCA TCT TAT CCY AGT GGA AGG A 3' (Y= 0 6-Carboxymethylguanine)
15.5’ AAT TTC CTT CCA CTC YGA TAA GAT GC 3' (Y= 0 6-Carboxymethylguanine)
Table 2.1: Sequences o f modified oligonucleotides synthesised on Expedite™8909 series instruments 
DNA Synthesiser.
The final capping involves capping free OH groups with acetic anhydride. If the 
amino group of guanine is protected with phenoxyacetyl group, then phenoxyacetic
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anhydride should be used as a capping agent to avoid partial replacement with acetic 
anhydride (Xu, 2002).
Oligonucleotides of different lengths were synthesised to serve 
different purposes. Pentamers were mainly synthesised because these are short 
sequences, which makes it easy to detect 0 6-alkylguanine adducts incorporated in to 
these sequences. 1 2 mer is an ideal length for any self-complementary sequence to 
study the melting temperature of DNA adducts. Despite a large number of 
characterised G-mutations specific to potassium diazoacetate (KDA)(Gottschalg et al., 
2006), none of these sites between codons 120-260 of the p53 sequence lay within a 
short sequence between two unique restriction sites which lies between codons 192- 
200. Codon 196 was the site chosen for insertion of modified DNA adduct. 25 and 
26mers were chosen because they are complementary p53 sequences occurring 
between two unique restriction sites and have codon 196 at which 0 6-alkylguanine 
adducts could be incorporated. These complementary sequences can form duplex 
containing single 0 6-alkylguanine adduct, which will allow construction of an 
adducted shuttle vector for mutagenesis studies. CPG support was removed from the 
column, dissolved in 1ml of ammonium hydroxide for normal oligonculeotides, and 
left overnight at room temperature. Next day the oligonucleotide in ammonium 
hydroxide solution was left at 55°c for two hours. Ammonium hydroxide cleaves the 
oligonucleotide from the solid support and removes other protecting groups as well. 
The modified oligonucleotide containing 0 6-methyl -2'-deoxyguanosine adduct were 
deprotected by dissolving the CPG support in 1ml of 10% DBU in methanol solution 
and left in dark for 5 days. The oligonucleotides containing O6- 
methoxycarbonylmethyl-2 '-deoxyguanosine adduct were deprotected by dissolving 
solid support in 1ml of 0.5M aqueous sodium hydroxide solution overnight.
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Note: The mode of oligonucleotide synthesis which was used in this work is DMT- 
ON i.e., 5-DMT (4,4'-dimethoxytrityl chloride) of the final base at 5’-end will not be 
cleaved. This group plays an important role during separation of full length sequences 
from truncated sequences.
All the oligonucleotides were synthesised at the scale of 1 pinole. The sequences of 
oligonucleotides synthesised were given in Table 2.1. The monomers and supports 
were obtained from Glen research, Virginia, 20164, USA. The synthesis was carried 
out on Expedite™ 8909 series instruments [PE Biosystems, Foster city, CA 94404] 
DNA synthesizer.
2.2.3 Purification of Oligonucleotides using NENSORB™ PREP cartridges
Milligram quantities of Trityl-on oligonucleotides were purified and detritylated using 
this cartridges. The oligonucleotides in 0.1M triethylammonium acetate (TEAA) 
buffer pH 7.0 or concentrated ammonium hydroxide were applied to the 
NENSORB™ PREP cartridges. Salts, failure sequences and synthetic by-products 
were washed away while the DMT-ON oligonucleotides remain bound to the 
cartridge. The trityl group was then hydrolysed from the 5'-end of the oligonucleotide 
with a 0.5% trifluoroacetic acid wash, leaving the trityl-off oligonucleotide bound to 
the cartridge. Subsequent recovery of the purified, trityl-off oligonucleotide was 
accomplished with a 35% methanol wash.
Procedure:
1. Activate the cartridge with 10ml of methanol.
2. Pre-equilibrate the cartridge with 5ml of 0.1M TEAA buffer (pH 7.0).
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3. Add the oligonucleotide in the concentrated ammonium hydroxide to the cartridge 
and pull the sample in to the resin bed until the meniscus reaches the top of the 
bed.
4. Wash the cartridge with 10 ml of (1:9) acetonitrile / 0.1M TEAA (pH 7.0) 
solution. Failure sequences, salts, and synthetic by-products will be washed away 
during this procedure, while DMT-ON oligo remains bound to the column.
5. Wash the cartridge with 25 ml of 0.5% TFA. The trityl group is hydrolysed in this 
step and trityl-off oligo remains bound to the support.
6. Wash the support with 10 ml of 0.1M TEAA, pH 7.0, to remove any traces of acid 
left on cartridge.
7. Prepare 10ml of (35%) methanol solution. Elute the support using 10ml of this 
solvent system and collect ten fractions of 1ml each.
8. Check the OD260 value of each fraction (1:10 dilutions are usually required). Oligo 
is usually found between fraction 3 to fraction 5.
9. Dry the desired fractions using lyophilisation or vacuum centrifugation 
Oligonucleotides concentration is referred in the terms of OD units. One OD unit is 
defined as the amount of product, which has an absorbance of 1.0 when dissolved in 
lml buffer (i.e., 20mM sodium phosphate, 0.1M NaCl, pH 7.0), and measured in 1cm 
cuvette at 20° c at absorbance 260nm.
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2.2.4 Preparative Purification of Oligonucleotides using Fast Protein Liquid 
Chromatography
The synthesis of oligonucleotides containing normal bases has become routine, but 
recently interest in the preparation of modified oligonucleotides has increased, due to 
overwhelming evidence implicating the role for 0 6-alkylguanine and O4- 
alkylthymine in mutation and carcinogenicity. In many molecular biological 
experiments, the effects due to modified oligonucleotides are obscured by the 
presence of impurities of even small amount of oligonucleotides, especially its parent 
oligo containing normal bases. Therefore, it is of great importance to produce 
modified oligomers with high purity.
At present short oligomers are purified by preparative PAGE 
using neutral buffer. The recovery of DNA using this process is not quantitative. This 
might be due to technical difficulties in extraction process. Reverse Phase HPLC is 
also used to separate short oligomers using weakly acidic buffer (e.g., KH2PO4 buffer, 
pH 6.3). Though it is very effective in separating short oligomers differing by one 
nucleotide, reverse phase HPLC is not good at separating oligomers of medium length
i.e. 24mers. When modified oligomers are prepared, the problem is to separate the 
oligomer containing the base of interest from oligomers of same length, which can be 
difficult to achieve.
These modified oligomers are in particular useful for point 
mutation studies. Xu and Swann have optimised a method to separate and purify 
oligomers of identical length but different base composition (Xu and Swann, 1992). 
This is called FPLC (Fast protein liquid chromatography). This technique is based on 
separation by charge difference between oligomers. Certain anion exchange columns 
can be used at high pH 12. Under these basic conditions not only phosphates (pKa 6 .8 )
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display negative charges but also imino protons of thymine and guanine can dissociate 
and display negative charge. Therefore, oligonucleotides of identical length, but 
different base composition should be separable by An-ion exchange chromatography 
at higher pH.
Liquid chromatography was carried out on a Dionex BIOLC 
system with a DIONEX variable wavelength detector using Mono Q HR 5/5 column 
[Amersham Biosciences, Uppsala, Sweden, SE-75184] equipped with UV detector. 
The gradient is given in the Table 2.2
Timefmin] Flow [ml/min] % Buffer A % Buffer B
0.00 1.0 100 0
2.00 1.0 100 0
5.00 1.0 60 40
15.0 1.0 40 60
20.0 1.0 0 100
25.0 1.0 0 100
26.0 1.0 100 0
Table 2.2: FPLC gradient used for Preparative Purification o f  Oligonucleotides 
Buffer A: 0.4M NaCl in lOmM NaOH (pH 11)
Dissolve sodium chloride (23.376g) in 750ml of water and add 10ml o f 1M aqueous 
sodium hydroxide to the above solution and make up to lltr with sterile water.
Buffer B: 1.2M NaCl in lOmM NaOH (pH 11)
Dissolve sodium chloride (70.128gms) in 750ml of water and add 10ml o f 1M 
aqueous sodium hydroxide to the above solution and make up to lltr with sterile 
water.
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The maximum pressure and flow rate recommended for this column were 580psi and 
3ml/min. Hence, buffers were used at a flow rate of lml/min at optimal pressure 
360psi. The amount of sample injected on HPLC for analysis and preparative 
purification purposes were 10 and 200pl. The percentage of the buffer B was 
increased gradually to 100% to elute the desired component. Chromatography was 
monitored at 260nm.
The oligonucleotides eluted using the above buffers will not 
remain stable due to high pH and presence of salts. Hence, the fractions containing 
oligos were neutralised with 5pi of 50% acetic acid solution. The fractions of oligos 
were desalted using C l8 Sep-Pak Reverse-phase cartridge.
2.2.5 Desalting of Oligonucleotides Using Cis Sep-Pak Reverse-Phase Cartridges
The procedure was as follows
1. Prepare a Cig Sep-Pak(TM) cartridge by washing with 15 - 20ml of HPLC-grade 
acetonitrile.
2. Wash the column with 10 ml of distilled or sterile water.
3. Add the FPLC fractions containing the oligonucleotide to the column.
4. Wash the column with 10ml of distilled or sterile water to remove salt.
5. Elute the column with 5ml of 50% acetonitrile solution. Collect five fractions of 
lml each in an eppondorf tube.
The OD260 values of each fraction were measured on UVICON photo spectrometer 
from BIOTEK instruments.
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2.2.6 FPLC Analysis of Pentamers containing 0 6-aIkylguanine adducts: O6- 
methyl-2’-deoxyguanosine and 0 6-carboxymethyl-2’-deoxyguanosine
Pentamer analysis was carried out on Dionex BIOLC system with a DIONEX variable 
wavelength detector using Mono Q HR 5/5 column [Amersham Biosciences, Uppsala, 
Sweden, SE-75184] equipped with UV detector. The gradient is given in the Table
2.3.
Time[min] Flow [mI/m in] | % Buffer A % Buffer B
0.00 1.0 | 100 0
2.00 1.0 | 100 0
5.00 1.0 | 60 40
25.0 1.0 | 0 100
28.0 1.0 | 0 100
30.0 1.0 | 100 0
Table 2.3: FPLC gradient used for the characterisation o f pentamers.
Buffer A: 0.0M NaCl in lOmM NaOH (pH 11)
Prepare the above solution by adding 10ml of 1M aqueous sodium hydroxide to lltr 
of distilled water.
Buffer B: 0.4M NaCl in lOmM NaOH (pH 11)
Dissolve sodium chloride (23.376gms) in 750ml of water and add 10ml of 1M 
aqueous sodium hydroxide to the above solution and make up to lltr with sterile 
water.
The maximum pressure and flow rate recommended for this 
column were 580psi and 3ml/min. Hence, buffers were used at a flow rate of lml/min 
at optimal pressure 360psi. The percentage of buffer B was rapidly increased to 40%
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by 5 minutes and then gradually to 100% by 25 minutes to determine the retention 
time of each individual pentamer. Chromatography was monitored at 260nm.
2.2.7 HPLC Analysis of Oligonucleotides Containing Normal 2f- deoxyguanosine, 
0 6-methyl-2,-deoxyguanosine and 0 6-carboxymethyl-2'-deoxyguanosine
HPLC analysis of 0 6-alkylguanines containing oligonucleotides was carried out on 
Waters™ 2690 Separations Module using xTerra R MS Ci8 (2.5pm, 4.6x50 mm) 
column equipped with Waters™ 996 Photodiode Array detector. Analysis was 
monitored at 260 nm at a flow rate of lml/min and gradient is given in the Table 2.4.
Time %A % B %C Column ° C
0.00 80 20 0.00 60° C
15 42.5 57.5 0.00 60° C
15.01 0 0 100 60° C
16 0 0 100 60° C
16.01 100 0 0 60° C
17 100 0 0 60° C
17.01 80 20 0 60° C
22.05 80 20 0 60° C
Table 2.4: Gradient used fo r characterisation o f the purity o f the longer oligomers (25 and 26 mers).
Solvents Used:
Mobile Phase A: 5% Acetonitrile in 0.1 M TEAA Buffer 
Mobile Phase B: 15% Acetonitrile in 0.1 M TEAA Buffer 
Mobile Phase C: 100% Acetonitrile
Chapter 2: Materials and Methods
2.2.8 Nucleoside Composition Analysis
1.0 OD units of standard pentamers AGGCT, AGXCT and AGYCT were dissolved in 
160pl of water and lOpl of 0.6M Tris-HCl, 0.06M MgCl2 (pH-4.5) solution. 10 units 
of Nuclease PI was added to the reaction mixture and incubated for 2 hrs (AGGCT, 
AGXGCT) and overnight for AGYCT at 37°C. 20pl of 0.6M Tris-HCl, 0.06M MgCl2 
(pH-8.0) buffer was added followed by 10 units of alkaline phosphatase and incubated 
for 2hrs in a water bath at 37° C. This reaction was followed on Reverse Phase HPLC 
using Atlantis (5pm, 4.5><25mm) Cig column on Waters™ 616 pump equipped with 
Waters™ 996 photodiode Array detector. 0.01M KH2PO4 buffer (pH- 
6.52)/Acetonitrile was used as a mobile phase, monitoring at 260nm at a flow rate of 
lml/min. The gradient is given the Table 2.5.
Time Flow %B %C %D
0.00 1.00 75.0 5.0 20.0
3.00 1.00 75.0 5.0 20.0
11.00 1.00 65.0 15.0 20.0
13.00 1.00 63.0 17.0 20.0
15.00 1.00 62.0 18.0 20.0
20.00 1.00 60.0 20.0 20.0
22.00 1.00 50.0 30.0 20.0
28.00 1.00 50.0 30.0 20.0
28.01 1.00 75.0 5.0 20.0
40.00 1.00 75.0 5.0 20.0
41.00 1.00 75.0 5.0 20.0
Table 2.5: Gradient used for HPLC characterization o f modified pentamers using Nucleoside 
Composition Analysis.
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Solvents Used:
Mobile Phase A: Methanol
Mobile Phase B: Water
Mobile Phase C: Acetonitrile
Mobile Phase D : 0.01M KH2P04 buffer (pH-6.52)
2.2.9 Fluorescence Analysis of 25 and 26mers containing Modified Guanine 
bases: 0 6-methyl-2’-deoxyguanosme and 0 6-carboxymethyl-2'-deoxyguanosine.
1.0 OD units of 25 and 26mers containing modified 2'-deoxyguanosine bases (O6- 
methyl-2!-deoxyguanosine and 0 6-carboxymethyl-2'-deoxyguanosine) were dissolved 
in 160pl of water and lOpl of 0.6M Tris-HCl, 0.06M MgCl2 (pH-4.5) solution. 10 
units of Nuclease PI was added to the reaction mixture and incubated 2 hrs for the 
oligonucleotides containing 0 6-methyl-2'-deoxyguanosine and overnight for the 
oligonucleotides containing 0 6-carboxymethyl-2'-deoxyguanosine at 37°C. 20 j l x 1 of 
0.6M Tris-HCl, 0.06M MgCl2 (pH-8.0) buffer was added followed by 10 units of 
alkaline phosphatase and incubated for 2hrs in a water bath at 37° C. This reaction 
was followed on Reverse Phase HPLC using Phenomenex, Synergy 4pm, Hydro-RP 
80A (150x2.00mm) column on Waters™ 2690 Separations Module equipped with 
Waters™ 996 Photodiode Array detector and Waters™ 474 scanning florescence 
detector. 0.01M KH2P04 buffer (pH-6.52)/Acetonitrile was used as a mobile phase, 
monitoring at excitation wavelength 286nm and emission at 378nm at a rate of 
0.25ml/min. The gradient is given the Table 2.5.
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Time Flow %B %C %D
0.00 0.25 75.0 5.0 20.0
3.00 0.25 75.0 5.0 20.0
11.00 0.25 65.0 15.0 20.0
13.00 0.25 63.0 17.0 20.0
15.00 0.25 62.0 18.0 20.0
20.00 0.25 60.0 20.0 20.0
22.00 0.25 50.0 30.0 20.0
25.00 0.25 50.0 30.0 20.0
28.00 0.25 75.0 5.0 20.0
35.00 0.25 75.0 5.0 20.0
Table 2.6: HPLC gradient used fo r characterization o f  oligonucleotides (mutation assay sequences 12- 
15) containing O6-alkylguanine adducts using fluorescence detector.
Solvents Used:
Mobile Phase A: Methanol 
Mobile Phase B: Water 
Mobile Phase C: Acetonitrile 
Mobile Phase D: 0.01M KH2P 0 4 pH-6.62
2.2.10 Melting curve (Tm) Measurements on Modified Self -Complementary 
DNA Sequences.
Melting curve measurements were performed in stoppered quartz cuvettes using 
U V IC O N xl spectrophotometer from BIOTEK instruments, which is connected to a 
programmable thermo system (Peltier system) from BIOTEK instruments. This
91
Chapter 2: Materials and Methods
programmable thermo system is capable of maintaining the temperature in cell holder 
over a range from 10°C - 100°C in a 10mm path length, 500pi capacity quartz cell. 
The self-complementary DNA strand was dissolved in 0.1 M Hepes buffer at pH -7.0. 
The temperature dependent change in absorbance was measured at 260nm. The rate of 
temperature increase was l°C/min. The Tm values were determined as the maximum 
values of the first derivative graph of the absorbance vs. temperature.
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2.3 M ethods applied for C haracterisation o f  M utations Induced by O6- 
alkylguanine adducts Incorporated Site- specifically in to p53 cD N A  
Sequence
2.3.1 Extraction o f  P lasm id pL S76 D N A  using Q IA filter P lasm id M id i k it
Plasmid, pLS76 is a 9kb p53 expression vector, was first described and constructed by 
Ishioka (Ishioka et al., 1993) [Figure 4.3]. It expresses full length p53 cDNA from the 
ADH1 constitutive promoter [Appendix 3]. The vector also contains CYC1 
(terminator) downstream of the p53 cDNA, yeast origin of replication, CEN6/ARSH4 
and LEU2 as a selectable marker. Plasmid, pLS76 DNA was used to construct a 
shuttle vector containing single 0 6-carboxymethyl-2'-deoxyguanosine adduct for our 
mutagenesis studies. Plasmid DNA was extracted from E.coli using QIAfilter plasmid 
midi purification kit from QIAGEN ltd. This kit can be used to purify up to lOOpg of 
low or high copy number plasmid or cosmid DNA. The advantage of QIAfilter 
cartridges over conventional centrifugation is it enables filtration to clear bacterial 
lysates.
A single colony was picked up and streaked on to a fresh LB- 
agar plate containing lOOpg/ml of ampicillin. 2ml of starter culture (LB medium) 
containing ampicillin (lOOpg/ml) was inoculated with single E.coli colony containing 
plasmid, pLS76. Starter culture was incubated for ~ 8hrs at 37° C with vigorous 
shaking (~200 rpm) in an orbital shaker. Then this starter culture was diluted at a ratio 
of lpart per 50 parts in to LB medium containing ampicillin lOOpg/ml and incubated 
at 37° C for 12 -  16 h with vigorous shaking (~200 rpm). The bacterial cells were 
harvested by centrifugation at ~4000 rpm for 15min at 4° C. The pellet was 
resuspended in 4ml of buffer PI (50mM Tris-Cl, pH 8.0; lOmM EDTA, lOOpg/ml 
RNase A). (Note: RNase A should be added to buffer PI to get a final concentration
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of 100|ug/ml before using). The bacterial cells were completely re-suspended by 
vortexing or pipeting up and down until no cell clumps remain. 4ml of buffer P2 
(200mM NaOH, 1% (w/v) SDS) was added to allow lysis of bacterial cells in 
suspension. Buffer was mixed gently by inverting 4-6 times and incubated at room 
temperature for 5min. (Note: Do not vortex and do not allow lysis reaction to proceed 
no more than 5 minutes).
During the incubation, QIAfilter cartridge was prepared by 
screwing the cap onto the outlet nozzle. QIAfilter cartridge is a device, which is 
similar to a syringe with a screw top outlet. This was used at later stage to filter 
bacterial lysate. 4ml of chilled buffer P3 (3.0M potassium acetate, pH5.5) was added 
to neutralise the lysate. The lysate was mixed by shaking 4-6 times immediately, but 
gently. The buffers were mixed thoroughly to allow neutralisation proceed to 
completion. On adding buffer P3, a fluffy white precipitate containing genomic DNA, 
proteins, cell debris and SDS becomes visible. This lysate was immediately 
transferred in to the barrel of the QIAfilter cartridge and incubated for 10 min. (Note: 
Do not insert plunger in to the barrel). Meanwhile a QLAGEN-tip is equilibrated using 
10ml of Buffer QBT (750mM NaCl, 50mM MOPS pH 7.0, 15% isopropanol (v/v), 
0.15% Triton X-100 (v/v). QLAGEN-tip 100 is a portable chromatographic column 
from which we can elute the desired components by changing the pH of the eluate. 
After 10 min of incubation, outlet nozzle of QIAfilter cartridge was unscrewed. The 
plunger was inserted gently and cell lysate was filtered in to previously equilibrated 
QIAgen-tip 100. (Note: Do not apply extreme force).
The cleared lysate containing plasmid DNA and other 
contaminants enters the QLAGEN-tip by gravity flow and binds to the resin. 
QLAGEN-tip was washed with 2* 10ml of buffer QC (1.0M NaCl, 50mM MOPS (pH
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7.0), 15% isopropanol (v/v). First wash is sufficient to remove contaminants in all 
major plasmid preparations. Second wash is necessary if bacterial strains producing 
large amounts of carbohydrates are used. This was followed by extraction of plasmid 
DNA by eluting the QIAGEN-tip with 5ml of buffer QF (1.25M NaCl, 50mM Tris-Cl 
(pH 8.5), 15% isopropanol (v/v). Buffer QF fraction containing plasmid DNA was 
precipitated by adding 3.5ml of room-temperature isopropanol. The precipitate was 
mixed and centrifuged immediately at ~4000 rpm for 30min at 4° C. Isopropanol 
pellets have a glassy appearance and are more difficult to see than salt containing 
pellets that result from ethanol precipitation. Hence, due care was taken during 
decanting the supernatant. These pellets were washed with 2ml of room -temperature 
70% ethanol and centrifuged at ~4000 rpm for lOmin. The supernatant was carefully 
decanted with out disturbing the pellet. The pellet was air-dried for 5-10 min and re­
dissolved in 300j l x 1 of TE buffer (pH 8.0).
2.3.2 C onstruction o f  G enetically Engineered P lasm id, pL S76 containing O6- 
alkylguanine A dducts
2.3.2.1 D ouble digestion o f P lasm id, pLS76 D N A  w ith  BbvCl and S a d  
R estriction enzym es
30pg of plasmid DNA was added to a clean 1.5ml micro-centrifuge tube. I O j l i I  of both 
10X NE buffer 4 and I O j l i I  of 10X BSA were added to the plasmid DNA and mixed 
thoroughly by pipeting up and down. Five units of restriction enzymes BbvC I and 
SaC I were added to the above reaction mixture and mixed thoroughly by brief 
centrifugation. The reaction mixture was incubated overnight at 37° C in a water bath.
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2.3.2.2 Double digestion of Plasmid, pLS76 DNA with Apol and S a d  
Restriction enzymes
Enzymes Apo I and Sac I differ in their reaction temperatures as well as in their 
percentage of activities in different NE buffers. Both these enzymes were showing 
considerable amount of activity in NE Buffer 3. Hence, NE buffer 3 was chosen for 
this double digestion reaction. Apo I requires 50° C to react, where as Sac I reacts at 
37° C. Therefore, it was decided to cut the plasmid DNA with both enzymes one after 
another. 30pg of plasmid DNA was added to a clean 1.5ml micro-centrifuge tube. 
IOjliI of both 10X NE buffer 3 and lOpl of 10X BSA were added to the plasmid DNA 
mixed thoroughly by pipeting. Initially five units of Apo /, was added to the reaction 
mixture and incubated at 50° C for 6-8 h. Later, five units of sa d  was added to the 
above reaction mixture and incubated overnight at 37° C in a water bath.
2.3.2.3 Extraction of BbvC I + Sac I and Apo I + Sac I Fragments Using QIAquick 
Gel Extraction Kit from QIAGEN.
This is a protocol based on using microcentrifuge and is designed to extract and purify 
DNA fragments of 70bp to lOkb from standard and low-melt agarose gels in TAE or 
TBE buffer. Both the BbvC I + SaC I and Apo I + Sac I fragments were extracted from 
the respective excised DNA fragments from the agarose gel using a clean and sharp 
scalpel. These gel slices were weighed in a colourless centrifuge tube (approximately 
200-400mg). Three volumes of buffer QG (Composition of this buffer is not 
mentioned anywhere by Qiagen. However, it contains chaotropic salt, guanidine 
thiocyanate which acts as a pH indicator) was added for 1 volume of gel (lOOmg ~ 
lOOpl). The gel slices in buffer QG were dissolved by incubating at 50° C for 10 min 
and dissolving was aided by vortexing the sample tubes every 2-3 min during
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incubation. The mixture was checked for its yellow colour (similar to buffer QG with 
out dissolved agarose) which indicates that pH of the buffer QG is 7.5. Any change in 
pH is clearly indicated by change in the colour of the mixture to either violet or 
orange. This is due to the presence of the pH indicator in Buffer QG. This change in 
the pH of buffer QG will affect the DNA adsorption to Qiaquick membrane, which 
was used in the later stage. One gel volume of isopropanol was added to each agarose 
gel slice (lOOmg ~ lOOpl) and mixed thoroughly.
A QIAquick spin column was placed in a provided 2ml 
collection tube. This is a device similar to micro-centrifuge tube with a filter to collect 
elute. The sample in buffer QG was applied to this QIAquick column and centrifuged 
for 1 min at 13,000 rpm in a bench top centrifuge. (Note: The maximum volume of 
the column reservoir is 800pl). The flow-through was discarded and the QIAquick 
column is placed back in to the same collection tube again. Another 0.5ml of buffer 
QG was added to the QIAquick column and centrifuged for 1 min at 13,000 rpm to 
remove any additional traces of agarose. 0.75ml of buffer PE was added to wash the 
QIAquick column and centrifuged for 1 min at 13,000 rpm. (Note: add 96 -100% 
ethanol to buffer PE before use). The flow-through was discarded and the QIAquick 
column is centrifuged again at 13,000 rpm for 1 min to remove any residual ethanol. 
This QIAquick spin column was transferred to a clean 1.5ml eppondorf tube. The 
DNA fragments were eluted by adding 50pl of buffer EB (lOmM Tris-Cl, pH 8.5) to 
the centre of the QIAquick membrane and centrifuging the column at 13,000 rpm for 
lmin. Purity of the DNA fragments extracted from agarose gel were checked on 1% 
agarose gel.
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D u p l e x  1 D u p l e x  2 D u p l e x  3  | D u p l e x  4  | D u p l e x  5
1 0 / 1 1 1 2 / 1 1 1 0 / 1 3  1 1 4 / 1 1  | 1 0 / 1 5
Table 2.7: Different types o f duplexes constructed with the adduct present either on sense or anti-sense 
strand.
• Duplex 1: Normal 25mer (sequence 10) and Normal 26mer (sequence 11) were annealed 
to form control DNA duplex 1.
• Duplex 2: Modified 25mer containing 0 6-MedG adduct (sequencel2) and Normal 26mer 
(sequence 11) were annealed to form DNA duplex 2 with 0 6-MedG adduct on sense 
strand.
• Duplex 3: Normal 25mer (sequence 10) and Modified 26mer containing 0 6-MedG 
(sequence 13) were annealed to form DNA duplex 3 with 0 6-MedG adduct on Anti-sense 
strand.
• Duplex 4: Modified 25mer containing 0 6-CMdG adduct (sequence 14) and normal 
26mer (sequence 11) were annealed to form DNA duplex 4 with 0 6-CMdG adduct on 
sense strand.
• Duplex 5: Normal 25mer (sequence 10) and Modified 26mer containing 0 6-CMdG 
adduct (sequence 15) were annealed to form DNA duplex 5 with 0 6-CMdG adduct on 
Anti-sense strand.
2.3.2.4 Annealing of Complementary Single stranded 25mer and 26mers to 
Construct Single 0 6-alkylguauine Adduct Containing duplex DNA.
Despite a large number of characterised G-mutations specific to potassium 
diazoacetate (KDA)(Gottschalg et al., 2006), none of these sites between codons 120- 
260 of the p53 sequence lay within a short sequence between two unique restriction 
sites which lies between codons 192-200. Codon 196 was the site chosen for 
insertion of modified DNA adduct at nucleotide position 587 on sense strand and at 
nucleotide position 586 on anti-sense strand. The sequences chosen for mutagenesis 
studies are complementary sequences (sequences numbered 10-15) [see Table 2.1 and 
Figure 4.8]. Dr. Phil Bums, Dept of Pathology, University of Leeds designed these
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sequences. Sequences 10 and 11 are standard 25 and 26mers chosen from tumour 
suppressor gene, p53 cDNA comprising codon 190 to codon 202. The sequences 12 
and 13 are methylated counterparts and sequences 14 and 15 are carboxymethylated 
counterparts of standard sequences. Annealing reactions were carried out on a PCR 
heat block, PTC-200 Peltier thermal cycler, DNA engine from MJ Research. 
2.5nmoles (20pg) of each single stranded oligonucleotide (25mer and 26mer) were 
mixed in a microcentrifuge tube and heated up to 95° C on a PCR heat block to 
denature the DNA fragments. Then it was rapidly cooled down to 70° C. It was left 
for 2 minutes at 70° C to prevent any chances of forming secondary structures. The 
reaction mixture was cooled down slowly to room temperature in an hour. The 
complementary sequences were annealed in such a way that duplex formed will 
contain adduct either on sense or anti-sense strand. The information on types of 
duplex constructed is given in Table 2.7.
2.3.2.5 Separation of Annealed duplex DNA from Single Stranded 
Oligonucleotides using 19:1 Non-Denaturing Polyacrylamide Gel 
Electrophoresis (PAGE)
2.3.2.5.1 Preparation of 19:1 Polyacrylamide Gel:
IPX TBE Buffer:
Tris Base -  108g
Boric Acid -  55g 
EDTA (pH 8.0) - 40pi
10% APS: Take lg of Ammonium persulphate and dissolve it in 10ml of 
distilled water.
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8ml of 40% w/v 4x crystallised polyacrylamide with iV,iV-methylenebisacrylamide 5C 
± 0.2 in deionised water solution was mixed with 4ml of 10X TBE buffer. The 
volume was made up to 20ml with distilled water. 450pi of 10% APS and 45 pi of 
TEMED were added at the same time. The solution was swirled to mix completely 
and poured between the glass plates fixed with spacers to set the gel.
Acrylamide is a monomer, which in the presence of free 
radicals supplied by ammonium persulfate and stabilised by TEMED, a chain reaction 
is initiated in which monomers of acrylamide are polymerised in to long chains. When 
the bifunctional agent N,N -  methylenebisacrylamide is included in the 
polymerisation reaction, the chain becomes cross-linked to form a gel. Annealed 
oligonucleotides were loaded on to gels with 6x typel loading buffer (0.25% 
Bromophenol blue, 0.25% Xylene Cyanol and 40% w/v sucrose in H2O) to separate 
from single stranded oligonucleotides in IX TBE buffer.
2.3.2.5.2 Isolation of Duplex DNA Fragments from Polyacrylamide Gel Using 
User Developed Protocol from QIAGEN
This procedure has been adapted from QIAquick Gel extraction kit protocol and 
Sambrook et al., (Sambrook et al., (1989). Polyacrylamide gel was stained in ethidium 
bromide solution and the band of interest was located by visualising the gel under UV 
light. The band of interest was excised using clean sharp scalpel and transferred to a 
clean microfuge tube. The gel slice was weighed in a microfuge tube and crushed 
against the wall of the tube. 1-2 volumes of diffusion buffer (0.5M ammonium 
acetate; lOmM magnesium acetate; ImM EDTA, pH 8.0; 0.1% SDS) was added to 1 
volume of gel (lOOmg ~ 100-200pl). The samples were incubated at 37° C overnight 
in a water bath. The samples were centrifuged for 1 min and the supernatant was
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carefully removed using a pipette and transferred in to a clean microfuge tube. An 
additional 0.5 volume of diffusion buffer was added to the gel slice and centrifuged 
for 1 min. The two supernatants were combined by mixing. The supernatant was 
filtered using a GF/C disposable sterile filter to remove any traces of polyacrylamide 
gel. The volume of the supernatant was determined and 3 volumes of buffer QG was 
added to 1 volume of gel (lOOmg ~ 300j l i 1). A Qiaquick spin column was arranged in 
a 2ml collection tube. The supernatant in buffer QG was applied to QIAquick spin 
column to bind DNA and centrifuged for 1 min. The flow-through was discarded and 
the spin column was placed in the same collection tube. The column was washed by 
adding 0.75ml of buffer PE and centrifuged for 1 min. The flow-through was 
discarded and Qiaquick column was placed back in the same collection tube. The 
column was centrifuged for another 1 min to remove any residual traces of ethanol. 
Qiaquick column was transferred in to a clean microfuge tube. 50pl of elution buffer 
(lOmM Tris-Cl, pH 8.5) was added to the centre of Qiaquick column to elute DNA 
fragments.
23.2.6 Ligation of BbvCl + Sacl and Apol + Sad  and Annealed Duplex DNA 
using Quick-Stick™ Ligase Kit to form an Intact Plasmid with Single O6- 
alkylguanine adduct.
Unfortunately, cohesive ends formed by BbvCl restriction enzyme were not very 
sticky. Quality control assay of this enzyme claims after 2-fold over digestion with 
BbvC I < 5% of the DNA fragments can be religated with BbvCl. Hence, ligation 
reactions were tried at 2-fold, 4-fold and 8-fold concentrations of BbvCl + Sacl 
double stranded DNA. 8-fold reactions were repeated multiple times to get enough 
circularised plasmid for transformations in to E.coli cells. Five different types of
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plasmids were constructed of which one is control plasmid, two of them were 
plasmids containing methylated adduct present either on sense strand or anti-sense 
strand and the remaining two were carboxymethylated plasmids with adduct present 
either on sense strand or anti-sense strand [Table 2.7]. The reaction was assembled in 
a microfuge tube by mixing all the three DNA fragments in the appropriate ratios 
given in the Table 2.8. lpl of the enzyme, QS ligase was added to the reaction 
mixture followed by addition of 5 pi of 4X QS buffer. Contents were mixed 
thoroughly by pipetting. The reaction mixture was incubated at room temperature for 
5 minutes. The ligation mixture was analysed by running 5pi of the sample on 1% 
agarose gel.
Reaction Contents:
DNA Fragment 2- Fold reaction 4-Fold reaction 8-Fold reaction
BbvC I A-Sac I 2Hg 8ng 16ng
Apol + Sacl 2Hg 2gg 2(ig
Duplex DNA 80ng 80ng 80ng
Table 2.8: 2,4 and 8 fold amounts of BbvCl + Sacl double stranded DNA were used to find an optimal 
concentration of double stranded plasmid DNA required to construct an intact adduct containing 
plasmid.
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Types of Plasmids Constructed:
•  Control plasmid —Plasmid with duplex 1
•  Plasmid, pLS76 - 2 -  Plasmid with duplex 2
•  Plasmid, pLS76 - 3 -  Plasmid with duplex 3
•  Plasmid, pLS76 - 4 -  Plasmid with duplex 4
•  Plasmid, pLS76 - 5 -  plasmid with duplex 5
• Duplex 1: Normal 25mer (sequence 10) and Normal 26mer (sequence 11) were annealed 
to form control DNA duplex 1.
• Duplex 2: Modified 25mer containing 0 6-MedG adduct (sequence 12) and Normal 26mer 
(sequence 11) were annealed to form DNA duplex 2 with 0 6-MedG adduct on sense 
strand.
• Duplex 3: Normal 25mer (sequence 10) and Modified 26mer containing 0 6-MedG 
(sequence 13) were annealed to form DNA duplex 3 with 0 6-MedG adduct on Anti-sense 
strand.
• Duplex 4: Modified 25mer containing 0 6-CMdG adduct (sequence 14) and normal 
26mer (sequence 11) were annealed to form DNA duplex 4 with 0 6-CMdG adduct on 
sense strand.
• Duplex 5: Normal 25mer (sequence 10) and Modified 26mer containing 0 f-CMdG 
adduct (sequence 15) were annealed to form DNA duplex 5 with 0 6-CMdG adduct on 
Anti-sense strand.
Table.2.9: Different types of plasmids, pLS76 containing 06-alkylguanine adducts constructed
2.3.3 Transformations of Ligation Mixture in to NOVABLUE E.coli 
Competent cells using Standard kits
Novablue competent cells (Merck biosciences) enable convenient, efficient 
construction of plasmid recombinants. They can be obtained both as standard and 
single kits. The cells in the standard kits were provided as frozen 0.2ml aliquots and 
each vial can be used for 10 transformations. The cells in the single kits were 
provided as single-use-5Opl aliquots for greater efficiency and convenience, and were 
packed in kits for either 11 or 22 transformations. Appropriate numbers of competent 
cell aliquots were taken including one extra sample for the test plasmid positive 
control. All the tubes were immediately placed in the ice, so that all but the cap is
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immersed. The cells were allowed to thaw on ice for 2-5minutes. They were visually 
checked to see that they have thawed by gently flicking the tubes 1-2 times to evenly 
resuspend the cells. The cells were then immediately aliquoted. Ten 1.5ml microfuge 
tubes were pre-chilled by keeping them on ice. 20pl aliquots of cells were pipetted 
into the pre-chilled tubes. 1 pi (0.2ng) of test plasmid was added to one of the tubes 
containing cells to determine transformation efficiency, lpl of (1/10) and (1/100) 
dilutions of ligation mixture and purified plasmid were added to the separate tubes 
containing competent cells. Cells were stirred gently to mix and returned to ice, so 
that the tube was remained immersed in the ice, except for the cap. The tubes were 
incubated on the ice for 5 minutes. Heat shock was given to the cells by placing them 
in a water bath at 42° C for 30sec (do not shake). The tubes were placed on ice for 2 
minutes. 80pl of room temperature SOC (Full form of SOC abbreviation was not 
mentioned anywhere in the literature) medium was added to each tube. (Do not 
remove cells from ice until all have received SOC). The tubes were incubated at 37° 
C by shaking at 250rpm for 30 minutes prior to plating them on selective media. 
During outgrowth, the selective plates containing ampicillin (50pg/pl) were dried by 
placing them in an incubator at 37° C. (Note: If the plates contain a lot of moisture, 
place them cover-side up and open the cover 1/3 of the way to allow the plates to dry 
for 30 -  45 min). The plates were removed from the incubator and 5pi of 
transformants containing test plasmid, 5 pi and 50 pi volumes of transformants 
containing ligation mixture and purified plasmid were transferred on to selective 
plates by spreading them with bent glass rod. (If plating less than 25 pi, it is best 
plating it on a pool of SOC). The plates are incubated overnight at 37° C.
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2.3.4 Amplification of p53 cDNA from Plasmid, pLS76 Containing 2f- 
deoxyguanosine and 0 6-methyl-2’-deoxyguanosine and O6-
carboxymethyl-2’-deoxyguanosine Adducts by Polymerase Chain 
Reaction
An appropriate volume (2pi) of DNA template (plasmid pLS76 DNA containing 
either normal 2'-deoxyguanosine or 0 6-alkylguanine adducts) was mixed with 5 pi of 
10X PCR gold buffer (Mg2+ Free) (Applied Biosystems, Foster City, USA), 2pl of 
25mM MgCl2 solution (Applied Biosystems, Foster City, USA), 4pl of 2.5mM dNTP 
mix, lpl of primer BB5 (5'- Biotin-CCAGGTCCAGATGAAGCTCC-3', lOpmol/pl), 
lpl of primer NBE3 (5'- GGAGAGGAGCTGGTGTTGTT-3', lOpmol/pl), 0.25pl 
Amplitaq plus DNA polymerase (5U/pl) (Catalogue no-4311814, Applied 
Biosystems, Foster City, USA) and water to make up final volume to 50pl. The DNA 
was amplified using the following program [95° C/9 min, (95° C/lmin, 55° C/lmin, 
72° C/2min) * 30times) 72° C/5min, and hold at 4° C for an hour] in the MJ 
Research, DNA Engine, PTC-225 (programmable thermal controller) PCR machine.
2.3.5 Detection of Mutations in Adducted Plasmid, pLS76 using ARMS-PCR 
(amplification refractory mutation system)
p53 cDNA was amplified from both normal plasmid and adducted plasmid constructs. 
An appropriate volume (2pi) of DNA template was mixed with 5 pi of 10X PCR gold 
buffer (Mg2+ Free) (Applied Biosystems, Foster City, CA, USA), 2pl of 20mM 
MgC12 solution (Applied Biosystems, Foster City, CA, USA), 4pl of 25mM dNTP 
mix, 0.25pl of Amplitaq plus DNA polymerase (5u/pl) (Catalogue no-4311814,
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Applied Biosystems, Foster City, USA) and site-specific primer sequences depending 
on the reaction.
Sequences of sequence specific primers used for ARMS-PCR assay with Plasmid, 
PLS76-2 and plasmid, pLS76-4:
Sequence specific primers for analysis on Anti-sense strand which differ a t3 ’-end
Primer AG 5’ CCC TCC TCA GCA TCT TAT CCG 3
Primer AC 5' CCC TCC TCA GCA TCT TAT CCC 3
Primer AA 5’ CCC TCC TCA GCA TCT TAT CCA 3
Primer AT 5' CCC TCC TCA GCA TCT TAT CCT 3
Conserved primers:
Primer SI 5’ TGT GAT GAT GGT GAG GAT GG y
Primer S2 5' CTT CCA GTG TGA TGA TGG TGA y
Sequence specific primers for analysis on Sense strand which differ at 3*-end
Primer SC 5* ACG CAA ATT TCC TTC CAC TC 3*
Primer SG 5’ ACG CAA ATT TCC TTC C AC TG y
Primer SA 5* ACG CAA ATT TCC TTC CAC TA y
Primer ST 5’ ACG CAA ATT TCC TTC CAC TT y
Conserved primers:
Primer A1 5’ CAA CTG GCC AAG ACC TGC y
Primer A2 5’ CCC TCA AC A AGA TGT TTT GCC y
Table 2.10: Sequence specific primers usedfor base pairing analysis on plasmid, pLS76 - 2 containing 
methylated adduct and plasmid, pLS76 - 4 containing carboxymethylated adduct on sense strand at 
nucleotide position 587 in codon 196. Primers used for analysis on Sense strand were given prefix (S) 
and for Anti-sense strand (A) will differ at 3'end, which is indicated in red colour. Conserved primers 
for sense strand were prefix (S) and for anti-sense strand (A).
In the Chapter 4 Prefixes will be not used in the explanation of ARMS-PCR assay and conserved 
primer sequences were given justfor information purpose. These will not be mentioned in the chapter 4.
Sequences of sequence specific primers used for ARMS-PCR assay with Plasmid, 
PLS76-3 and plasmid, pLS76-5
Sequence specific primers for analysis on Anti-sense strand which differ at 3f-end
Primer AC 5’ CCC CTC CTC AGC ATC TTA TCC 3'
Primer AA 5’ CCC CTC CTC AGC ATC TTA TCA 3'
Primer AG 5’ CCC CTC CTC AGC ATC TTA TCG 3'
Primer AT 5’ CCC CTC CTC AGC ATC TTA TCT 3’
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Conserved primers:
Primer SI 5’ CAA ACA CGC ACC TCA AAG C 3’
Primer S2 5' CGC ACC TCA AAG CTG TTC C 3*
Sequence specific primers for analysis on Sense strand which differ at 3*-end 
Primer SG 5’ ACG CAA ATT TCC TTC CAC TCG 3’
Primer SA 5’ ACG CAA ATT TCC TTC CAC TCA 3’
Primer SC 5* ACG CAA ATT TCC TTC CAC TCC 3’
Primer ST 5’ ACG CAA ATT TCC TTC CAC TCT 3*
Conserved Primers:
Primer A1 5* TCT GTG ACT TGC ACG TAC TC 3*
Primer A2 5’ ATT CTG GGA CAG CCA AGT CT 3*
Primer A3 5' AGT CTG TGA CTT GCA CGT ACT C 3'
Primer A4 5’ GTC TGT GAC TTG CAC GTA CT 3’
Table 2.11: Sequence specific primers used for base pairing analysis on plasmid, pLS76 - 3 containing 
methylated adduct and plasmid, pLS76 - 5 containing carboxymethylated adduct on anti-sense strand 
at nucleotide position 586 in codon 196. Primers used for analysis on Sense stmnd were given prefix 
(S) and for Anti-sense strand (A) will differ at 3 'end, which is indicated in red colour. Conserved 
primers for sense strand were prefix (S) and for anti-sense strand (A).
In the Chapter 4 Prefixes will be not used in the explanation of ARMS-PCR assay and conserved 
primer sequences were given just for information purpose. These will not be mentioned in the chapter 4.
The site-specific primer sequences are given in Tables 2.10 and Table 2.11. The site- 
specific primer pairs used for each PCR reaction are given in Tables 2.12 and 2.13. 
The PCR conditions designed for this assay are given in Table 2.14. The PCR 
conditions used vary depending on the primers used. The PCR reaction format for 
each plasmid is given in Tables 2.15 and 2.16. These PCR reactions were carried out 
on MJ research, DNA engine, Programmable Thermal Cycler 225 (PTC-225) PCR 
machine. Dr. Phil Bums, Dept of Pathology, University of Leeds, Leeds, UK 
designed all the primers sequences and PCR conditions.
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Primer pairs used for mutation assays with control plasmid and genetically 
engineered plasmids, pLS76-2 and pLS76-4 (O -alkylguanine adducts present on 
sense strand)
Type of 
Plasmid Anti-sense Strand Sense Strand
Control AT&S2 AC&S1 AA& S2 AG&S1 SC&A2 ST& A1 SA &A1 SG& A2
Plasmid 2 AT&S2 AC&S1 AA& S2 AG&S1 SC&A2 ST& A1 SA &A1 SG& A2
Plasmid 4 AT&S2 AC&S1 AA&S2 AG&S1 SC&A2 ST & A 1 SA &A1 SG& A2
Table 2.12: Sequence specific primers used fo r  base pairing analysis on plasmid, pLS76 - 2 containing 
methylated adduct and plasmid, pLS76 - 4 containing carboxymethylated adduct on sense strand at 
nucleotide position 587 in codon 196.
Primer pairs used for mutation assays with control plasmid and genetically 
engineered plasmids, pLS76-3 and pLS75-5 (Q6-alkvlguanine adducts present on 
anti-sense strand)
Type of 
plasmid Anti-sense Strand Sense Strand
Control AT&S2 AC&S1 AA& S2 AG&S1 SC&A3 ST & A4 SA&A2 SG& A1
Plasmid 3 AT&S2 AC&S1 AA& S2 AG& SI SC&A3 ST & A4 S A &A2 SG& At
Plasmid 5 AT &S2 AC&S1 AA& S2 AG&S1 SC &A3 ST & A4 SA &A2 SG& A 1
Table 2.13: Sequence specific primers used for base pairing analysis on plasmid, pLS76 - 3 containing 
methylated adduct and plasmid, pLS76 - 5 containing carboxymethylated adduct on anti-sense strand 
at nucleotide position 586 in codon 196.
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Optimal PCR reaction conditions designed for mutation assays with different 
pairs of primers
Temp 1 2 3 4 5 6 7 8
95 9 min 9 min 9 min 9 min 9 min 9 min 9 min 9 min
95 1 min 30 sec 30 sec 30 sec 30 sec 30 sec 30 sec 30 sec
58 30 sec
55 1 min 30 sec 30 sec
59 30 sec
60 30 sec
62 30 sec
56 30 sec
72 1 min 30 sec 30 sec 30 sec 30 sec 30 sec 20 sec 30 sec
Cycles 30 25 30 25 35 25 25 25
55 2 2 2 2 2 2 2 2
72 5 5 5 5 5 5 5 5
Table 2.14: Optimal PCR conditions designed fo r  ARMS-PCR assays for characterisation o f  mutations 
induced by O6-alkylguanine adducts (Os-MedG and 0 6-CMdG).
PCR Reaction format used for AMS-PCR assays for control and adducted 
plasmids, pLS76-2 and pLS76-4
Type of 
Plasmid
Anti-sense strand Sense strand
T c A G c T A G
Control 4 2 7 2 2 2 3 8
Plasmid 2 4 2 7 2 2 2 3 8
Control 2 2 7 2 2 2 3 8
Plasmid 4 2 2 7 2 2 2 3 8
Table 2.15: PCR conditions used for ARMS-PCR assay for determining base pairing at adduct site i.e., 
nucleotide position 587 on sense strand - Control plasmid, 0 6-MedG adduct containing plasmid, 
pLS76 - 2 and O6-CMdG adduct containing plasmid, pLS76 - 4.
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PCR Reaction format used for AMS-PCR assays for control and adducted 
plasmids, PLS76-3 and pLS76-5
Type of 
Plasmid
Anti-sense strand Sense strand
T c A G c T A G
Control 2 2 2 2 2 6 2 2
Plasmid 3 2 2 2 2 2 6 2 2
Control 2 2 2 2 2 6 2 2
Plasmid 5 2 2 2 2 2 6 2 2
Table 2.16: PCR conditions used for ARMS-PCR assay fo r determining base pairing at adduct site i.e., 
nucleotide position 586 on anti-sense strand - Control plasmid, O6-MedG adduct containing plasmid, 
pLS76 - 3 and O6-CMdG adduct containing plasmid, pLS76 - 5.
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2.4 Methods used in the determination of Mutation Spectrum of KDA using 
Human p53 Knock-in (Hupki) Mouse Primary Embryonic Fibroblast Cell 
lines
2.4.1 Synthesis of Potassium Diazoacetate
Ethyl diazoacetate (1.14g, 1.06ml) was stirred in dark with a solution of potassium 
hydroxide (1.14g, 2 mol equivalents) in water (11.4ml) until the mixture becomes 
homogenous (ca. 4h). The resulting solution of KDA (0.9M) was stored at -80°C until 
required when it is thawed and diluted in water to a suitable concentration and used 
without further purification. Attempts to purify the material were known to result in 
extensive decomposition and polymerisation (Kreevoy and Konasewich, 1970). 
Potassium diazoacetate was characterised by research technician Mr Gerhard Erben at 
core facilities, German Cancer Research Centre, Heidelberg, Germany using both 
positive and negative ion mode on ESI Triple Quadrupole; Thermoquest TSQ 7000 
Mass spectrometer.
Reaction: q
-  + ii
N =N =C H —C -O —Et +  KOH
(Ethyl diazoacetate)
LC-MS data of Potassium diazoacetate:
MS (m/z): Positive ion Mode - (M+H+) found at 123.96, (M+K)+ found at 162.8, 
(2M+K)+ found at 286.7 and (3M+K)+found at 410.8. Negative ion Mode - (M-H)" 
found at 84.9, (2M-2H++K+)' found at 208.8, (3M-3H++2K+)'found at 332.7 and (4M- 
4H++3K+)_ found at 456.7.
-  + II _ +
+  N=N=CEP-C—O—K
(Potassium diazoacetate)
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2.4.2 C ytotoxicity Tests o f  K D A  on H upki M ouse Prim ary E m bryonic F ibroblast 
C ell Lines
Two independent cytotoxicity tests were carried out to determine and confirm the 
optimal mutagenic dose of potassium diazoacetate. Primary embryonic fibroblasts 
from Hupki embryos (Trp53tml/Ho11, homozygous for the humanised knock-in p53 
allele harbouring) were distributed at 2xl05 cells/per well into six-well plates and 
grown in DMEM medium supplemented with 10% FCS. Cytotoxicity test 1 consists 
of one control six-well plate and three individual six-well plates treated with KDA 
concentrations of 0.1 pM, lpM and lOpM. Where as, cytotoxicity test 2 comprised 
one control six-well plate and four individual six-well plates treated with KDA 
concentrations of lpmol, 5pmol, lOpmol and 20pmol. Embryonic fibroblast cells 
were plated and allowed to attach overnight. After 24hrs, cells were washed with PBS 
and replaced with DMEM medium containing KDA for 1 hour. Treatment was 
terminated by washing with DMEM medium and replacing with fresh medium. 
Response to KDA was observed by monitoring cell growth. The sensitivity and 
percentage viability of cells was monitored at regular intervals of every 24hrs by cell 
counting on haemocytometer using trypan blue exclusion method.
2.4.3 Cell culture o f  K D A  treated Prim ary Em bryonic F ibroblast C lones o f  
H upki M ouse
Primary embryonic fibroblasts from Hupki mouse were distributed at 2xl05 cells/per 
well into six-well plates and grown in DMEM medium supplemented with 10% FCS. 
Two independent experiments were set up, of which one set of experiment consists of 
8x6-well plates of totally 48 clones incubated with lOpM KDA and the other set 
containing 4x6-well plates of 24 clones incubated with lOOpM of KDA at passage 2
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as described in section 2.4.2. 6x6 well plates were just seeded with 2xl05 untreated 
embryonic fibroblast cells/per well to be used as positive controls. Cultures were 
passaged at ratios ranging from 1:2 - 1:4 dilutions, until mutant selection and clonal 
expansion occurred to form a homogenous mutant clone. The genomic DNA was then 
extracted from the above homogenous clones as mentioned in section 2.4.5 to analyse 
p53 gene mutations.
2.4.4 p53 M utation A nalysis
KDA induced DNA binding domain (DBD) sequence changes in the p53 gene of 
HUPKI mouse embryonic fibroblasts were examined by PCR amplification of p53 
exons 4-9 using primers defined by Affymetrix (Santa Clara, CA) and direct 
fluorescent dideoxynucleotide cycle sequencing (Model 310 Genetic analyser) using 
standard protocols from Applied Biosciences International (Salt Lake City, UT) (Liu 
et al, 2004). DNA sequencing experiments were carried out by research assistant Mr. 
Karl Muelbhar in Dept of Genetic Alterations in Carcinogenesis, German Cancer 
Research Centre, Heidelberg, Germany.
2.4.5 G enom ic D N A  Extraction from  K D A  treated Cells for A dduct analysis
The Hupki mouse primary embryonic fibroblasts were exposed in vitro to lOpM, 
lOOpM, 200pM, 300pM, 400pM and 500pM KDA for 24hrs. DNA was extracted 
from these cells using the following procedure.
1. Cell pellet in FBS medium was transferred to a 1.5 ml microcentrifuge tube and 
spinned for 2 minutes. Supernatant was decanted.
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2. The pellet was resuspended in 500 pi of TE buffer by repeated pipetting. 30pl of 
10% SDS and 3pi of 20mg/ml proteinase K were added to the above solution 
followed by thorough mixing. The reaction mixture was incubated overnight at 37°C 
on a heat block.
3. An equal volume of phenol/chloroform was added and mixed well by inverting the 
tube until the phases were completely mixed, followed by centrifugation for 2 minutes.
CAUTIO N: PH E N O L  CA U SES SE V ER E BU R N S, W E A R  G LO V ES
G O G G L ES, A N D  LA B C O A T A N D  K EEP TU BE S CA PPED T IG H T LY .
4. The upper aqueous phase was transferred to a new tube and an equal volume of 
chloroform reagent was added and centrifuged for 2 minutes. The upper aqueous 
phase was collected and transferred to a new tube.
5. 1/10th volume of sodium acetate was added to the aqueous phase.
6. 0.6ml of isopropanol was added and mixed gently until the DNA was precipitated. 
The supernatant was carefully decanted.
7. DNA was washed with 1 ml of 70% ethanol for 30 sec until the DNA was 
precipitated. The supernatant was carefully decanted. DNA was resuspended in 
100-200 pi of TE buffer.
8. RNase mix (100 pg of RNase A, or 10U of RNaseT) was added to the above 
solution and incubated for 30 min at 37°C.
9. 100 pg of Proteinase K was added to the above solution and incubated for another 
30 minutes at 37°C.
10. Steps 5 - 7  were repeated again.
11. The concentration of DNA was calculated from absorbance readings obtained at 
260nm by diluting 10 pi of DNA into 1 ml of TE (1:100 dilutions).
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3.0 IN T R O D U C TIO N
DNA is a long chain polymer made up of three basic units: bases (guanine, adenine, 
cytosine and thymidine), sugar (2-deoxyribose) and phosphate. DNA can be damaged 
via a variety of agents by modifying these three parts. DNA is highly susceptible to 
the chemicals from internal and external sources due to the presence of multiple 
functional groups such as amine, ketone, double bond and hetero-rings. Synthetic 
chemistry of base-modified DNA has provided powerful tool for studying DNA- 
related subjects like mechanisms of mutations, DNA damage and repair. Base 
modification has an effect on genetic information stored in bases. If these modified 
bases are left unrepaired, they can result in mutations in important genes like p53 
tumour suppressor gene and may give rise to cancer. The recent advances in synthetic 
chemistry of base-modified DNA and automated synthesis of DNA has provided a 
powerful tool for studying DNA related subjects such as mechanisms of mutagenesis, 
DNA damage and repair (Xu, 2002).
Chemical Synthesis of DNA was started in the mid-1950’s 
primarily from Sir Alexander Todd’s lab in Cambridge. In 1960, Khorana and his co­
workers developed phosphodiester chemistry [Figure 3.1]. The major drawback of 
this approach was the difficulty of purifying the desired oligomers after each 
elongation step. This purification was used to be carried out with anion exchange 
chromatography. Later phosphotriester chemistry is introduced which made 
purification less tedious, but still took many days to make a short oligomer [Figure 
3.1]. With the rapid development of molecular biology, the synthetic chemistry of 
DNA had to be further improved. In the mid -1980’s Merrifield’s solid-phase method 
was adapted for DNA and this eliminated the need for purification of intermediates.
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This solid phase approach is coupled with fast reacting phosphoramidites, which 
allowed rapid synthesis of DNA [Figure 3.1]. Automated DNA synthesis with 
phosphoramidite chemistry is the method of choice for routine synthesis of DNA in 
many labs (Xu, 2002).
Cl
O O I
II II (Me)2 R
R.O P OR, RiO-----P-----OR, V . /  \L-jW x V^rv2 rv-j w  I w i \2
O ' o r 3
N OCH2CH2CN 
(Me),
(a) (b) (c)
Figure 3.1: Different types o f phosphorous chemistries used in synthesising DNA monomers:
(a) Phosphodiester, (b) Phosphotriester, (c) Phosphoramidite
There are two major approaches to synthesize base modified nucleosides. One 
approach is to synthesise a modified base, and then to join the base with suitably 
protected deoxyribose moiety via chemical coupling or enzymatic method to produce 
the base modified nucleosides. The other approach is direct modification of a 
naturally occurring nucleoside. Chemical approach provides the possibility to link 
almost any un-natural base or purpose-designed base (e.g.7-deazeadenine) to a 
suitable deoxyribose precursor to form modified nucleoside. The enzymatic method 
involves an enzymatic deoxyribosyl transfer reaction to the modified base. Chemical 
coupling is always problematic. This is because of the instability of the intermediates 
to the conditions of synthetic transformations, incorrect stereo forms of the products 
and multiple protecting groups. Comparatively the enzymatic method provides the 
required isomer (p form) under mild conditions. However, the availability of required 
enzymes and poor solubility of modified nucleosides is another problem. The
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chemical modification can be carried out directly on the existing base of the 
nucleoside. To modify the base of a nucleoside, the hydroxyl groups of the sugar 
moiety must be protected to ensure that the reaction takes place site specifically on the 
base (e.g. 0 6-methylguanine and 0 4-methylthymidine) (Xu, 2002).
The major application of base modified nucleosides is in DNA damage 
studies. DNA is constantly damaged in the cells and modified bases are formed and 
repaired. To understand these cellular processes it is vital to have base-modified DNA. 
A classic example is 0 6-methylguanine. This adducts are formed when methylating 
agents react with DNA. It can base pair with both cytosine and thymine, hence 
causing GC to AT transitions. This adduct was found to be repaired by DNA repair 
protein called 0 6-methylguanine-methyltransferase. This repair involves transferring 
the methyl group from the oxygen at the Opposition of guanine to cysteine on the 
protein. The base modified DNA containing 0 6-methylguanine and O4- 
methylthymidine can be used as substrate for this enzyme to study DNA repair 
process. They can also be used to crosslink with proteins to trap unstable DNA- 
protein complexes. They are also used for NMR structure analysis of DNA structure 
or its interaction with proteins. It is a useful tool in constructing a universal base to 
pair indiscriminately with all four natural bases for mutagenic and recombinant DNA 
experiments (Xu, 2002).
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3.1 R esults
3.1.1 Synthesis o f  5 f-0 -(4 ,4 f-dim ethoxytriphenylm ethyl)-iV  -p h en y lacety l-0  - 
m ethoxycarbonylm ethyl-2'-deoxyguanosine-3’-0-(2-cyanoethyl-A yV - 
diisopropylam ino)-phosphorainidite (com pound 7)
5'-0-(4,4'-dimethoxytriphenylmethyl)-A -phenylacetyl-0 -methoxycarbonylmethyl- 
2'-deoxyguanosine-3'-0-(2-cyanoethyl-7V,A-diisopropylamino)-phosphoramidite 
[compound 7] was synthesised according to reported synthetic route (Xu, 2000) 
[Section 2.2]. The starting material, 2'-deoxyguanosine was purchased from 
Cruachem [Transgenomics, Bioconsumables]. All the chemicals used in this synthesis 
were obtained from either Acros or Fisher Scientific UK Ltd. The exocyclic amino 
group is protected using phenyl acetyl group. The hydroxyl groups of the nucleoside 
were protected with acetyl groups, which is cost cost-efficient. Triethylamine in 
methanol was used for selective removal of the acetyl groups, but not the phenyl 
acetyl group. This synthesis involves facile sulfonylation of the 6-oxygen of the 
guanine. The 0 6-sulfonated derivative is quiet reactive to be displaced by amine and 
then alkoxide ions. The intermediates [Figure 3.2 (compounds 1-6)] obtained during 
the synthesis were characterised using both !H NMR [Appendix 1] and LC-MS
*3 1
[Appendix 2] and the final product (compound 7) was characterised using P NMR.
3.1.2 Synthesis o f  O ligonucleotides containing M odified  bases 0 6-methyl-2*- 
deoxyguanosine and 0 6-carboxym ethyl-2'-deoxyguanosine.
Modified oligonucleotide synthesis was carried out on Expedite™ 8909 series 
instruments DNA synthesizer, later deprotected to remove all protecting groups 
[Section 2.2.2]. All the oligonucleotides were synthesised at a scale of 1 pinole [see
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Table 2.1 in chapter 2]. The yield of the oligonucleotides was estimated from trityl 
yield curves and by measuring OD260 values. Oligonucleotides were initially purified
Structures o f  C om pounds 1-7:
o—I
W 1
32
m
1
N H - P a cN H - P a c D M T -
OCIiCOOCIJ
NH-PAc
DMT-O
7
N H - P a c
Figure 3.2: Structures of compounds 1-7. compound(l): 3',5 -diacetyl-2’-deoxyguanosine, 
compound(2): 3\5 ’-diacetyl-N2-phenylacetyI-2-deoxyguanosine, compound(3): 3 ',5'-diacetyl-N2-
phenylacetyl-06-mesitylenesulphonyl-2 -deoxyguanosine, compound(4): 3,,5,-diacetyl-N2-phenylacetyl- 
0 6-methoxycarbonylmethyl-2 -deoxyguanosine, compound(5): N2-phenylacetyl-06-
methoxycarbonylmethyl-2-deoxyguanosine, compound (6): 5'-O'-(4,4 ’-dimeth oxytriph enyl)-N2-
phenylacetyl-(f-methoxycarbonylmethyl-2'-deoxyguamsinef compound (7): 5'-0'-(4,4'-
dimethoxytriphenyl)-N2-phenylacetyl-06-methoxycarbonylmethyl-2'-deoxyguanosine-3'-0-(2- 
cyanoethyl-N,N-diisopropylamino)-phosphoramidite.
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on NENSORB™ PREP nucleic acid purification columns [Section 2.2.3] followed by 
further purification on FPLC using Dionex BIOLC system equipped with a DIONEX 
variable wavelength detector using Pharmacia MonoQ HR 5/5 column equipped with 
UV detector [Section 2.2.4]. Finally, oligonucleotides were desalted on Sep-pak® 
C l8 cartridges [Section 2.2.5].
3.1.3 Pentam er A nalysis
The charge and size differences between site-specifically modified and normal 
sequences become insignificant as the size of the oligonucleotide increases. This will 
pose a problem especially when it is required to characterise a site-specifically base 
modified sequence present in a mixture of normal sequences of the same size. 
However, it is relatively easy to characterise a site-specifically modified short 
sequence such as pentamer from other normal pentamers. The standard pentamer 
AGGCT and modified pentamers AGXCT (X = 0 6-MedG adduct) and AGYCT (Y = 
0 6-CMdG adduct) were synthesised to demonstrate that 0 6-alkylguanine adducts 
were successfully incorporated site-specifically in to oligonucleotides by nucleoside 
composition analysis. These results can be applied to all other sequences used in this 
project. All the pentamers have four standard bases A, G, C and T except with 
pentamers AGXCT and AGYCT, which have an additional modified base. The 
presence of this modified base creates a charge and size difference when compared 
with standard pentamer. This charge difference was exploited to prove that all the 
three pentamers are different. Anion exchange chromatography is good at separating 
individual pentamers based on charge difference. This analysis was carried out on 
Dionex BIOLC system equipped with DIONEX variable wavelength detector 
wavelength detector using Mono Q HR 5/5 column [Section 2.2.6].The gradient is
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given in Table 2.3. The retention times for all the three pentamers were established 
and then co-injected to demonstrate that all the three pentamers were different. 
Retention time of pentamer AGGCT is 19.0 minutes [Figure 3.3(a)], AGYCT is 18.0 
minutes [Figure 3.3(b)] and AGXCT is 15 minutes [Figure 3.3(c)]. The separation of 
0 6-CMdG containing pentamer from the one containing 0 6-MedG pentamer could be 
ascribed to the fact that former has an extra charge from the carboxylate anion [Figure 
3.3(d)]. At pH 12, the pentamer containing 0 6-CMdG has the same number of charges 
as its parent oligomer containing guanine. However, the later elution of the parent 
oligomer may be due to its relatively high hydrophobicity compared to <96-CMdG 
containing pentamer [Figure 3.3(d)]. Thus, pentamer analysis results indirectly 
confirms that the sequences used in this project were site specifically modified with 
0 6-alkylguanine adducts. These results were further supported by the results obtained 
from the nucleoside composition analysis [Section 3.1.4].
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Pentamer Analysis
AU
AU
AU
AU
Minutes
Figure 3.3: Pentamer analysis was done on DIONEX BIOLC system using Pharmacia MonoQ HR 5/5 
FPLC column. Fig 3.3(a) FPLC trace o f standard pentamer AGGCT (R,-19.0 min), Fig 3.3(b) FPLC  
trace o f pentamer AGYCT (R,-18.0 min), Fig 3.3(c) FPLC trace o f  pentamer AGXCT(Rt-15.0 min). Fig 
3.3(d) FPLC trace o f  co-injection o f  three pentamers.
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3.1.4 Nucleoside Composition Analysis
Pentamers (1 OD) AGGCT, AGXCT and AGYCT were digested by incubation with 
nuclease PI in a solution of pH 4.5 at 37° C and then with alkaline phosphatase in a 
solution of pH-8.0 for 2hrs at 37° C [Section 2.2.8]. These reactions were followed on 
Reverse Phase HPLC using Atlantis (5pm, 4.5x25mm) Cib column on Waters™ 616 
pump equipped with Waters™ 996 Photodiode Array detector. 0.01M KH2PO4 buffer 
(pH-6.52)/acetonitrile was used as a mobile phase, monitoring at 260nm at a flow rate 
of lml/min [Table 2.5]. HPLC analysis of standard pentamer AGGCT on digestion 
with nuclease PI and alkaline phosphatase gave four peaks that correspond to 
standard bases 2'-deoxycytidine (Rt - 9.0 min), 2-deoxyguanosine (Rt - 13.0 min), 2'- 
deoxythymidine (Rt -14.0 min) and 2'-deoxyadenine (Rt - 16.0 min) [Figure 3.4(a)]. 
However, with the modified pentamers AGXCT and AGYCT, an additional peak was 
observed apart from the peaks that correspond to standard bases. This additional peak, 
(X) was observed at Rr  18.0 min with pentamer AGXCT [Figure 3.4(b)], where as 
this extra peak (Y) was observed at Rt- 12.0 min with the pentamer AGYCT [Figure 
3.4(c)]. The UV profile of peak X and peak Y were quite similar in shape but, 
different from normal bases. This kind of UV spectrum is typical for O6- substituted 
compounds. Both the peaks i.e., X and Y exhibit Xmax at 247 and 280nm. The UV data 
and Rt of the peaks X and Y confirms the presence of modified bases X (0 6-methyl- 
2-deoxyguanosine) and Y (0 6-carboxymethyl-2'-deoxyguanosine) in the pentamers. 
The fluorescence studies provide an additional piece of evidence for the presence of 
modified bases [Section 3.1.6].
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Figure 3.4: Nucleoside Composition Analysis:
C- 9.578 
G-13.973 
T-14.798 
A-16.841
0 .20 -
0.20  -
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Figure 3.4(a): HPLC and UV profiles o f  nucleoside composition analysis on pentamer AGGCT.
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Figure 3.4(b): HPLC and UV profiles o f  nucleoside composition analysis on pentamer AGXCT (X =
O -methyl-2 ’-deoxyguanosine).
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Figure 3.4(c): HPLC and UV profiles o f  nucleoside composition analysis on pentamer AGYCT (Y —
O6-carhoxymethyl-2'-deoxyguanosine).
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3.1.5 HPLC analysis of purity of mutation assay sequences numbered 10-15.
The sequences numbered 10-15 [Table 3.1] were the sequences that were used for 
adduct specific mutation assays to study the types of specific mutations induced by 
modified bases. These complementary sequences comprise the region of p53 cDNA 
from codons 190-202 with restriction enzymes BbvC 1 and Apol overhanging ends. 
The sequences i.e., all 25mers and 26mers have same structure on both 5’-end and 3’- 
ends of modified base sequences. The important prerequisite for mutation assays is to 
have pure sequences. Impurities could seriously affect the outcome of the mutation 
assay results, especially if the impurity was more efficient at inducing mutations. 
Initially, the premise behind this HPLC analysis is to both characterize the 25 and 
26mers to verify the presence of 0 6-alkylated guanine derivatives just like pentamer 
analysis and to determine the purity of sequences. However, these sequences are 
much longer and have similar length, which makes the differences of size and charge 
between individual oligonucleotides insufficiently different to characterise the 
individual oligonucleotide by observing difference in retention times on C l8 columns. 
Even though standard 25mer and 26mer show differences in retention times with their 
corresponding 25 and 26mer containing 0 6-MedG adduct, the same difference can not 
be demonstrated on HPLC with the 25 and 26mer containing 0 6-CMdG adduct as 
observed with pentamer analysis on FPLC. This is because standard 25mer and 26mer 
were having same charge as their corresponding 25 and 26mer containing 0 6-CMdG 
adduct. Hence, this analysis of longer sequences i.e., 25 and 26mers is just limited to 
determination of purity of sequences. The HPLC analysis of oligonucleotides was 
carried out on xTerra R MS Cis column (2.5pm, 4.6x50mm) using 0.1M TEAA buffer 
(pH-7.0)/acetonitrile [Section 2.2.7 and Table 2.4]. Standard 25 and 26mer have 
retention times 10 and 11 minutes [Figure 3.5(a) and 3.5(b)]. 25 and 26mer containing
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0 6-MedG adducts have retention time’s 12 and 13 minutes [Figure 3.5(c) and 3.5(d)]. 
Finally 25 and 26mer containing 0 6-CMdG adducts have retention times 11 and 12 
minutes [Figure 3.5(e) and 3.5(f)]. All the oliognucleotides were found to be pure and 
devoid of any impurities from the HPLC traces.
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Figure 3.5: HPLC Analysis on Mutation assay sequences (10 -15) for Purity:
AU
8 10 12 1420 4 6
Minutes
AU
o 2 64 8 10 12 14
Minutes
AU
10 12 140 42 6 8
AU
0 2 4 106 8 12 14
Minutes
(c)
Minutes
(d)
AU
0 2 4 8 10 12 146
AU
0 10 122 4 6 8 14
Minutes Minutes
(e) (f)
Figure 3.5: HPLC profiles o f  mutation assay oligonucleotides sequences numbered 10-15. Sequences 
were purified preperatively on FPLC using Dionex BIOLC system equipped with DIONEX variable 
wavelength detector. Sequences were analysed on j f  ena® C\$HPLC co lum n with specification 2.5pm
6 650 x 4.6mm. Traces a, c and e correspond to sequences 10, 12, 14 (25mers with G, O -MedG and O - 
CMdG). Traces b, d and f  correspond to sequences 11, 13, 15 (26mers with G, O^-MedG and ( f -  
CMdG).
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3.1.6 Fluorescence Assays
Modified pentamers are very short and simple sequences in which a single modified 
base is present, apart from four normal bases. Hence, it is quiet easy to detect signal 
from modified base from enzymatically digested pentamer sequence on HPLC. In the 
case of modified oligonucleotides, which are quite long (12, 25 and 26mers), it is 
comparatively difficult to detect signal from single modified base. This is because the 
signal from single modified base is overshadowed by signals from normal bases that 
are present in large amounts. The oligonucleotides synthesised in this work contains 
0 6-substituted alkylguanines. It was reported previously that 0 6-alkylguanines are 
somewhat more fluorescent than the corresponding deoxynucleosides (Gaffney and 
Jones, 1982). This provides an advantage by allowing the detection of fluorescence 
signal from single modified base that is present in longer oligonucleotides (12, 25 and 
26mers). Melting temperature analysis sequences (sequences numbered from 6-9) and 
mutation assay sequences (sequences numbered from 12-15) [Table 3.1] were 
digested with nuclease PI (pH-4.5) and alkaline phosphatase (pH-8.0) [Section 2.2.9]. 
The digested samples were analysed on Reverse Phase HPLC using Syngery 4p, 
Hydro-RP 80A (150 x 2.00mm) column on Waters™ 2690 Separations Module 
equipped with Waters™ 996 Photodiode Array detector and Waters™ 474 scanning 
florescence detector. 0.01M KH2PO4 buffer (pH-6.52)/acetonitrile was used as a 
mobile phase, monitoring at excitation wavelength 286nm and emission at 378nm at a 
rate of 0.25ml/min [Table 2.6].
3.1.6.1 Fluorescence Analysis on Sequences numbered 6-9
Sequences numbered from 6-9 were synthesised for melting curve (Tm) analysis.
/•
Sequences 6 and 7 contain O -methyl-2-deoxyguanosine at position X, where as
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sequences 7 and 9 contain 0 6- carboxymethyl-2'-deoxyguanosine at position Y. O6- 
MedG standard monitored using both fluorescence scanning and photodiode array 
detector was observed to have Rt -15.0 minutes [Figure 3.6(a) and 3.7(a)]. 0 6-MedG 
adduct from the enzymatically digested samples of sequences 6 and 7 were observed 
to have retention times of 14.932 min [Figure 3.6(b)] and 14.850 min [Figure 3.7(b)] 
when monitored using fluorescence detector. The UV data was observed to be similar 
with standard 0 6-MedG with Xmax at 247 and 280. This data confirms the presence of 
0 6-MedG in sequences 6 and 7. An additional piece of evidence, which confirms the 
presence of 0 6-MedG, comes from co-injection of standard 0 6-MedG with digested 
samples. Both the enzymatically digested sequences 6 and 7 on co-injection with 
standard 0 6-MedG adduct gave single peak which were observed to have retention 
times at 14.938 min and 14.932 min [Figure 3.6(c) and Figure 3.7(c)]. 0 6-CMdG 
standard monitored using both fluorescence and photodiode array detector was 
observed to have Rt -  2.692 minutes [Figure 3.8(a) and Figure 3.9(a)]. 0 6-CMdG 
adducts from the enzymatically digested samples of sequences 8 and 9 were observed 
to have retention times of 3.161 min [Figure 3.8(b)] and 3.194 min [Figure 3.9(b)] 
when monitored using fluorescence detector. The UV data was observed to be similar 
with standard Oe-CMdG with A,max at 247 and 280. This data confirms the presence of 
0 6-CMdG in sequences 8 and 9. An additional piece of evidence, which confirms the 
presence of 0 6-CMdG comes from co-injection of standard <96-CMdG adduct with 
enzymatically digested samples. Both the sequences 8 and 9 on co-injection with 
standard 0 6-CMdG adduct gave single peak which were observed to have retention 
times at 3.023mins [Figure 3.8(c)] and 3.194 min [Figure 3.9(c)].
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Fluorescence Assay on melting curve (tm) sequence 6 for detection of O -MedG 
adduct
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Figure 3.6: Fluorescence assay on self-complementaty melting curve sequence(t„J no-6 containing O6 - 
MedG adduct. Fig 3.6(a) Fluorescent absorbance profile o f  standard 0 (’-MedG adduct showing XmcLX at 
247 and 280nm. Fig 3.6(b) Fluorescent absorbance profile o f nuclease PI digested, melting curve 
sequence ( t j  no-6 containing O6-MedG adduct. Fig 3.6(c) Fluorescent absorbance profile o f  co­
injected standard O6-MedG adduct and nuclease Pldigested, melting curve sequence (tni) no-6 
containing O -MedG adduct.
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Fluorescence Assay on melting curve (tm) sequence no 7 for detection of O 
MedG adduct
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Figure 3.7: Fluorescence assay on self-complementaiy melting curve sequence(t„) no-7 containing ( t -  
MedG adduct. Fig 3.7(a) Fluorescent absorbance profile o f  standard 0 6-MedG adduct showing Amax at 
247 and 280nm. Fig 3.7(b) Fluorescent absorbance profile o f nuclease PI digested, melting curve 
sequence (tm) no-7 containing 0 6-MedG adduct. Fig 3.7(c) Fluorescent absorbance profile o f  co­
injected standard O6 -MedG adduct and nuclease PI digested, melting curve sequence ( t j  no-7 
containing O6-MedG adduct.
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Fluorescence Assay on melting curve (tm) sequence no 8 for detection of O 
CMdG adduct
Fluorescence
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Figure 3.8: Fluorescence assay on self-complementary melting curve sequence(t,J no-8 containing O6- 
CMdG adduct. Fig 3.8(a) Fluorescent absorbance profile o f standard Cf -CMdG adduct showing Xmax 
at 247 and 280nm. Fig 3.8(b) Fluorescent absorbance profile o f nuclease PI digested, melting curve 
sequence (t„) no-8 containing O6-CMdG adduct. Fig 3.8(c) Fluorescent absorbance profile o f  co­
injected standard O6-CMdG adduct and nuclease Pldigested, melting curve sequence (t„) no-8 
containing O6-CMdG adduct.
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Fluorescence Assay on melting curve (tm) sequence no 9 for detection of O - 
CMdG adduct
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Figure 3.9: Fluorescence assay on self-complementary melting curve sequence(tm) no-9 containing O6- 
CMdG adduct. Fig 3.9(a) Fluorescent absorbance profile o f  standard 0 6-CMdG adduct showing 
at 247 and 280nm. Fig 3.9(b) Fluorescent absorbance profile o f nuclease PI digested, melting curve 
sequence ( t j  no-9 containing 0 (,-CMdG adduct. Fig 3.9(c) Fluorescent absorbance profile o f  co­
injected standard O6-CMdG adduct and nuclease Pldigested melting curve sequence (t„J no-9 
containing 0 6-CMdG adduct.
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3.1.6.2 Fluorescence Analysis on Mutation assay Sequences numbered 12-15
Sequences numbered from 12-15 are synthesised for mutation assays. Sequences 12 
and 13 contain 0 6-methyl-2'-deoxyguanosine at position X, where as sequences 14 
and 15 contain O6- carboxymethyl-2'-deoxyguanosine at position Y. 0 6-MedG 
standard monitored using both fluorescence scanning and photodiode array detector 
was observed to have Rt -  19.569 minutes [Figure 3.10(a) and Figure 3.11(a)]. O6- 
MedG adduct from the digested samples of sequences 12 and 13 were observed to 
have retention times of 19.155 min [Figure 3.10(b)] and 19.082 min [Figure 3.11(b)] 
when monitored using fluorescence detector. The UV data was observed to be similar 
with standard <96-MedG with ^max at 247 and 280. This data confirms the presence of 
0 6-MedG in sequences 12 and 13. An additional piece of evidence, which confirms 
the presence of 0 6-MedG, comes from co-injection of standard 0 6-MedG with 
digested samples. Both the sequences 12 and 13 on co-injection with standard O6- 
MedG adduct gave single peak which were observed to have retention times at 19.913 
min and 19.100 min [Figure 3.10(c) and Figure 3.11(c)]. 0 6-CMdG standard 
monitored using both fluorescence and photodiode array detector was observed to 
have Rt -  2.692 minutes [Figure 3.12(a) and Figure 3.13(a)]. 0 6-CMdG adducts from 
the digested samples of sequences 14 and 15 were observed to have retention times of 
3.161 min [Figure 3.12(b)] and 3.194 min [Figure 3.13(b)] when monitored using 
fluorescence detector. The UV data was observed to be similar with standard O6- 
CMdG with A,max at 247 and 280. This data confirms the presence of <96-CMdG in 
sequences 14 and 15. An additional piece of evidence, which confirms the presence of 
<96-CMdG comes from co-injection of standard 0 6-CMdG with digested samples. 
Both the sequences 14 and 15 on co-injection with standard 0 6-CMdG gave single
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peak which were observed to have retention times at 3.023 min [Figure 3.12(c) and 
3.194 min [Figure 3.13(c)].
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Fluorescence Assay on mutation assay sequence no 12 for detection of O -MedG 
adduct
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Figure 3.10: Fluorescence assay on Mutation assay sequence no-12 containing Cf -MedG adduct. Fig 
3.10(a) Fluorescent absorbance profde o f standard O6-MedG adduct showing XmtLX at 247 and 280nm. 
Fig 3.10(b) Fluorescent absorbance profile o f  nuclease PI digested, mutation assay sequence no-12 
containing 0 6-MedG adduct. Fig 3.10(c) Fluorescent absorbance profile o f co-injected standard O6- 
MedG adduct and nuclease PI digested, mutation assay sequence no-12 containing 0 6-MedG adduct.
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Fluorescence Assay on mutation assay sequence no 13 for detection of O -MedG 
adduct
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Figure 3.11: Fluorescence assay on Mutation assay sequence no-13 containing (f-M edG  adduct. Fig 
3.11(a) Fluorescent absorbance profde o f standard 0 6-MedG adduct showing A.mux at 247 and 280nm. 
Fig 3.11(b) Fluorescent absorbance profile o f  nuclease PI digested, mutation assay sequence no-13 
containing 0 6-MedG adduct. Fig 3.11(c) Fluorescent absorbance profile o f co-injected standard O6- 
MedG adduct and nuclease Pldigested, mutation assay sequence no-13 containing Q6-MedG adduct.
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Fluorescence Assay on mutation assay sequence no 14 for detection of 0 6-CMdG 
adduct
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Figure 3.12: Fluorescence assay on Mutation assay sequence no-14 containing 0 6-CMdG adduct. Fig 
3.12(a) Fluorescent absorbance profile o f  standard O6 -CMdG adduct showing 2muxat 247 and 280nm. 
Fig 3.12(b) Fluorescent absorbance profde o f nuclease PI digested, mutation assay sequence no-14 
containing O6-CMdG adduct. Fig 3.12(c) Fluorescent absorbance profile o f co-injected standard O - 
CMdG adduct and nuclease Pldigested, mutation assay sequence no-14 containing O6-CMdG adduct.
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Fluorescence Assay on mutation assay sequence no 15 for detection of O -CMdG 
adduct
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Figure 3.13: Fluorescence assay on Mutation assay sequence no-15 containing 0 6-CMdG adduct. Fig 
3.13(a) Fluorescent absorbance profile o f standard O6-CMdG adduct showing Xmax at 247 and 280nm. 
Fig 3.13(b) Fluorescent absorbance profile o f nuclease PI digested, mutation assay sequence no-15 
containing O6-CMdG adduct. Fig 3.13(c) Fluorescent absorbance profile o f co-injected standard (/'- 
CMdG adduct and nuclease PI digested, mutation assay sequence no-15 containing 0 6-CMdG adduct.
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3.1.7 Melting curve measurements of modified DNA sequences numbered 4-9
DNA melting curves were obtained by measuring the changes in absorption at 260nm 
with increasing temperatures. All the melting curves were measured in a solution of 
0.1M Hepes, 0.01M NaCl and 0.02MgCl2 at pH-7 [Section 2.2.10]. The temperature 
is increased at the rate of 1° C/min. The melting curves obtained were not ideal s- 
shaped curves. Hence, the exact melting temperatures were not determined. 
However, UV absorbance changes plotted against different temperature points and 
first derivative melting curves have given some insights of stability of different O6- 
alkylguanine base pairs [see table 3.1]. Derivative curve of self complementary 
sequence 4, indicated that the denaturation of self complementary sequence 4 
containing G:T base pair starts around 25° C and have maximum absorbance around 
45° C and remain stable there after over a range of temperatures. The possible 
explanation for this unusual pattern might be due to the problems occurred during 
reannealing to form hairpin structure by self-complementary sequence 4 containing 
mismatch base pair G:T [Figure 3.15(a)]. Sequence 5 containing G:C base pair, starts 
denaturising around 50° C and have maximum absorbance around 70 ° C. [Figure 
3.15(a)]. These temperatures relating to the starting point of denaturation exactly 
corresponds to the temperatures at which increasing in absorbance (inflection points) 
were observed. Taken together the data of derivative curves and the melting curve 
(Tm) profiles of self complementary sequences 4 [Figure 3.14(a)] and 5 [Figure 
3.14(b)] it is clear that sequence 4 containing mismatch base pair G:T is causing 
strong destabilising effect on hairpin structure than sequence 5 containing G:C base 
pair. The results obtained from melting curve measurements of self-complementary 
sequences 6 and 7 in which 0 6-MedG is incorporated to form 0 6-MedG:T base pair 
[Figure 3.14(c)] and 0 6-MedG:C base pair [Figure 3.14(d)] have confirmed the
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Fig 3.14: Melting temperature (Tm) measurements o f modified DNA sequences. Traces (a) and (b) 
Melting curves o f  G:T (sequence 4) & G:C (sequence 5). Traces (c) and (d) Melting curves o f  O6- 
MedG:T (sequence 6) and O6-MedG:C (sequence 7). Traces (e) and (f) Melting curves o f 0 6-CMdG:T 
(sequence 8) and O -CMdG.C (sequence 9).
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Comparison of derivative Tm curve changes 
between G:T and G:C base pairs
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Figure 13.5: Derivative curves o f melting Tm profiles obtained for 0 6-alkylgyanuine adducts. Fig 
13.5(a) derivative o f  melting curves o f  sequence 4 and 5. Fig 13.5(b) derivative o f melting curves o f  
sequence 6 and 7. Fig 13.5(c) derivative o f  melting curves o f  sequence 8 and 9.
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Table 3.1 Melting (Tm) Temperature data of self-complementary sequences 
containing 0 6-alkvlguanme adduets:
Base Pair
Tm(° C)at which 
denaturisation 
starts
Tm (° C) 
(App. Values)
G:T 25 45
G:C 50 70
0 6-MedG:T 50 7 0 -8 0
0 6-MedG:C 35 60
0 6-CMdG:T 75 n.d.
0 6-CMdG:C 65 n.d.
Table 3.1: Melting (Tm) temperatures at inflection (starting point of denaturation) points o f normal 
12mer self complementary sequences and modified self complementary sequences containing O6- 
methyl-2'-deoxyguanosine and 0 6-carboxymethyl-2'-deoxyguanosine adduets. n.d. denotes not 
determined.
results obtained previously by Li (Li and Swann, 1989). The observed increase in 
absorbance (inflection point) plotted against melting temperature (Tm) has confirmed 
that 0 6-MedG:T base pair is much more stable, inducing an increase in melting 
temperature than 0 6-MedG:C base pair [Figure 3.15(b)]. The derivative curve 
obtained for the melting temperature profile of the sequence 6 indicated that 
denaturation of 0 6-MedG:T base pair starts around 50° C and have maximum 
absorbance around 70 - 80° C. The denaturation of 0 6-MedG:C base pair started 
around 35° C, which can be observed as increase in the absorbance on derivative 
curve and have maximum absorbance around 60° C. These results are suggesting that
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0 6-MedG adduct predominantly base pairs with T rather than C. The results with 
sequences containing 0 6-CMdG are not very conclusive. The melting curves obtained 
from self-complementary sequence 8 containing 0 6-CMdG:T base pair [Figure 
3.14(e)] and sequence 9 containing 0 6-CMdG:C base pair [Figure 3.14(f)] suggested 
that the sequences containing 0 6-CMdG adduct require temperatures higher than 80° 
C, for melting. Since the maximum temperature used to monitor melting curve is 80° 
C, it is difficult to extract the exact melting temperature of the above base pairs. 
Nevertheless, from the temperatures at which raise in absorption (inflection point) 
was observed on the melting (Tm) curves, it appears that 0 6-CMdG:T base pair is 
more stable, than 0 6-CMdG:C base pair. These observations are further supported by 
data obtained from derivative curve of the melting profiles of O -CMdG:T and O - 
CMdG:C base pairs [Figure 3.15(c)]. The derivative curve of melting profile obtained 
for CMdG:T base pair clearly indicates that the sequence containing this base pair 
starts denaturising after 75°C, whereas sequence containing CMdG:C base pair starts 
denaturising around 65°C. These results, suggests that 0 6-CMdG might preferentially 
base pair with T. However, the exact temperatures at which they were having 
maximum UV absorption is not possible to detect from this derivative curves.
144
Chapter 3: Synthesis and Characterisation of 0 6-alkylguanine adduct containing Oligonucleotides
3.2 Discussion
Many studies from the laboratory of Miller showed that carcinogenic activity of most 
chemicals dependent upon their ability to act as electrophiles (Miller, 1978). It was 
found that some carcinogens are inherently eletrophilic, whereas others spontaneously 
hydrolyse to active species in solution or are activated by cellular enzymes. The 
resultant reactive intermediates modify the constituents of DNA, RNA, and protein, 
forming covalent adduets in which the carcinogen residue is joined to nucleophilic 
atoms of the constituent nucleotides or amino acids. Although all damaged 
macromolecules can potentially compromise cellular welfare, adduets within DNA 
have special significance in view of their potential to force replication or repair errors 
and thus be the chemical progenitors of heritable genetic alterations. It would be 
interesting to (1) Assess the impact of adduct on local DNA structure and chemistry. 
(2) Determine the contribution of adduct to the spectrum of mutations induced by 
chemical or radiation treatment (3) Assess the ability of DNA adduct to act as a 
cytotoxic lesion. (4) Ascertain the identities of the repair proteins responsible for 
protecting cells from specific forms of damage (Basu and Essigmann, 1988). Recent 
advances in the field of nucleic acid chemistry and molecular biology has made it 
possible to explore the contributory role of DNA adduets to the biological end-points, 
especially in the progression of cancer disease. Candidate adduct for the above- 
mentioned studies are identified by using information from three areas. First is the 
examination of the structure of adduets formed in vivo treatment with a DNA 
damaging agent that herald a likely change in the Watson-Crick base-pairing. 
Secondly, examination of spectrum of mutations within a target gene treated with a 
DNA damaging agent can implicate the base-pairs and DNA sequence contexts that 
are more prone to mutations. These data in turn provide clues to the identities of the
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pre-mutagenic lesions. Finally, facile methods are available in which adduct inserted 
DNA and RNA templates are used for primer extension assays to determine the type 
and amount of base mis-incorporation, or termination of chain elongation, can be 
assessed (Basu and Essigmann, 1988).
X
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Primer Extension
f ---------------
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Figure 3.16: Applications ofSite-specifically modified Oligonucleotides (Basu and Essigmann (1988).
There is a great and increasing interest in the synthesis of oligonucleotides containing 
carcinogen-modified bases, in particular in those containing O6-alkylguanine because 
this base is believed to play the important role in the carcinogenic action of N-nitroso 
compounds. Some of the applications of these sites-specifically modified 
oligonucleotides are DNA repair, 2D NMR studies, cross-linking and mutagenesis 
studies [Figure 3.15]. It was found that simple nitrosated bile acid conjugate N-
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nitrosoglycocholic acid reacts with DNA to from 0 6-CMdG and 0 6-MedG adduets. 
The latter has already been established as a toxic, pro-mutagenic lesion and is repaired 
by DNA repair protein, O6- alkylguanine-DNA-alkyltransferase (ATase). It was also 
reported that 0 6-CMdG was not repaired when incubated with the same enzyme. This 
is further confirmed by observation that concomitant methylation and 
carboxymethylation is the general property of A-nitrosoglycine derivatives such as N- 
(A'-acetyl-L-prolyl)-iV-nitrosoglycine (APNG) azaserine and diazoacetic acid 
derivative, potassium diazoacetate (KDA). Information from random mutagenesis 
studies, using p53 yeast expression assays on KDA, a carcinogen of our particular 
interest predominantly formed O6- CMdG adduct, which was found to induce mainly 
GC -  AT transitions and some GC -  TA transversion mutations in p53 gene 
(Gottschalg et al., 2006). The preliminary information obtained from the above 
biochemical studies has suggested that 0 6-CMdG is an ideal candidate adduct for 
further investigation on its mutagenic properties. The first step towards the evaluating 
the genetic and structural effects of an adduct involves its synthesis as part of an 
oligonucleotide. Generally, three types of synthetic routes are currently available. The 
first one is total synthesis. This method involves preparation of a protected monomer 
of the adduct deoxynucleoside [phosphotriester or phosphoramidite] followed by 
solution or solid phase synthesis of the oligomer by a DNA synthesis protocol. The 
second method is modification of a preformed oligonucleotide. This involves 
treatment of an unmodified oligonucleotide with a chemical carcinogen or its 
activated derivative or with radiation, followed by purification of the desired adducted 
oligomer. The third method is enzymatic synthesis. DNA polymerase and 
bacteriophage T4 RNA ligase have been used to build site-specifically modified 
oligonucleotides biochemically (Basu and Essigmann, 1987). In our studies, total
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synthesis was the method chosen for synthesising oligomer containing <96-CMdG 
adduct. The key advantages of this method were high yields, Precise adduct 
placement in the oligonucleotide chain, and, often better control over final purity than 
other methods. Fortunately, methods have already been established for <96-CMdG 
adduct to stand against the harsh conditions of synthesis and deprotection, which is a 
major disadvantage of total synthesis. Traditionally 0 6-subsituted base-modified 
guanines were synthesised either by reaction with diazoalkanes (Friedman et al., 
1965) or via the 6-chloro derivative of 2'-deoxyguanosine (Mehta and Ludlum, 1978). 
The former reaction is cumbersome in that it generates a mixture of alkylated 
products and hence rigorous chromatographic purification is necessary to obtain the 
desired product. Although preferable to the diazoalkane approach, the chlorination of 
the 2-deoxynucleoside can result in extensive depurination. Later, a more convenient 
route of synthesis involving the facile sulfonylation of the 6-oxygen of the guanine 
was designed by Gaffney and Jones (Gaffney and Jones, 1982). The 0 6-sulfonated 
derivative is quiet reactive to be displaced by amine and then alkoxide ions. O6- 
CMdG monomer (phosphoramidite) synthesis is primarily based on the preparation of 
0 6-arylsulfonate derivative i.e., 0 6-methoxycarbonylmethyl-2'-deoxyguanosine. The 
acetyl groups, probably more cost-efficient are used instead of methoxyacetyl groups 
previously used for the protection of 3'-OH and 5-OH groups of the nucleosides 
(Harrison et al., 1997). In the conventional synthesis of DNA, an isobutyryl group is 
generally used for the protection of exocyclic amino group of guanine. However, it
9 6has been documented that acyl groups at N  - position of O -substituted guanines are 
much more resistant to removal by ammonia than those at 0 6-unmodified guanine. 
Therefore, base-labile group such as phenylacetyl group have been chosen to protect 
exocyclic N  -position of guanine. This will allow selective removal of acetyl groups
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at 3' and 5'-OH position with out removing phenyacetyl group at N2-position of 
guanine. The 3',5'-diacetyl-N2-phenylacetyl-2'-deoxyguanosine was first converted in 
to 3',5'-diacetyl-N2-phenylacetyl-6-mesitylenesulphonyl-2'-deoxyguanosine. This was 
converted in to quinuclidinium salt, which in turn was replaced by methylglycolate. 
The acetyl groups protecting the hydroxyl groups of the sugar can be selectively 
removed by triethylamine in methanol. This treatment did not remove the 
phenylacetyl group protecting the N2-amino group of the guanine. This procedure is 
preferred over the alternative deprotection using aqueous NaOH because it is less 
specific and there is always a high risk of losing N2-phenylacetyl protecting group. 
Finally, the 3',5'-diacetyl-N2-phenylcaetyl-06-methoxycarbonylmethyl-2'- 
deoxyguanosine was converted to a monomer by protecting the 5'-OH group with 
DMT-C1 and 3'-OH group with 2-cyanoethyl-iV,iV-diisopropylchlorophosphoramidite. 
The characterisation of intermediates using ^-NM R, LC-MS confirmed the presence 
of phenylacetyl group at exocyclic amino position of guanine base, 
methoxycarbonylmethyl modification at Opposition of guanine, DMT modification at
5'-OH position of sugar molecule and the characterisation of final compound, O6-
-2 1
CMdG monomer using P NMR confirmed the presence of 2-cyanoethyl-7V,./V- 
diispropylphosphoramidite groups. The NMR and LC-MS data was compared with 
published data confirmed that product obtained was 0 6-CMdG monomer. All the 
oligonucleotides that were used in this study are synthesised on an automated DNA 
synthesiser, Expedite™ 8908 instruments at 1pm scale. The modified 
oligonucleotides were synthesised using PUSH and PULL method. This method 
involves interruption of automated DNA synthesis at adducted site and addition of 
modified DNA adduets on to support manually. The modified adduct in activator 
solution was added on to DNA chain by gently pushing and pulling adduct containing
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solution in the syringe connected to the DNA synthesising support. The modified 
oligonucleotides containing 0 6-MedG adduct were synthesised using commercial O6- 
MedG phophoramidite. The next step is the deprotection of oligonucleotides. This 
involves removal of all protecting groups on the sugar molecule as well as on 
individual bases to obtain normal DNA sequence. Final deprotection of normal 
oligonucleotides was done by treating with ammonium hydroxide solution overnight 
at room temperature followed by incubation at 55° C for 2 hrs. A disadvantage of the
deprotection of oligonucleotides containing 0 6-MedG by ammonia is that it stabilises
2 6 6 the exocyclic amino protecting N  -isobutyryl group of O -MedG. Hence, O - alkyl
groups are more prone to displacement by ammonia leading to the production of 
oligomers containing 2,6-diaminopurine. Modified oligonucleotides containing O6- 
MedG adduets were deprotected by treating with 10% DBU in methanol solution and 
left in the dark for 5 days. Finally modified oligonucleotides containing 0 6-CMdG 
adduct when deprotected with ammonia produced mainly an oligonucleotide 
containing amide at O6 position of guanine. Hence, these oligomers were deprotected 
by treating with 0.5M NaOH solution overnight. This method of deprotection will 
only just hydrolyse the ester group at O6- position of guanine and will not remove O6- 
carboxymethyl group. This phenomenon was explained by claiming that alkaline 
solution initially hydrolyses the ester group and the resultant negatively charged 
carboxylate anion prevents further nucleophilic attack by hydroxide ion on the ex­
position of the guanine. All synthetic oligonucleotides will be subjected to some level 
of contamination depending upon the method of preparation. If they are to be used in 
NMR studies to evaluate the effect of adduct on DNA confirmation, the purity 
requirement is not strict. If the oligonucleotides were to be used for genetic studies, 
the levels of tolerable impurities are very low. Hence, the oligonucleotides that are
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used in our studies are initially purified with Nensorb Prep cartridges to remove all 
reaction intermediates, salts and incompleted short sequences. Then a second 
purification step was carried out using fast protein liquid chromatography. This is an 
anion exchange chromatography used to separate impurities from the desired 
oligomer based on charge difference. Finally the purity of all the oligonucleotides that 
were synthesised (sequences numbered 1 - 1 5 )  were analysed on HPLC. All the 
oligonucleotides that are to be used in genetic studies observed to be 100% pure from 
HPLC analysis. Finally, the amount of oligonucleotide obtained after purification was 
determined by measuring OD values at 260nm on UV Cary photo spectrometer. The 
characterization of oligonucleotides is very important to verify the presence of 
modified adduets. The analysis that was routinely used in this project to characterize 
the oligonucleotides is nucleoside composition analysis. This is an enzymatic reaction 
in which the oligomers were hydrolysed to individual bases and peaks formed from 
individual bases will be monitored on HPLC using UV detector. Pentamers 
(sequences 1-3) were synthesised for this purpose. Since pentamers are short 
sequences, it is easy to detect signal from modified base when analysed on HPLC 
with UV detector. All the pentamers that were used in our studies are initially 
characterised on FPLC. The results of FPLC analysis on pentamers confirmed that all 
three pentamers were different from each other. This was done by observing the 
differences in the retention times of individual pentamers separately and by co­
injection of all three pentamers together. All the three pentamers were enzymatically 
digested to individual nucleosides and were analysed on HPLC. Apart from peaks 
observed with normal nucleosides in pentamer AGGCT, peaks from modified bases 
0 6-MedG and <96-CMdG adduets were observed with modified pentamers AGXCT 
and AGYCT. The UV spectrum of these modified adduets with A,max at 247 and 280
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also buttressed the results of nucleoside composition analysis. However, this analysis 
is practically difficult on longer oligonucleotides. The peak from single modified 
adduct is overshadowed by peaks from normal bases. It was previously reported that 
0 6-alkylguanines are slightly more fluorescent than the corresponding 
deoxynucleosides. It is possible to detect signal from modified adduct present in 
longer oligonucleotides when the samples are analysed with fluorescence detector. 
The fluorescence assays on longer oligonucleotides (sequences numbered 4-15) have 
confirmed the presence of modified adduets 0 6-MedG and 0 6-CMdG adduets. The 
peaks obtained from modified adduets have same retention times and UV spectrum as 
their corresponding standards. Additional evidence confirming the presence of 
adduets comes from co-injection of the enzymatic digested samples with their 
corresponding standard 0 6-alkylguanine adduets gave single peaks. The results of 
nucleoside composition analysis and fluorescence assays have confirmed the presence 
of modified 0 6-alkylguanine adduets in the oligonucleotides that were used for further 
adduct specific physical and mutagenesis studies. The melting temperature studies on 
self-complementary sequences have suggested the possible base-pairing preferences 
of site-specifically incorporated 0 6-alkylguanine adduets. 0 6-CMdG adduct was 
incorporated in two 12mer self-complementary sequences of the type 5' CGC XAG 
CTT GCG 3' and 5' CGC XAG CTC GCG 3’. Similar sequences containing 0 6-MedG 
adduct were used as positive controls. Incorporation of 0 6-MedG adduct in to the self 
complementary sequence 7 to form 0 6-MedG:C base pair has induced only a marginal 
decrease in melting temperature with respect to normal sequence 5 containing G:C 
base pair. However, the complementary sequence 6 containing 0 6-MedG:T base pair 
has induced a striking increase in melting temperature with respect to normal 
sequence 4 containing mismatch base pair G:T. It is clear from the data, that O6-
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MedG:T base pair caused little destabilisation of hairpin structure formed by self- 
complementary sequence than that caused by introducing G:T base pair. The above 
results also support the fact that 0 6-MedG predominantly induces GC—»AT transition 
mutations due to preferential base pairing with thymidine. The sequences containing 
0 6-CMdG adduets require more than 80° C to destabilise the hairpin structures. Due 
to the technical limitation of the UV spectroscopy, the melting experiments were not 
carried out beyond 80° C. Hence, the melting temperatures of self-complementary 
sequences 8 and 9 containing 0 6-CMdG adduct were not exactly determined. When 
the derivative curves of sequence 8 containing 0 6-CMdG:T base pair compared with 
sequence 9 containing 0 6-CMdG:C base pair, it appears that 0 6-CMdG:T base pair is 
comparatively stable than 0 6-CMdG:C base pair. Both 0 6-CMdG:T and 0 6-CMdG:C 
base pairs induced an increase in melting temperature with respect to normal sequence 
4 containing mismatch base pair G:T and sequence 5 containing G:C base pair. O6- 
CMdG:T base pair caused very little destabilising effect than that could be caused by 
introducing a mismatch base pair G:T. However, when the temperatures at which 
denaturisation commences were compared between sequences containing O6- 
CMdG:T and 0 6-CMdG:C base pairs, it is clear that the sequence 8 containing O6- 
CMdG:T base pair is much more stable with denaturisation starting around 75° C. 
The above results are indicating that 0 6-CMdG might preferentially base pair with 
thymine. The 0 6-alkylguanine derivatives have received much attention from the 
original proposal of loveless that reaction of guanine at the 0 6-atom would fix the 
enol tautomer of the base and facilitate the base-pairing with thymine (Loveless, 
1969). 0 6-MedG predominantly induces GC-AT transition mutations. Two possible 
explanations are that the DNA polymerase might mistake 0 6-methylguanine for 
adenine because of the physical similarity between these bases. 0 6-methylguanine and
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adenine are similarly lipophilic and the X-ray crystallography studies on the 
nucleosides have shown a close similarity in bond angles and lengths between O6- 
methylguanine and adenine. The second possible explanation is that the important 
factor in the miscoding is that the alkylG.T mismatch pairs retain the Watson-Crick 
alignment with N1 of the purine juxtaposed to N3 of the pyrimidine (Swann, 1990). 
Support for the role of 0 6-alkylguanines in carcinogenesis initially comes from 
experiments of Rajewsky. A strong correlation was observed between the incidence of 
brain tumours in A-ethyl-A-nitrosourea treated rats and the persistence of 0 6-EtGua in 
brain DNA (Goth and Rajewsky, 1974). The support for the role of 0 6-MedG in the 
carcinogenesis comes from the experiment in which the methylating agent A-methyl- 
A-nitrosourea induces mammary carcinomas that suffer ras gene mutations of exactly 
the type caused by 0 6-MedG adduct (Zarbl et al., 1985). Many in vitro and in vivo 
studies have suggested a causative role for the 0 6-MedG in mutagenesis and 
carcinogenesis. Hence, 0 6-MedG was chosen by several laboratories as the prototype 
for synthesis of site-specifically modified oligonucleotides (Borowy-Borowski and 
Chambers, 1987; Fowler et al., 1982; Kuzmich et al., 1986) and adduct specific 
mutagenic studies (Bhanot and Ray, 1986; Chambers et al., 1985; Hill-Perkins et al., 
1986; Loechler et al., 1984; Topal et al., 1986). From the research findings of the 
above classic studies it is clear that 0 6-alkylguanine adduets plays a pivotal role in the 
carcinogenesis. The observation that nitrosoglycine derivatives and diazoacetate 
derivatives react with DNA to form 0 6-MedG, 06-CMdG adduets concomitantly, and 
the latter is not prone to repair by DNA repair protein, AGT is interesting. In addition, 
mutagenesis studies on KDA have already indicated that 0 6-CMdG adduct can induce 
GC—>AT transitions. Hence, it would be particularly useful to study the 0 6-CMdG 
adduct specific effects on double helix structure of DNA, type and amount of base
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mis-incorporation by this modified base, adduct specific mutagenesis, mutation 
frequency and sequence context effects on mutagenesis.
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4.0 Introduction
The structurally diverse group of compounds called alkylating agents cause a wide 
range of biological effects, including cell death, mutation and cancer. These appear to 
be mediated predominantly by attack at O6 position of guanine. The biological 
properties and their mode of action have been extensively explored in cell and animal 
model systems over several decades (Druckrey et al., 1967). Apart from being 
carcinogenic, these agents are mutagenic, toxic, clastogenic and teratogenic. The 
spontaneous or metabolical breakdown of these agents in to alkylating species that 
interact with cellular macromolecules is well-documented (Margison and O’ Connor, 
1979). These agents react with DNA base’s producing 12 different nitrogen and 
oxygen adducts as well as phosphotriesters (Margison and O’ Connor, 1990; 
O’Connor et al., 1979). Alkylating agents, damaged DNA contains widely different 
amounts of 12 alkylated purines / pyrimidines and two phosphotriester isomers. These 
adducts are found to be substrates for DNA repair proteins (Singer and Hang, 1997). 
This allowed making a significant progress in establishing a relationship between 
specific DNA lesions and the biological effects of the agents responsible. Attention 
has been focused on 0 6-alkylguanine and, to a lesser extent, O4- alkylthymine and 3- 
alkyladenine and the vast majority of the work has been undertaken on the methyl 
version of these lesions. The earliest revelations of the toxic and clastogenic effects of 
the alkylating agents can be a consequence of the formation of 0 6-methylguanine in 
DNA were obtained following the isolation of a prokaryotic gene encoding the repair 
protein 0 6-alkylguanine-DNA-alkyltransferase.
The presence of 0 6-MedG has been linked to carcinogenesis 
via several mechanisms. Most of the attention has been focused on the point 
mutational effects. G-A transition mutations arise following two rounds of replication
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of DNA containing 0 6-MedG. Several lines of evidence support this. One is the 
spectrum of associated mutations found in genes that are crucial for malignant 
transformation. These include H-ras oncogene, in which transition mutations have 
been reported in codons 12, 13 and 61 (Barch et al., 1991; Rumsby et al., 1991). The 
transitions are found in a number of locations in tumour suppressor gene p53 (Ohgaki 
et al, 1992). Sukumar et al., (1983) established that these mutations are dependent on 
exposure to alkylating agents. They are also dependent on the absence or lack of AGT 
activity (Estellar et al., 2001; Mitra et al., 1989). Another line of evidence comes from 
transgenic murine models. Mice, which are over-expressing Atase are more resistant 
and Atase null mice are more susceptible to carcinogenesis by methylating agents 
(Kawate et al., 1998; Sakumi et al., 1997). This potential of inducing G-A transitions 
is also confirmed using both in vitro experiments (Loechler et al., 1984; Safhill et al., 
1985) and in vivo experiments using shuttle vector systems (Altshuler et al., 1996).
The possible contribution of recombination mechanism seems 
to be largely ignored. The contribution of this pathway has not been extensively 
investigated. There is also experimental evidence to suggest that the toxic effects of 
this lesion could play a major role in carcinogenesis. The toxic effects of alkylating 
agents will result in elimination of cells with, presumably highest levels of DNA 
damage. However, sub-lethally damaged cells, in spite of the presence of 0 6-MedG in 
the DNA undergo restorative hyperplasia will replace the dead cells in the tissue to 
become the predominant population. This will have a substantial effect on genomic 
stability.
Kyrtopoulos (1998) and Povey (2000) have detected varying 
levels of O6 - MedG in human DNA in several studies on various populations. This 
may be a consequence of exposure either to known methylating agents that are
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present in cigarette smoke or the diet or to unknown exogenous agents. However, 
endogenous DNA processes may also contribute to DNA alkylation (Mamett and 
Burcham, 1993; Hecht, 1999). These endogenous processes include the aberrant 
methylation of guanine by S-adenosylmethionine and the endogenous nitrosation of 
compounds containing primary amino groups and their subsequent breakdown to 
methylating species (Sedgwick, 1997). Shuker and Margison (1997) have showed that 
N-nitrosated bile acid conjugate, N-nitrosoglycocholic acid is able to methylate DNA 
in vitro and in vivo. Similar results have been obtained with other nitrosated glycine 
derivatives like APNG, Azaserine, mesyloxyacetic acid & potassium diazoacetate. It 
has also been observed that nitrosated glycine derivatives react with DNA giving rise 
to 0 6-CMdG and 0 6-MedG adducts using combined immunoaffinity/HPLC method 
(Harrison et al., 1999). 0 6-MedG is well established as a toxic and premutagenic 
lesion and is a substrate for DNA repair protein, 0 6-alkylguanine-DNA- 
alkyltransferase. In contrast, this protein does not repair 0 6-CMdG. So it is interesting 
to characterise the type of mutations specifically induced by 0 6-CMdG adduct in 
isolation.
4.0.1 p53 Yeast expression Assays
Richard Iggo originally developed the yeast p53 functional assay. This yeast 
functional assay can be used to determine highly specific mutational fingerprints of 
carcinogens and mutagens in the human p53 cDNA sequence. Flaman et al. 
developed a functional assay for the detection of p53 mutations in which human p53 
expressed in the haploid Saccharomyces cerevisiae strain yIG397 activates/controls 
transcription of the ADE2 gene as illustrated in Figure 4.1 (Flaman, 1995). Yeast cells 
containing wild-type p53 express ADE2, and form white and normal sized colonies
158
Chapter 4: 0 6-alkylguanine adduct specific Mutagenesis studies
on plates containing limited adenine. On the contrary, cells containing mutant p53 fail 
to express the ADE2 gene. Because of adenine being limiting for growth, relatively 
small, red colonies are formed. The red colouring observed in these colonies 
originates from a build-up of an intermediate metabolite of adenine metabolism.
TRANSCRIPTION
normal white colonies
NO TRANSCRIPTION
accumulation o f  red metabolite
Figure 4.1: Yeast-based p53 Functional Assay. The ADE2 gene is not expressed i f  the p53 
transactivation function is inactivated by mutation. Transformants are selected on plates that lack 
leucine but contain sufficient adenine for adenine auxotrophs to grow and turn red due to build-up o f  
an intermediate metabolite. Mutant clones appear as small red colonies against the background o f  
white adenine prototrophs (picture courtesy o f P. Burns)
Ishioka has established germ line mutations in p53 by screening patients heterozygous 
for p53 mutations using functional analysis of separated alleles in Yeast (FASAY) 
technique (Inga et al., 1997)]. Inga has established characteristic mutagenic and lethal 
properties of CCNU (A-(2-chloroethyl)-A-cyclohexyl-A-nitrosourea) [Inga et al., 
1997). Their results suggested that CCNU has a mutation spectrum, which is unique 
and is consistent with the hypothesis that 0 6-alkylguanine is the causative lesion. 
Frebourg has established germ-line mutations in patients with LFS (Li-fraumeni 
syndrome) using p53 cDNA obtained from lymphocytes of patients (Frebourg et al., 
1992). Murata used yeast p53 functional assay to study induction of mutation by nitric
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oxide in the p53 tumour suppressor gene and the effect of cytosine methylation on 
mutation spectrum (Murata et al., 1997).
Initially it was decided to apply the yeast-based p53 functional 
assay to study the mutagenecity of 0 6-carboxymethyl-2'-deoxyguanosine adduct in 
isolation. This part of the research project was carried out in the labs of our 
collaborator Dr Philip A. Bums, School of Medicine, Academic Unit of Pathology, 
University of Leeds. The yeast p53 functional assay described earlier was routinely 
applied in their laboratory in Leeds to study the p53 mutation spectrum induced by 
wide variety of mutagens. During the course of mutagenesis studies, it was found that 
frozen stocks of yeast cells (Saccharomyces cerevisiae strain, ylG 397) were not 
showing any signs of viability after plating. This strain is also not commercially 
available. Therefore, transformations in to NOVABLUE E.coli cells standard kit was 
tried to fix the mutations from 0 6-CMdG. Although the principle of this mutation 
assay is different from p53 yeast expression assays, the important thing here is to fix 
the mutations from <96-CMdG in cellular environment. Novablue competent cells 
(Merck Biosciences) enable convenient, efficient constmction of plasmid 
recombinants. However, BbvCl restriction enzyme over-hanging ends required to 
attach duplex DNA in to the plasmid is not sticky enough to form large amounts of 
ligation mixture to transform these cells with adducted plasmid, pLS76. The 
practicalities of site-specific incorporation of 0 6-alkylguanine containing 
oligonucleotides limit the number of possible sites of insertion. Despite a large 
number of characterised KDA derivative specific G-mutation sites between codons 
120-260 of the p53 sequence, none of these lay within a short sequence between two 
unique restriction sites, which lies between codons 190-202. These codons fall 
between restriction enzyme sites BbvCl and Apol. Hence, the above restriction
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enzymes were used to construct a plasmid, pLS76 containing single 0 6-alkylguanine 
adduct. However, religation inefficiency problem of the enzyme BbvCl was not 
foreseen at this time of research project.
4.0.2 Amplification Refractory Mutation System-PCR Assays 
ARMS-PCR is an assay designed to discriminate between target DNA sequences that 
differ by a single nucleotide in the region of interest. The primers used for this assay 
differ at the nucleotide that occurs at the extreme 3'-terminus In a PCR reaction the 
DNA synthesis step is crucially dependent on correct base-pairing at 3’-end. This 
difference will enable us to determine the exact base pairing at adducted site by 
monitoring for primer extension products, which happens only when primer binds to 
the region of interest. This is similar in principle to primer extension assays, except 
that in this assay we used double stranded template to double check the nucleotides 
present on both strands at adducted site to confirm base-pairing unambiguously and 
the incoming base is already present on the primer at extreme 3-end. This method is 
particularly useful in detecting pathogenic mutations [Figure 4.2].
Ultraviolet radiation is the major carcinogenic component of 
sunlight. UV generates two kinds of pyrimidine dimers in DNA, a cyclobutane dimer 
and a pyrimidine-pyrimidone photo product. These dimers lead to mutations, notably 
C to T and CC to TT. The CC -  TT mutation is considered to be UV specific mutation. 
Although there are many reports of a correlation between qualitative exposure to 
sunlight and non-melanoma skin cancer (NMSC), the relationship with the 
quantitative exposure is not clear. This is because, it is difficult to measure objectively 
and exactly how long a person has been exposed to sunlight in their life.
161
Chapter 4: 0 6-alkylguanine adduct specific Mutagenesis studies
Kawasaki et al., (2000) has tried to exploit the point that UV 
specific CC-TT mutations are not reversible to develop a method to measure 
cumulative UV exposure. Unlike other mutation assays, which rely on phenotypic 
selection of the mutants, they designed mutation assay that is very sensitive and based 
on genotypic selection. This assay uses site-specifically designed primers (Allele
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Figure 4.2: The Principle o f AMRS-PCR assay. X  - Incoming nucleotide in question.
specific primers) to detect mutations at codons 247/8 of the p53 gene of mitochondrial 
(Mt) DNA in normal skin. Since, CC-TT mutation is a tandem mutation the allele-
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specific primers used were having a two-base mismatch to the wild-type sequence. 
Even though this assay did not show any quantitative correlation between 
accumulation of the mutation and the level of the UV exposure, but they managed to 
show a correlation between the presence of mutation in Mt DNA and UV exposure 
(Kawasaki et al., 2000).
In our current studies, this assay has been used to characterize 
the 0 6-carboxymethylguanine specific mutations. Five different types of plasmids 
were constructed of which, one of them is a control plasmid with no adduct and 
another two plasmids were having O -MedG adduct and the remaining two with O - 
CMdG adduct incorporated in to the p53 cDNA. The p53 cDNA amplified from 
these plasmids containing adducts were studied with sequence specific mismatched 
primers using ARMS-PCR assay to characterize the type of specific mutations 
induced by 0 6-CMdG and 0 6-MedG adducts.
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4.1 Results
4.1.1 Extraction of Plasmid, pLS76 DNA using QIAfilter plasmid Midikit
Plasmid, pLS76 is a 9kb p53 expression vector, was first described and constructed by 
Ishioka (Ishioka et al., 1993) [Figure 4.3]. It expresses full length p53 cDNA from the 
ADH1 constitutive promoter [Appendix 3]. The vector also contains CYC1 
(terminator) downstream of the p53 cDNA, yeast origin of replication, CEN6/ARSH4 
and LEU2 as a selectable marker. pLS76 DNA was extracted for genetic 
manipulations with restriction enzymes BbvC l, Apol and S a d ,  which is necessary 
for incorporation of modified duplex DNA containing 0 6-alkylguanine adducts (O6- 
methyl-2'-deoxyguanosine or 0 6-carboxymethyl-2'-deoxyguanosine). Plasmid 
purification procedure is an optimized protocol based on the alkaline lysis method of 
Bimboim and Doly [Section 2.3.1]. The results of plasmid extraction [Figure 4.4] 
confirms the presence of plasmid DNA in the fractions of plasmid extractions. The 
two bands in figure 4.4 are super-coiled (lower band) and open circular (upper band) 
plasmid DNA.
Figure 4.3: pLS76 p53 yeast expression vector. The p53 expression vector was first described 
and constructed by Ishioka et al. [Ishioka (1993)]. The vector harbours human wild-type p53 
cDNA under the control o f an ADH1 promoter and the LEU2 gene as a selectable marker 
(picture courtesy o f P. Burns).
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Figure 4.4: Agarose gel showing the pLS76 DNA bands extracted from E.coli
1 2 3 4 5 6  7 8
j^ggH| WUK* W H ttf Ijgfliltp
Figure 4.4: /%  Agarose gel Profile showing plasmid extraction. Two bands correspond to 
super-coiled (lower band) and Open-circular (upper band) plasmid fonns. Lanes (1-8) 
corresponds to the plasmid, pLS76 DNA.
4.1.2 Construction of Genetically Engineered Plasmids Containing O6- 
alkylguanine Adducts
The mutation assay sequences [Table 2.1] synthesised i.e., 25mer (sense strand) 
containing either (2’-deoxyguanosine or 0 6-MedG or 0 6-CMdG adduct) at nucleotide 
position 587 in codon 196 and 26mer (anti-sense strand) containing (2’- 
deoxyguanosine or 0 6-MedG or 0 6-CMdG adduct) at nucleotide position 586 in 
codon 196 were the sequences chosen from p53 CDNA, comprises the region from 
codons 190-202. This sequence is between the restriction sites BbvCl and Apol in 
p53 cDNA. Initially it was planned that plasmid, pLS76 DNA is digested with 
restriction enzymes BbvCl and Apol to obtain double stranded plasmid DNA. The 25 
and 26mer, which comprises this region, will be annealed to form a duplex DNA with 
BbvCl and Apol specific cohesive ends. This DNA duplex was planned to be
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incorporated in to the double stranded plasmid DNA using Quick stick™ Ligase kit. 
Plasmid, pLS76 DNA was digested separately with both the restriction enzymes 
BbvCl and Apol to cheque if they are unique restriction sites. Unfortunately, it was 
found that even though, Apol site is a unique site in p53 cDNA, it is not a unique 
restriction site in whole plasmid, pLS76 DNA. This posed a problem to construct a 
vector with single O6- alkylguanine adduct. The p53 sequences were designed to 
construct a duplex DNA containing single 0 6-alkylguanine adduct, long before the 
mutagenesis studies were started. Hence, at that point of research project, these 
problems were not foreseen. Therefore, preliminary experiments of restriction enzyme 
mapping of whole plasmid DNA were not executed. However, further restriction 
enzyme analysis was carried out on plasmid DNA to find another restriction site, 
which is unique in both plasmid DNA and p53 cDNA. Sad  is another unique 
restriction site found downstream to Apol site. It was then proposed to double digest 
the plasmid, pLS76 DNA initially with BbvCl and SaCl to obtain a double stranded 
plasmid DNA (8.5kb approximately) with BbvCl and SaCl specific cohesive ends. 
Then another intact plasmid, pLS76 DNA will be digested with Apol and S a d  to 
obtain the 650bp restriction fragment with Apol + S a d  specific cohesive ends. 
Finally all the three DNA fragments, which means double stranded plasmid DNA 
(8.5kb), Apol + SaCl restriction fragment and duplex DNA will be ligated together to 
form an intact plasmid using Quickstick™ ligase kit [Figure 4.5].
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Figure 4.5: Genetic Engineering of plasmid, pls76 to incorporate Q6-alkylguanine 
Adducts
650bp restriction fragment
Apo I + Sac I
.............. — Apo 1 wmmmmmmmmmmmmmmmmmmmmmm Sac I
BbvC l>
+
X Duplex DNA 
1
Apo 1 
1
+
Double stranded DNA
Duplex DNA
^ BbvC I i  Apo I
X
Sac I
BbvC I + Sac I
..............   BbvC i mmmmmmmmmmmmmmmmmmmm Sac I
BbvC I
I
BbvC I
Figure 4.5: Diagram illustrating the strategy o f  constructing genetically engineered plasmid, pLS76 
containing O6-alkylguanine adducts by site-specific incorporation o f  synthetic oliognucleotide DNA 
duplex containing O6-alkylguanine adducts. Letter X  in red indicates O6-alkylguanine adduct
4.1.2.1 Double digestion of Plasmid, pLS76 DNA with Restriction enzymes 
BbvCl and SaCl
Plasmid, pLS76 DNA (30pg) was digested with 10 units of each restriction enzyme 
BbvCl and SaCl at 37° C in a water bath. This reaction was repeated to obtain 
substantial amounts of this fragment for further genetic manipulations [Subsection
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2.3.2.1 in Section 2.3.2]. The lane 2 of the gel in Figure 4.6(a) is showing two clear 
bands formed from double digestion. The band, which is about 8.5(kb) is the double 
stranded plasmid DNA with BbvCl and S a d  overhanging ends that is required to 
incorporate duplex DNA and Apol + Sa d  restriction fragment (650bp). This 8.5 kb 
fragment [Figure 4.6(b)] was purified from agarose gel using QLAGEN’s QIAquick 
gel extraction kit [Subsection 2.3.2.3 in Section 2.3.2].
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Figure 4.6(a): 1% Agarose Gel profile showing double digestion o f Plasmid, pLS76 DNA with 
Restriction enzymes BbvCl and Sacl. Lanes 1 and 6 contains High Mass DNA Ladder, Lane 2 
contains pLS76 + BbvCl + SaCl double digest, Lane 3 contains pLS76 + SaCl digest, Lane 4 
contains pLS76 + BbvCl digest, Lane 5 contains plasmid, pLS76 DNA. Figure 4.6(b): 1% Agarose 
gel profile showing purified 8.5kb Double stranded plasmid DNA. Lanes 1 and 6 contain High Mass 
DNA ladder. Lanes 2-5 contain purified 8.5kb Double stranded plasmid DNA.
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Figure 4.7(a): 2% Agarose gel profile showing double digestion o f Plasmid, pLS76 DNA with 
restriction enzymes Apol and SaCl. Lane 1 High Mass DNA Ladder, Lane 2 contains plasmid plS76 
DNA, Lane 3 contains pLS76 + SaCl digest, Lane 4 contains pLS76 + Apol digest, Lane5 contains 
pLS76 + Apol+Sacl double digest, Lane 6 contains Hyperladder IV. Figure 4.7(b): 2% Agarose Gel 
profile showing purified Apol + SaCl restriction fragment. Lanes 1 and 6 contains Hyperladder IV. 
Lanes 2-5 contains purified 650bp Apol + SaCl restriction fragment
4.1.2.2 Double digestion of Plasmid, pLS76 DNA with Restriction enzymes Apol 
and Sacl
Another fresh batch of plasmid, pLS76 DNA (30pg) was digested with 10 units of 
each restriction enzyme Apol and Sacl. The optimal temperature required for the 
enzymatic activity of these two enzymes is different. Hence, the plasmid DNA was 
digested, one at a time with each enzyme [Subsection 2.3.2.2 in Section 2.3.2]. The
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lane 5 [Figure 4.7(a)] of the double digest gel shows a clear band around 650bp, 
which is the Apol + Sacl restriction fragment. This 650bp Apol + SaCl restriction 
fragment [Figure 4.7(b)] was purified from agarose gel using QIAGEN’s QIAquick 
gel extraction kit [Subsection 2.3.2.3 in Section 2.3.2],
4.1.2.3 Construction of DNA duplex Containing 0 6-alkylguanine Adducts
The DNA sequences [Table 2.1] were chosen from p53 cDNA encompassing the 
region from codon 190 to 202 of p53 cDNA. These codons fall between restriction 
enzyme sites BbvCl and Apol. The sequences 10-11 are standard 25 and 26mer, 
where as sequences 12-13 are their corresponding methylated counterparts and 
sequences 13-14 are carboxymethylated counterparts. These complementary 
sequences were annealed on a PCR heating block to form a duplex with BbvCl and 
Apol overhanging ends [Subsection 2.3.2.4 in Section 2.2.2]. The DNA was mixed in 
such a way to form a duplex structure with adduct present on only one of the strands 
i.e. either on the sense strand of duplex or anti-sense strand of the duplex [Figure 4.8 
and Table 2.7]. The duplex DNA was separated from single stranded DNA using 19:1 
non-denaturing polyacrylamide gel electrophoresis [Subsection 2.3.2.5 in Section 
2.3.2]. The gels are not shown in this result section. This is because DNA fragments 
are very small, it is often difficult to stain them with ethidium bromide and also the 
single stranded DNA are not very well stained with ethidium bromide. Hence, gels 
did not show very clear and tight bands distinguishing double stranded DNA from 
single stranded DNA. The gels appear like a smear with a blob separating single 
stranded fragments from double stranded DNA.
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Figure 4.8: Construction of Duplex DNA with 0 6-alkylguauine Adduct present 
on either sense or anti-sense strand
A
BbvC 1 Apol
190 i  i  202
5’- CCT CCT CAG CAT CTT ATC CXA GTG GAA GGA AAT TTG CGT-3’ 
3’- GGA GGA GTC GTA GAA TAG XCT CAC CTT CCT TTA AAC GCA-5’
TCA GCA TCT TAT CCX AGT GGA AGG A TCA GCA TCT TAT CCG AGT GGA AGG A
CGT AGA ATA GGC TCA CC T TCC TTT AA CGT AGA ATA GXC TCA CCT TCC TTT AA
( D u p l e x  w i t h  a d d u c t  o n  sense s t r a n d )  ( D u p l e x  w i t h  a d d u c t  o n  a n t i - s e n s e  s t r a n d )
X = indicates sites at which 0 6-MedG or 0 6-CMdG are inserted on sense and anti-sense strands
Figure 4.8: Complementary sequences 25 and 26mer chosen from P53 CDNA encompass the region 
from codon 190-202. These sequences lay between restriction sites BbvCl and Apol. The 
complementary sequences are annealed to form duplex DNA with adduct present either on sense or 
anti-sense strand.
'X'yThe oligomers can be radiolabelled with p to distinguish between single stranded 
sequences from duplex DNA. However, the lack of necessary facilities, equipment 
and training personnel at the labs of Department of Chemistry, The Open University 
means that radiolabelling option cannot be opted. In addition, the time allotted for 
this part of research project had not allowed further radioactive manipulations on 
DNA sequences. The gel slice containing duplex DNA was excised and purified by 
using a combination of techniques called CRUSH and SOAK method (Because the
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desired fragment of DNA is extracted from the gel band by crushing and soaking in 
extraction buffer, therefore the method is called CRUSH and SOAK method) and user 
developed protocol from QIAGEN.
4.1.2.4 Ligation of Double Stranded Plasmid DNA with Apol + SaCl (650bp) 
Restriction fragment and duplex DNA to Construct an Intact Adducted Plasmid.
All the three purified DNA fragments i.e., double stranded DNA with BbvCl + Sacl 
overhanging ends, Apol + Sacl restriction fragment and duplex DNA were mixed in 
appropriate ratios [Subsection 2.3.2.6 of Section 2.3.2] were ligated using Quick- 
Stick™ ligase kit. The cohesive ends formed by BbvCl are not very sticky and only < 
5% of the ends will re-ligate. Hence, 2, 4 and 8 fold amounts of BbvCl + Sacl double 
stranded DNA were used on trial and error basis to find optimal concentration to form 
enough ligation mixture [Table 2.8]. This procedure was repeated to obtain 
substantial amounts of ligation mixture for further experiments. Five different 
plasmids containing (/-alkylguanine adducts including control plasmid with no 
adduct were constructed. The information on the type of plasmids constructed is given 
in Table 2.9. The results of the ligation reaction are shown in Figures 4.9(a) and 
4.9(b). The 9kb band in lane 3 and 4 of Figure 4.9(a) indicated the successful 
incorporation of duplex 1 in to control plasmid, pLS76 -  1. The bands in the lane 3 
and 4 of Figure 4.9(b) indicated that duplex 2 and 3 containing (/-MedG adducts 
were successfully incorporated in to plasmids, pLS76 -2 an pLS76 -  3 with respect to 
control plasmid, pLS76 - 1. The bands in the lane 4 and 5 of Figure 4.9(b) indicated 
that duplex 4 and 5 containing 0 6-CMdG adducts were successfully incorporated in to 
plasmids, pLS76 -4 an pLS76 -  5 with respect to control plasmid, pLS76 -1.
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Figure 4.9(a): 1% Agarose gel profile showing ligation o f control duplex DNA in to Plasmid, pLS76 
DNA. Lane 1 contains High Mass DNA Ladder, Lane 2 contains plasmid plS76 DNA, Lane 3 and 4 
contains plasmid, PLS76 - 1 incorporated with duplex DNA I. Figure 4.9(b): I % Agarose Gel profile 
showing ligation o f  O6-alkylguanine adduct containing duplex DNA in to Plasmid, pLS76. Lanes I 
contains High Mass DNA Ladder, Lanes 2 contains plasmid plS76 DNA, Lanes 3 and 4 contains 
plasmid, PLS76 -  2 and 3 DNA incorporated with duplex 2 and 3 containing 0 6-methylguanine adduct, 
Lanes 5 and 6 contains plasmid, PLS76 -  4 and 5 DNA incorporated with duplex 4 and 5 containing 
O6-carboxy’methylguanine adduct
4.1.3 Amplification of p53 cDNA from Genetically Engineered Plasmid 
Constructs containing Single (/-alkylguanine Adducts
The practicalities of site-specific incorporation of (/-alkylguanine containing 
oligonucleotides limit the number of possible sites of insertion. Ideally we would have 
liked to insert 0 6-CMdG adduct at a guanine that was a known site for mutation.
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Figure 4.10: 1% Agarose gel profile o f amplified p53cDNA from both normal and adducted plasmid, 
pLS76 DNA. Lanes 1 and 9 Contain Hyperladder IV, Lane2 is negative control (No Plasmid DNA), 
Lane 3 is positive control (plS76 DNA), Lane 4 contains p53 cDNA from control plasmid, Lane 5 
contains p53 cDNA from plasmid, pLS76 - 2 Lane 6 contains p53 cDNA from plasmid, pLS76 - 3, Lane 
7 contains p53 cDNA from plasmid, pLS76 - 4, Lane8 contains p53 cDNA from plasmid, pLS76 - 5.
However, despite a large number of characterised KDA derivative specific G- 
mutation sites between codons 120-260 of the p53 sequence, none of these lay within 
a short sequence between two unique restriction sites, which lies between codons 190- 
202. Codon 196 is the site chosen for insertion of modified adducts both on sense 
strand at nucleotide position 587 and on anti-sense strand at nucleotide position 586. 
25 and 26mers synthesised were complementary sequences, annealed to produce five 
different types of DNA duplexes with BbvCl and Apol overhanging ends. Apol site
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is unfortunately, a unique restriction site in p53 cDNA but not in whole plasmid DNA. 
Hence, it took an additional double digestion step with another restriction enzyme 
Sacl, which in unique in both whole plasmid DNA and P53 cDNA to construct an 
intact plasmid with adduct. The restriction ends formed by BbvCl are not very sticky. 
Quality control assay of this enzyme claims after 2-fold over digestion with BbvC I < 
5% of the DNA fragments can be re-ligated. Hence, failure to ligate sufficient 
material means transfection of adduct containing plasmid in to bacterial cells, fixing 
mutations induced by DNA adducts is not possible in cellular environment. PCR is a 
rapid and versatile method for amplifying target DNA sequences present within a 
source of DNA. Most importantly, it is a useful method to amplify target DNA 
sequences from little amounts of source DNA. This technique acts in the same way as 
most other commonly used mutation systems, except for the fact that it is an in vitro 
system. Nevertheless, the important thing here is to fix mutation from the adducted 
plasmid.
The Principle of the most p53 mutation assays is to fix mutation 
in the cellular environment and establish these mutated cells by further sub-culturing 
techniques. Then, DNA will be extracted from these cells for sequencing to detect the 
mutations in the p53 cDNA. PCR can fix the mutations from adducted DNA in the 
same way as other mutations systems. p53 cDNA (800bp) from the genetically 
engineered plasmids containing adducts were amplified using the p53 specific primers. 
These primers can only amplify the p53cDNA from the intact plasmid. It is not 
possible to amplify p53 cDNA, unless the three DNA fragments i.e., double stranded 
DNA (8.5kb), Apol + Sacl restriction fragments (650bp) and duplex DNA that were 
ligated form an intact plasmid. The gel [Figure 4.10] shows the p53 cDNA amplified 
from all the genetically engineered plasmids. This result confirms that all plasmids
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engineered to incorporate adducted duplexes formed an intact plasmid, which 
otherwise would not be possible to form 800bp p53 cDNA. The p53 primers BB5 and 
NBE3 were used to amplify p53 cDNA, which comprises about 800bp [Section 2.3.4]. 
The gel in figure 4.10 shows the p53 cDNA amplified from both the plasmids 
containing either normal or adducted duplexes that contain 0 6-MedG or 0 6-CMdG 
adducts. Lanes 2 contains negative control (No plasmid DNA) and lane 3 contains 
positive control (cDNA from normal plasmid, pLS76 DNA). The lanes 4 shows the 
similar band (800bp) obtained from the control plasmid and lanes 5-6 contain 800bp 
band from plasmids containing 0 6-methyladducts i.e., plasmid, pLS76 - 2 and pLS76 
- 3 and lanes 7-8 contain 800bp from plasmids containing 0 6-carboxymethyl adducts 
i.e., plasmid, pLS76 - 4 and pLS76 - 5. This amplification was repeated to obtain 
substantial amounts for further experimentation.
4.1.4 Characterisation of Mutations Induced by 0 6-alkylguanine Adducts using 
ARMS-PCR Assay
p53 cDNA amplified from both normal plasmid and adducted plasmid DNA were 
analysed using sequence specific primers with ARMS-PCR assay to characterize the 
mutations induced by 0 6-alkylguanine adducts incorporated either on sense or anti­
sense strands in codon 196.
4.1.4.1 Characterization of Mutations Induced by 0 6-alkylguanine Adducts in 
Plasmid pLS76 - 2 and pLS76 - 4, at Nucleotide position 587 on Sense 
strand of p53 cDNA
P53 cDNA amplified from O -methyl adduct containing plasmid, pLS76 - 2 and O - 
carboxymethyl adduct containing plasmid, pLS76 - 4 were analysed using sequence
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specific primers [Section 2.3.5]. Two separate sets of primers, which differ at 
nucleotide that occurs at extreme 3'-end were designed for analysis on both sense and 
anti-sense strands to double check the base pairing at adducted site [Table 2.10]. The 
PCR reactions were carried out on PTC-225 PCR machine. These reactions were 
repeated twice to confirm the base-pairing at adducted site unambiguously. The 
sequence specific pairs of primers for each PCR reaction, PCR conditions and 
reaction format to analyse base-pairing at adducted site i.e., at nucleotide position 587 
on sense strand were given in Tables 2.12 2.14 and 2.15 for both the methylated 
plasmid, pLS76 - 2 and carboxymethylated plasmid, pLS76 - 4 in material and 
methods section, chapter 2. All the PCR reactions except with anti-sense strand 
specific primers T and A, sense strand specific primers A and G were done using PCR 
reaction condition 2 for both control plasmid and for the adducted plasmids, pLS76 - 
2 and pLS76 - 4. The PCR reaction condition 4 was used for the reaction with anti­
sense strand specific primer T with plasmid, pLS76 - 2. Where as, PCR condition 7 
with anti-sense strand specific primer A and conditions 3 and 8 were used with sense 
strand specific primers A and G in all the three cases i.e. control plasmid and plasmids, 
pLS76 - 2 and pLS76 - 4.
PCR amplifications with both control plasmid and adducted 
plasmids, pLS76 - 2 and pLS76 - 4 gave primer extension products with anti-sense 
strand specific primer G and sense strand specific primer C that confirms the presence 
of normal G:C base pairing at nucleotide position 587 in codon 196 [Figure. 4.11(a) 
and Figure 4.11(b)]. There were also additional primer extension products observed 
with plasmid, pLS76 - 2, apart from primer extension products with anti-sense strand 
specific primer G and sense strand specific primer C. Anti-sense strand specific 
primer A and sense strand specific primer T related primer extension products were
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observed with plasmid, pLS76 - 2 containing methylated adduct on sense strand 
[Figure. 4.11(a)]. This confirms that some of the plasmid 2 constructs have A:T base 
pair present in the codon 196 at adducted site as expected with DNA repair free 
system. This A:T base pair in codon 196 at adducted site i.e., at nucleotide position 
587 confirms GC-AT transition mutation inductions by the 06-MedG adduct. The 
results of the PCR assay with plasmid, pLS76 - 4 [06-CMdG adduct] were different 
from plasmid, pLS76 - 2 [Figure 4.11(b)], Primer extension products with anti-sense 
strand specific primer G and sense strand specific primer C were observed just as with 
control plasmid and plasmid, pLS76 - 2. Interestingly, they were also some additional 
primer extension products observed with plasmid, pLS76 - 4. Primer extension 
products with anti-sense strand specific primer T and sense strand specific primer A 
were also observed with plasmid, pLS76 - 4. These results were quiet opposite with 
the results obtained from plasmid, pLS76 - 2. These products prove that some of the 
plasmid, pLS76 - 4 constructs has T:A base pair substitution at adducted site. This 
suggests that a GC-TA transversion mutation was induced by 0 6-CMdG adduct in 
codon 196 at the adducted site (nucleotide position 587).
\
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Figure 4.11(a): Agarose gel showing Primer extension products obtained with 
methylated plasmid. pLS76 - 2
H 8 7 6 5 4 3 2 1  H
Control
pLS76- 2 *< : rrj t" 4
•tew * ■mmm
V.
SG SA ST SC AG AA AC AT
Figure 4.11(a): 2% Agarose gel profile of ARMS-PCR Assay with control plasmid and methylated 
plasmid, pLS 76 - 2. Lanes H  indicate lOObp ladder. Lanes 1-8 are PCR primer extension reactions 
with sequence specific primers in the order AT, AC, AA, AG, SC, ST, SA and SG. (Prefix ‘A ’-anti­
sense) (Prefix ’S ’- Sense strand).
Figure 4.11(b): Agarose gel showing Primer extension products obtained with 
carboxvmethvlated plasmid, pLS76 -  4
H
Control "<
7 6 5 4 3 2 1 H
r 4  :
pLS76 - 4 -<
SG SA ST SC AG AA AC AT 
Figure 4.11(b): 2% Agarose gel profile of ARMS-PCR Assay with control plasmid and 
carboxymethylatedplasmid, pLS 76 - 4. Lanes H indicatelOObp ladder. Lanes 1-8 are PCR primer 
extension products with sequence specific primers in the order AT, AC, AA, AG, SC, SA, ST and SG. 
(Prefix ’A ’-anti-sense) (Prefix ’S ’- Sense strand).
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4.1.4.2 Characterization of Mutations Induced by 0 6-alkylguanine Adducts in 
Plasmid pLS76 - 3 and pLS76 - 5, at Nucleotide position 586 on Anti-sense strand 
of p53 DNA
P53 cDNA amplified from 0 6-methyl adduct containing plasmid, pLS76 - 3 and O6- 
carboxymethyl adduct containing plasmid, pLS76 - 5 were analysed using sequence 
specific primers [Section 2.3.5]. Two separate sets of primers, which differ at 
nucleotide that occurs at extreme 3'-end were designed for analysis on both sense and 
anti-sense strand to double check the base pairing at adducted site [Table 2.11]. The 
PCR reactions were carried out on PTC-225 PCR machine. These reactions were 
repeated twice to confirm the base-pairing at adducted site unambiguously. The 
sequence specific pairs of primers for each PCR reaction, PCR conditions and 
reaction format to analyse base-pairing at adducted site i.e., at nucleotide position 586 
on anti-sense strand were given in Tables 2.13, 2.14 and 2.15 for both the 0 6-methyl 
adduct containing plasmid, pLS76 - 3 and 0 6-carboxymethyl adduct containing 
plasmid, pLS76 - 5 in material and methods section, chapter 2.
Surprisingly, ARMS-PCR assay results with both the plasmid,
f t  f\pLS76 - 3 containing O -MedG and plasmid, pLS76 - 5 containing O -CMdG adduct 
in the anti-sense strand were similar [Figure 4.12(a) and Figure 4.12(b)]. Control 
plasmids gave primer extended products with anti-sense strand specific primer C and 
Sense strand specific primer G. These results appear contrasting to the results 
obtained with control plasmids compared against plasmids containing adducts on 
sense strands. In fact, they are not different, but similar. The products obtained with 
control plasmids were in other way because, the adduct site analysed for mutation is 
on anti-sense strand, but not on sense-strand.
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Figure 4.12(a): Agarose gel showing Primer extended products obtained with
methylated plasmid. pLS76 - 3
H 8 7 6 5 4 3 2 1  H
Control *<
SG  SA ST SC  AG AA AC AT
Fig 4.12(a): 2% Agarose gel profile o f ARMS-PCR Assay with control plasmid and plasmid containing 
duplex 3. Lanes H  indicate lOObp ladder. Lane s 1-8 are PCR primer extension products with sequence 
specific primers in the order AT, AC, AA, AG, SC, ST, SA and SG, (Prefix ‘A ’-anti-sense) (Prefix ‘S ’- 
Sense strand).
Figure 4.12(b): Agarose gel showing Primer extension products obtained with 
carboxymethvlated plasmid. pLS76 -5
H 8 7 6 5 4 3 2 1  H
Control
pLS76 -5  < i m  m
***** m tm  *m m  ~ *
SG S A S T  SC  AG AA AC AT 
Figure 4.12(b): 2% Agarose gel profile of ARMS-PCR Assay with control plasmid and plasmid
containing duplex 5. Lanes H indicate lOObp ladder. Lanes 1-8 are PCR primer extension reactions 
with sequence specific primers in the order AT, AC, AA, AG, SC, ST, SA and SG. (Prefix ‘A ’-anti­
sense) (Prefix ‘S ’- Sense strand).
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It should always be remembered that primer extension products obtained with the 
plasmids containing adducts on anti-sense strand will appear opposite way and should 
not be confused during interpretation of results. The C and G primer extension 
products obtained with control plasmids confirms the normal G:C base pairing at 
codon 196 i.e., nucleotide position 586. Extra bands present in the control samples 
might be unamplified and non-specifically amplified p53cDNA impurities [Figure 
4.12(a)]. The primer extension products with anti-sense strand specific primer C and 
sense strand specific primer G were also observed with plasmid, pLS76 - 3 and 
plasmid, pLS76 - 5. Additional primer extension products were observed with the 
adducted plasmids, apart from the normal products C and G. The primer extension 
products with anti-sense strand specific primer T and sense strand specific primer A 
were observed with both plasmid, pLS76 - 3 and pLS76 -  5 [Figure 4.12(a) and 
4.12(b)]. The presence of these products confirms AT base pair substitution mutation 
at the adducted site in some of the plasmid, pLS76 - 3 and plasmid, pLS76 - 5 
constructs. In the other way it means, a GC-AT transition mutation was induced by 
both the 0 6-MedG and 0 6-CMdG adducts, when they were present on anti-sense 
strand.
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4.2 Discussion
0 5-alkylguanine base is believed to play the important role in the carcinogenic action 
of N-nitroso compounds. It was previously reported concomitant methylation and 
carboxymethylation is the general property of N-nitrosoglycine derivatives such as 
APNG and diazoacetic acid derivatives (KDA and MDA). It was found that simple 
nitrosated bile acid conjugate N-nitrosoglycocholic acid reacts with DNA to from O6- 
CMdG and (96-MedG adducts. The latter has already been established as a toxic, pro- 
mutagenic lesion and is repaired by DNA repair protein, 0 6-alkylguanine-DNA- 
alkyltransferase. It was also reported that 0 6-CMdG was not repaired when incubated 
with the same repair protein. The question, whether the mutagenecity of N- 
nitrosocompounds is totally because of 0 6-MedG adducts or it has to do anything in 
partly with O6- CMdG adduct has not been explored. Random mutagenesis studies, 
using p53 yeast expression assays on KDA, a carcinogen of our particular interest 
predominantly formed O6- CMdG adduct, which was found to induce mainly GC-AT 
transition and some GC-TA transversion mutations in p53 cDNA (Gottschalg et al., 
2006). KDA also reacts with DNA to form 0 6-MedG adducts. Thus it is practically 
difficult, if not impossible to determine which adduct causes which mutation and why. 
The best way to answer this question would be by incorporating single O6- CMdG 
adduct in to a vector to study site-specific mutagenesis of adduct in question. An 
adduct site- specific study is most useful when it is compared to a random 
mutagenesis study with its corresponding mutagen/carcinogen. Mutations induced by 
a particular carcinogen/mutagen can be influenced by DNA sequence context, 
mutagen/carcinogen dose, level of SOS induction, cell type and other factors. Adduct 
site-specific mutagenesis studies involves the synthesis of an oligonucleotide that 
contains an adduct of known structure at defined position and the use of recombinant
183
Chapter 4: 0 6-alkylguanine adduct specific Mutagenesis studies
techniques to incorporate this oligonucleotide in to an autonomously replicating 
plasmid or viral based vector. A variety of plasmid and phage-based systems have 
been used to perform adduct site-specific mutagenesis studies in a double stranded 
vector. The advantages of studying a lesion in double stranded vector is that the 
system comes as close as possible to resembling genomic replication. In our studies, 
plasmid based vector, pLS76, which contains p53 cDNA under p53 regulated 
promoter was used for adduct site-specific studies. The practicalities of site-specific 
incorporation of 0 6-alkylguanine containing oligonucleotides limit the possible sites 
for insertion. Ideally we would have liked to insert 0 6-CMdG adduct at a guanine that 
was a known site for mutation. However, despite a large number of characterised G- 
mutations specific to potassium diazoacetate, none of these sites between codons 120- 
260 of the p53 sequence lay within a short sequence between two unique restriction 
sites, which lies between codons 192-200. Codon 196 is chosen for insertion of 
modified adducts both on sense strand at nucleotide position 587 and on anti-sense 
strand at nucleotide position 586. The results section 3.1 of chapter 3 has described 
the procedures of synthesising adduct containing oligonucleotides. It has also 
discussed the results confirming the presence of adducts in oligonucleotides from the 
studies of nucleoside composition analysis, fluorescence analysis and melting curve 
measurement. 25 and 26mers that were synthesised are complementary sequences 
falling between BbvCl and Apol recognition sites. The complementary sequences 25 
and 26mers were annealed to form both normal and adducted duplex with BbvCl and 
Apol overhanging ends. Apol site is unfortunately a unique restriction site in p53 
cDNA but not in whole plasmid DNA. Hence, it took an additional step of double 
digestion at another restriction site, which is unique in both whole plasmid DNA and 
P53 cDNA to construct an intact plasmid containing 0 6-alkylguanine adduct. S a d  is
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a unique restriction site, which is located at downstream of Apol site. All the three 
DNA fragments i.e., BbvCl + S a d  double digest (8.5kb), Apol + S a d  (650kb) 
restriction fragment and duplex DNA containing adduct were ligated using the ligase 
enzyme to form an intact plasmid. Initially it was proposed to introduce this intact 
plasmid DNA containing O6-alkylguanine adduct in to some host cell and fix the 
mutations induced by O6-alkylguanine adduct with in the host cell. The idea was to 
use p53 yeast expression system, routinely used in the laboratories of academic unit of 
pathology, school of medicine, University of Leeds. This is a yeast system, which 
contains ADE2 gene under the control of p53 regulated promoter. Any mutation in a 
p53 gene interferes with its transactivation function. This is evident by formation of 
red colonies instead of normal white colonies. Unfortunately, frozen stocks of yeast 
cells (Saccharomyces cerevisiae strain, ylG 397) were not showing any signs of 
viability after plating. This strain is not commercially available. Thus, in vivo studies 
on mutagenesis of 0 6-CMdG adduct in yeast cells was given up. Later Novablue 
competent cells (Merck biosciences), were tried for fixing mutations in cellular 
environment. They enable convenient, efficient construction of plasmid recombinants 
[Section 2.3.3]. This system also works based on colour change reaction just as p53 
yeast expression system. However, for the purpose of this work, the goal was to fix 
mutation from adduct in cellular environment. The attempts to fix mutations from 
adduct in cellular host, hampered by re-ligation inefficiency of the restriction ends 
formed by BbvC 1 enzyme. Less than 5% of the ends formed by BbvCl can be re­
ligated. Hence, the amount of ligation mixture obtained was not enough to transform 
the cells with ligation mixture. The transfection of ligation mixture in to Novablue 
competent cells (Merck biosciences) was not successful. Finally, polymerase chain 
reaction was used to fix mutations. Even though the idea of fixing the mutations in
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cellular environment is faltered, the important thing here is to determine mutagenic 
specificity and types of mutation induced by (/-alkylguanine adducts. PCR is a very 
sensitive method and can amplify the desired sequences even from the small amounts 
of the target sources. p53 cDNA (800bp) from the genetically engineered plasmids 
containing adducts were amplified using the p53 specific primers. These primers can 
only amplify the p53cDNA from the intact plasmid. It is not possible to amplify p53 
cDNA, unless the three restriction fragments [double stranded plasmid (8.5kb), Apol 
+ S a d  restriction fragment (650bp) and duplex DNA] that were ligated form an intact 
plasmid. The PCR amplification results confirmed that all plasmids engineered to 
incorporate duplexes formed an intact plasmid, which otherwise would not be 
possible to amplify 800bp p53 cDNA, that was observed with positive control. p53 
cDNA amplified from both the normal and adducted plasmids were analysed using 
sequence specific primers with ARMS-PCR assay to determine the mutagenic 
potential of (/-alkylguanine adducts. ARMS-PCR is an assay designed to 
discriminate between target DNA sequences that differ by a single nucleotide in the 
region of interest. The primers are designed to differ at the nucleotide that occurs at 
the extreme 3' terminus. Since, the DNA synthesis step in a PCR reaction is 
dependent on correct base pairing at 3'-end, this method is particularly useful in 
detecting pathogenic mutations. Despite of having several disadvantages such as, 
inability to reflect the natural replication complexes of the cell systems, sequence 
context constraints, specificity of detecting and measuring point mutation but not any 
other genetic endpoints, purity of modified oligonuleotides, the in vitro system 
provide useful insights in to the type of mutations formed by adducts in question. Two 
separate sets of primers, which differ at the nucleotide that occurs at the extreme 3'- 
end were designed for analysis on both sense and anti-sense strand to double check
186
Chapter 4: 0 6-alkylguanine adduct specific Mutagenesis studies
the base pairing at adducted site. Different PCR conditions were designed to avoid 
unspecific amplification so that background is reduced which other wise will make 
results hard to interpret. The comparison of ARMS-PCR assay results of methylated 
adduct containing pLS76 - 2 and carboxymethylated adduct containing pLS76 - 4 
[both plasmids contain adduct on sense strand at nucleotide position 587- (codon 
196)] were quiet contrasting. ARMS-PCR assay results with control plasmid has 
confirmed normal GC base pairing as expected. Additional primer extension products 
were observed with plasmids, pLS76 - 2 and pLS76 -  4 apart from anti-sense strand 
specific primer extension product G and sense strand specific primer extension 
product C, confirming substitution mutations at adducted site. 0 6-MedG adduct from 
plasmid, pLS76 - 2, induced GC - AT transition at nucleotide position 587. The 
results with plasmid containing 0 6-CMdG adduct were quiet opposite. The 0 6-CMdG 
adduct induced GC - TA transversion mutation at nucleotide position 587. PCR 
condition 1 is a routine PCR program used in many molecular biology laboratories. 
This is not a very specific program and when used always ends up with non-specific 
amplifications making the gel look messy. Hence, more stringent conditions were 
designed that were specific for different primer pairs used in this assay. PCR 
conditions 7 and 3 were clearly making a striking difference between the types of 
mutations induced by 0 6-MedG and 0 6-CMdG adducts. At PCR condition 7, plasmid, 
pLS76 - 2 (06-MedG adduct) was giving the primer extension product with anti-sense 
strand specific primer A, where as plasmid, pLS76 - 4 (06-CMdG adduct) was not 
amplifiable. The other PCR conditions 2,3,4,5 and 6 were not able to demonstrate that 
difference. The similar result was observed with PCR condition 3. At PCR condition 
3, 0 6-methyl adduct containing plasmid, pLS76 - 2 was not amplifiable with sense 
strand specific primer A, where as 0 6-carboxymethyl adduct containing plasmid,
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pLS76 - 4 was amplifiable. At PCR conditions 2 and 3 both the plasmids, pLS76 - 2 
and pLS76 - 4 were amplifiable with anti-sense strand specific primer T. It was 
assumed that may be 0 6-CMdG and 0 6-MedG adduct are inducing both transition and 
transversion mutations. But the 0 6-methyl adduct containing plasmid, pLS76 - 2 was 
not amplifiable with sense strand specific program A with any of the PCR programs 
used, eliminating the scope of expecting a GC -  TA transversion mutation by O6- 
MedG adduct. However, in the assay, program 3 is used for this reaction mainly due 
to two reasons. First, one was to maintain similar conditions with all plasmids to 
avoid any scope of ambiguity in the interpretation of the results and secondly O6- 
carboxymethyl adduct containing plasmid, pLS76 - 4 was showing clear difference 
with control plasmid at this program. At the same time 0 6-carboxymethyl adduct 
containing plasmid, pLS76 - 4 was not amplifiable with sense strand specific primer T 
that, eliminates any scope of expecting a GC-AT transition mutation. Hence, it was 
assumed that anti-sense strand primer T specific primer extension product, observed 
with 0 6-methyl adducts containing plasmid, pLS76 -2 might be an artefact. Hence, the 
PCR condition 4 was used for the amplification at which no primer extension product 
with anti-sense strand specific primer T was observed with plasmid, pLS76 -  2. PCR 
condition 8 was used with both the plasmids to reduce unspecific amplification with 
sense strand specific primer G. The results with plasmids, pLS76 - 3 and pLS76 - 5 
containing adducts on anti-sense strand i.e., at nucleotide position 586 in codon 196 
were quiet different. Control plasmid on PCR reaction with sequence specific primers 
gave primer extension products with anti-sense strand specific primer C and sense 
strand specific primer G, which confirms the presence of normal GC base pair at 
nucleotide position 586 on anti-sense strand. These results look contrasting to the 
result obtained with control plasmid, analysed against plasmids containing adducts on
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sense strand. In fact, they were not different, but similar. This is because, the adduct 
site that is being analysed with 0 6-methyl adduct containing plasmid, pLS76 - 3 and
0 6-carboxymethyl adduct containing plasmid, pLS76 - 5 is present on anti-sense 
strand. It should always be remembered that primer extended products obtained with 
plasmids containing adducts on anti-sense strand will appear opposite way and should 
not be confused during interpretation of results. The results were obtained straight 
away with PCR condition 2 for plasmids containing adducts on anti-sense strand, 
except with sense strand specific primer T for which PCR condition 6 is used. Both 
methylated adduct containing plasmid, pLS76 -  3 and carboxymethylated adduct 
containing plasmid pLS76 -  5 induced GC-AT transition mutations. Many in vitro 
(Loechler et al., 1984; Safhill et al., 1985; Singer, 1989) and in vivo studies (Altshuler 
et al., 1996) have unanimously confirmed 0 6-MedG pairs with T and induce GC-AT 
transition mutation in repair free system. Results from this work are in agreement with 
literature. Interestingly ARMS-PCR assays results showed that 0 6-CMdG adduct can 
induce both transversion and transition mutations. These results are a bit puzzling. 
The next questions that immediately that comes in to our mind is how can a single 
adduct can induce multiple mutations? Usually in case of simple alkylating agents, 
that each adduct principally induces a single kind of mutation and that different 
mutations are induced by different adducts. For example, 0 6-MedG predominantly 
induces GC-AT transition, 0 4-alkylthymidines mainly induces AT-GC transition and
r\
O -alkylthymidines induces AT-TA tranversions. Two possible explanations are that 
the DNA polymerase might mistake 0 6-methylguanine for adenine and O4- 
alkylthymine for cytosine, because of the physical similarity of these bases. O6- 
methylguanine and adenine are similarly lipophilic and the X-ray crystallography 
studies on the nucleosides have shown a close similarity in bond angles and lengths
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between 0 6-methylguanine and adenine, and between 0 4-alkylthymine and cytosine. 
The second possible explanation is that the important factor in the miscoding is that 
the alkylG .T and alkyl T .G mismatch pairs retain the Watson-Crick alignment with 
N1 of the purine juxtaposed to N3 of the pyrimidine (Swann, 1990). However, in the 
case of 0 6-CMdG adduct, it seems that it is acting more like a bulky adduct that can 
induce multiple mutations. Previous KDA, carcinogen specific mutagenesis studies 
using p53 yeast expression assay demonstrated that majority of the mutations induced 
by 0 6-CMdG adduct were GC-AT transitions than any other substitution mutations 
(Gottschalg et al., 2006). The possible mechanism by which 0 6-CMdG adduct could 
induce multiple mutations are discussed below. The different conformations formed 
by 0 6-CMdG adduct might induce different mutations. The best evidence comes from 
the studies on the C8-oxo-Gua adduct, which pairs with C when it is anti- 
confirmation and with A when it is in syn confirmation (Loechler, 1996). 0 6-CMdG 
on sense strand might be in a configuration that can form base pair with A with lowest 
possible energy. Another possibility is that adenine is preferentially incorporated 
opposite a range of lesions in certain cases, and this preference has been called the 
“A-rule”. The A-rule is simply a categorization and not an explanation for mutation 
pattern. DNA polymerase could not be able to determine the base identity from its 
structural configuration and should simply have incorporated A opposite 0 6-CMdG 
base. In addition, the presence of extra charge on 0 6-CMdG adduct might affect the 
base incorporation by DNA polymerase. Not all mutagenic events cannot be 
interpretable in terms of mis-pairing properties, there is always a lesser or greater 
degree of ambiguity. It also cannot be ruled out that oligonucleotide containing O6- 
CMdG adduct might have undergone depurination at some stage. This may have led 
to the formation of abasic site in plasmid resulting in transversion mutation.
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Additional site-specific conformational studies on 0 6-CMdG adduct, kinetic studies 
on base pairing properties and sequence context effects on mutagenesis are to be 
explored to understand the mechanisms by which Oe-CMdG adduct induces multiple 
mutations.
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5.0 INTRODUCTION
The p53 tumour suppressor gene is at the forefront of cancer research because it is the 
most commonly mutated gene in human cancers. The p53 mutation spectrum provides 
clues to the etiology and molecular pathogenesis of cancer disease. This protein is 
clearly a vital component in biochemical pathways leading to carcinogenesis. Both the 
missense mutations and loss of p53 protein by non-sense or frameshift mutations 
provide a selective advantage for clonal expansion of preneoplastic and neoplastic 
cells. One explanation for the commonality of p53 mutations in human cancer is the 
potential for a missense mutation to cause loss of tumour suppressor function and gain 
of oncogenic activity, i.e., both endogenous and exogenous carcinogens as well as 
biological processes are known to cause mutations in the p53 gene. Classes of DNA 
damage include deletion, substitution, transition (change of a pyrimidine to 
pyrimidine or a purine to a purine) or transversion (change of a pyrimidine to a purine 
or vice versa). Chemical carcinogens and their metabolites induce mutations by 
forming covalent adducts with the nucleotides in DNA. Some pre-mutagenic lesions 
such as 0 6-methylguanine formed due to attack of alkylating agents on DNA, may 
cause DNA polymerase to misread the base pairing due to the altered hydrogen 
bonding of a base, which contains additional methyl or ethyl group. A well 
documented line of evidence established that the most common mutations caused by 
alkylating agents are GC-AT transitions, consistent with <96-methylguanine 
mispairing with thymine. Bulky carcinogen-DNA adducts may render the bases 
unreadable and stall the replication machinery. DNA polymerases fill these non- 
instructive sites preferentially with adenine. This leads to GC-TA transversions. Many 
studies using prokaryotic or eukaryotic cells and site-specific mutagenesis assays have 
shown that some carcinogenic agents produce fingerprints i.e., specific types and
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locations of adducts have been linked with the mutation spectrum of an agent 
(Greenblatt et al., 1994).
One of the goals of carcinogenesis research is to identify the 
precise molecular alterations responsible for neoplastic transformation, abnormal 
differentiation, and growth control. Molecular epidemiology has made an attempt to 
integrate traditional epidemiological investigation of cancer risk factors with the 
substantial expansion of knowledge of the molecular mechanisms of the cellular 
processes. Mutation spectrum analysis is the study of types and locations of DNA 
alterations. It describes the characteristic patterns of DNA changes caused by 
endogenous and exogenous mutagens. These alterations represent the interactions of 
carcinogens with DNA and cellular DNA repair processes. They also reflect the 
selection of those mutations, which provide premalignant and malignant cells with a 
growth advantage. Animal models provide opportunities for mutation spectrum 
studies that cannot be performed with human tumours. The carcinogen-induced 
mutations in cancer related and house keeping genes can be compared in rodent and 
human cells [Appendix 4]. This is useful to asses the relevance of these model 
systems to human carcinogenesis (Greenblatt et al., 1994).
The P53 tumour suppressor gene has very high frequency of 
point mutations in human tumours [Appendix 5]. The locations of inactivating tumour 
mutations are numerous and dispersed. In contrast to other tumour suppressor genes, 
about 87% of the somatic p53 mutations are missense mutations that lead to amino 
acid substitutions in proteins thus altering protein conformation. Approximately 13% 
are complex mutations and short insertions or deletions. More than 90% of all 
mutations identified today have been observed in the DNA binding domain and 
mainly affect amino acids in highly conserved regions. The residues most commonly
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Codon distribution of p53 Somatic Mutations:
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Figure 5.1: Codon distribution o f  somatic p53 mutations according to version o f R5 o f  the IARC p53 
mutation database (Hernandez-Boussard and Hainut, 1998).
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Figure 5.2: Codon distribution o f germ-line p53 mutations according to version o f  RIO o f  the IARC  
p53 mutation database [www-p53.iarc.fr].
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mutated (codons 175, 245, 248, 249, 273 and 282) represent about 30% of all somatic 
mutations [Figure 5.1] (Hainut and Hollstein, 2000). With the exception of codon 245, 
five of the six most frequently mutated codons encode arginine residues. These 
codons play distinct roles in protein-DNA interactions either via directly contacting 
DNA (residues 248 and 273) or via contributions to the stability of the DNA binding 
surface (residues 175, 249 and 282) (Cho, 1994). Hotspots at codon 175, 248 and 273 
account for approximately 21% of all mutations. This high rate can be explained in 
part by the presence of a CpG dinucleotide in these residues. CpG dinucleotides are 
known to be frequently methylated in the vertebrate genome increasing the 
probability of mutations at such sites. The high frequency of C—>T transitions found 
at CpG dinucleotides in general is believed to result from spontaneous deamination of
5-methylcytosine. Thymidine is formed via deamination of 5-methylcytosine thus 
resulting in a G:T mismatch, which, if not repaired, creates a C—>T transition. 
(Ehrlich,1981; Hussain and Harris, 1998). On average these mutations account for 
approximately 25% of tumour mutations in all human malignancies. The prevalence 
of GC—>AT transitions at CpG sites is higher in internal cancers such as colorectal 
cancer (-50%), whereas in patients with head and neck cancer, mutations in CpG sites 
are relatively uncommon (Sidransky and Hollstein, 1996; Moll and Schramm, 1998). 
According to the R10, IARC database contains 283 germ-line mutations of which 
85% are point mutations and approximately 15% are complex mutations and short 
insertions or deletions. Residues most commonly mutated are codons 133, 152, 153, 
175, 213, 233, 245, 248, 273, 282, 308 and 337 [Figure 5.2].
Many studies, which induced p53 mutations experimentally 
in mice that are exposed to carcinogens, have not contributed significantly in 
understanding mutagenic mechanisms and origin of mutations in human cancers. The
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experiments with the standard laboratory murine models used to generate the 
mutation pattern data from the mouse p53 genes. The experiments are clearly 
heterogeneous. This approach has limitation of species difference in the p53 gene 
between mouse and human sequences, which restrict interpretation of the distribution 
of mutations along the gene and their accumulation at preferential locations. This 
makes the process of inter-study comparisons and conclusions that can be drawn 
regarding the frequency of p53 mutations complicated. Hence, an experimental model 
is needed to induce p53 mutations in human p53 gene in vivo (Greenblatt et al., 1994).
Transcription Studies 
by E xpre s sion Micro an ay te clmolo gy
Mutation spectr aHupM
* *
by p53 Gene Chip technology
Genetic Network
Figure 5.3: The Hupki mouse: a new biomedical research tool (Zelinski et al., 2002).
Recently, Gene-targeting technology has allowed 
development of a new mouse model, which explores experimentally the endogenous 
and environmental factors that may contribute to neoplastic disease in humans. This 
mouse model is called human p53 knock-in mouse (Hupki) in which the core domain 
of the endogenous murine p53 allele has been replaced with the homologous, normal 
human p53 sequence. The exons 4-9 of the murine endogenous p53 gene are replaced 
with the homologous human sequences. This is a very useful model in comparing the 
frequency of mouse mutations at specific positions in the p53 gene following the
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carcinogen exposure directly with the human data. The mutation pattern in the p53
gene provides clues on the environmental agents or endogenous biological processes
that generate these mutations. The other applications of Hupki mouse are that it is also
useful in investigating the role of apoptosis in mice and humans as well as in drug
screening [Figure 5.3] (Zielinski et al., 2002).
It was observed that when epidermal cells of Hupki mouse
irradiated with single acute dose of UVB light, they accumulate UV photoproducts at
2 .
the same location as p53 gene of human cells. DNA preparations from 2cm sections 
of chronically irradiated Hupki epidermis harbour C to T and CC to TT mutations at 
two hotspots identified in human cancer, one at codons 278-279 and one at codons 
247-248 (Liu et al., 2004). Thus Hupki mouse offers an in vivo approach to such 
investigations. As we already know that nitrosoglycine derivatives react with DNA to 
give rise to modified 0 6-alkylguanine adducts. It is also known that this adducts 
induce GC-AT transition mutations in p53 tumour suppressor gene. Hence, it would 
be interesting to study the mutation spectrum of nitrosoglycine derivative, potassium 
diazoacetate (KDA) in p53, tumour suppressor gene using the above model. 
Potassium diazoacetate is particularly interesting because it is a stable nitrosoglycine 
derivative. This mouse model was used in this project to study the types and locations 
of mutations induced by nitrosoglycine derivative, potassium diazoacetate to 
understand the mechanisms of mutations by which this carcinogen induces mutations. 
This part of the research project was carried out in the labs of our collaborator Dr 
Monica Hollstein, Dept of Genetic Alterations in Carcinogenesis, German Cancer 
Research Centre, Heidelberg, Germany. The above-mentioned murine model studies 
were routinely carried out in their laboratory to study the p53 mutation spectrum 
induced by wide variety of mutagens.
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5.1 Results
5.1.1 Synthesis and Characterisation of Potassium diazoacetate (KDA)
Potassium diazoacetate was synthesised according to reported synthetic route 
(Kreevoy and Konsewich, 1970) [Section 2.4.1]. The starting material ethyl 
diazoacetate (Catalogue No: E-22201) was purchased from Sigma-Aldrich. Ethyl 
diazoacetate (1.14g, 1.06ml) was stirred in dark with a solution of potassium 
hydroxide (1.14g, 2mol equivalents) in water (11.4ml) until the mixture becomes 
homogenous (ca. 4h) [Figure 5.4]. The resulting solution (0.9M) was stored at -80°C 
until required when it is thawed and diluted in water to a suitable concentration and 
used without further purification. Attempts to purify the material are known to result 
in extensive decomposition and polymerisation. The potassium diazoacetate was 
freeze-dried to obtain a fine yellowish powder and was characterised using LC-MS.
Reaction:
o  o
-  + II -  + II _ +
N=N=CH— C -O -E t  +  KOH --------- ► N = M = C H -C -Q -K
(Ethyl diazoacetate) (Potassium diazoacetate)
Figure 5.4: Synthesis of Potassium diazoacetate (Kreevoy, 1970).
5.1.2 Results of Cytotoxicity tests of Potassium diazoacetate
Potassium diazoacetate is particularly interesting because it is a member of family of 
nitrosated glycine derivatives which decompose or rearrange to give 
carboxymethylating agents resulting in the formation of 0 6-carboxymethyl-2'- 
deoxyguanosine. Two independent cytotoxicity tests were performed to determine and 
confirm the optimal mutagenic dose of potassium diazoacetate [Section 2.4.2]. 
Qualitative data on sensitivity and percentage cell survival for controls and the KDA
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Toxicity Tests of Potassium diazoacetate (KDA) on Hupki fibroblast cells (HUF):
C y to to x ic ity  T e s t l  o n  H U F c e l l s  w ith  K D A
4.5 i
3.5 - -♦— Control
-a— 0.1 micromolar KDA 
■m— 1 micromolar KDA 
■x— 10micromolar KDA
o
0.5
48 72 9624
H o u r s
Figure 5.5: Cytotoxicity Test 1 o f  potassium diazoacetate (KDA) on Hupki mouse embiyonic fibroblast 
cells. Controls were treated with DMEM medium supplemented with 10% FCS with out any KDA. All 
the cells were exposed to KDA treatment for24 hrs. Cell viability was monitored for 96 hrs at regular 
intervals o f  24hrs by cell counting.
C y to to x ic ity  T e s t  2  o n  H U F  c e l l s  w ith  K D A
12.5
o 7.5T~
X
2.5
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-Tir-5m icromolar KDA 
lOmicromolar KDA 
20micromolar KDA
H o u r s
Figure 5.6: Cytotoxicity Test 2 ofpotassium diazoacetate (KDA) on Hupki mouse embryonic fibroblast 
cells. Controls were treated with DMEM medium supplemented with 10% FCS with out any KDA. All 
the cells were exposed to KDA treatment for24 hrs. Cell viability was monitored for 114hrs at regular 
intervals o f  24hrs by cell counting.
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Percentage Viability of HUF cells treated with KDA
P e r c e n t a g e  v ia b ility  o f  H U F c e l l s  tr e a te d  w ith  K D A
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Figure 5.7: Percentage viability o f HUF cells calculated from the results o f  cytotoxicity Test 1 o f  
potassium diazoacetate (KDA) on Hupki mouse embryonic fibroblast cells. Survival percentage 
represents total number o f cells present in the samples treated with KDA divided by total number o f  
cells present in the control samples at corresponding time point.
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Figure 5.8: Percentage viability o f  HUF cells calculated from the results o f cytotoxicity Test 2 o f  
potassium diazoacetate (KDA) on Hupki mouse embryonic fibroblast cells. Survival percentage 
represents total number o f  cells present in the samples treated with KDA divided by total number o f  
cells present in the control samples at corresponding time point.
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Table 5.1: Quantitative data of cytotoxicity test 1 showing sensitivity and 
percentage survival of HUF cells treated with KDA
H o u r s c o n tr o l 0 ,1 |lM 1jlM lO pM
2 4 0.4537 0.4537 0.4537 0.4537
4 8 0.8225 0.8675 0.7025 0.465
7 2 1.815 1.9 1.91 0.825
9 6 4.12 3.11 2.46 1.24
5.1(a)
H o u r s OuM 0 ,1  mm 1HM 10pM
2 4 100 100 100 100
4 8 100 100 85 57
7 2 100 100 100 45
9 6 100 75 60 30
5.1(b)
Table 5.1(a): Cell growth data o f cytotoxicity test 1. Growth is monitored by cell counting to determine 
the sensitivity o f cells to different concentrations of KDA. Table 5.1(b): Peixentage viability data of 
cytotoxicity test 1. Percentage viability is calculated to determine KDA concentration that reduced the 
number of cells to 50% of control (ICS0).
treated samples of two independent cytotoxicity experiments are displayed in figures
5.5, 5.6, 5.7 and 5.8. Percentage cell survival represents the total number of cells 
obtained for KDA treated samples divided by number of cells in control plates. Figure 
5.5 and Figure 5.6 shows the cell survival as measured by counting the number of 
cells from samples treated over the dose range of 0 -  10pm and 0 -  20pm at regular 
intervals of 24hrs. The viability of cells was monitored at regular intervals of every 
24hrs by cell counting for up to 96 hrs in test 1 and 144hrs in test 2. Figures 5.7 and 
5.8 shows percentage cell survival as measured by dividing the total number of cells 
obtained for KDA treated samples at each time point by total number of cells present 
in the control samples with respect to that particular time point. A dose dependent
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increase in sensitivity and decrease in the percentage of the cell survival was observed 
from both the experiments.
Table 5.2: Quantitative data of cytotoxicity test 2 showing sensitivity and 
percentage survival of HUF cells treated with KDA
H o u r s C o n tr o l 1|jM 5pM 10pM 20|JM
2 4 1.295 1.295 1.295 1.295 1.295
4 8 1.330 1.310 1.275 1 . 2 1 0 0.705
7 2 1.510 1.480 1.530 1.035 0.520
9 6 2.730 2.360 2 . 1 2 0 1.470 0.500
1 4 4 6.620 8.610 6.825 3.930 3.370
5.2(a)
H o u r s c o n  1 1pM 5pM 10pM 20p M
2 4 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0
4 8 1 0 0 98 96 91 53
7 2 1 0 0 98 1 0 0 69 34
9 6 1 0 0 8 6 78 54 18
1 4 4 1 0 0 1 0 0 1 0 0 59 51
5.2(b)
Table 5.2(a): Cell growth data o f  cytotoxicity test 2. Growth was monitored by cell counting to 
determine the sensitivity o f  cells to different concentrations o f  KDA. Table 5.2(b): Percentage viability 
data o f  cytotoxicity test 2. Percentage viability was calculated to determine KDA concentration that 
reduced the number o f cells to 50% o f control (IC50)-
Ideal toxic dose is the one that reduces the number of viable cells to 50% with respect 
to control. In cytotoxicity experiment 1, for lOpM KDA treatment a survival rate of 
57 and 45% were observed at 48 hrs and 72 hrs, whereas survival rate is almost 100% 
for 0.1 and lpM  KDA treatments with respect to control [Table 5.1(a) and 5.1(b)]. 
The above data shows that the sensitivity of HUF cells to KDA was increased 43 and
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55-fold following incubation with lOpM KDA by 48 and 72 hrs. HUF cells treated 
with 0.1 pM KDA had not shown any signs of sensitivity, whereas cells treated with 
lpM KDA showed 15-fold increase in sensitivity at 48 hrs and relatively no signs of 
sensitivity at 72hrs. The results from the above data indicate that concentration of 
lOpM KDA is an ideal IC50 concentration to carry our subsequent mutagenesis 
studies. However, the above data is further analysed by comparing the results from 
another set of experiments. This set of experiments excluded 0.1 pM KDA treatments, 
but additionally included 5pM and 20 pM KDA treatments to determine exact IC50 
dose of KDA. The results from second set of experiments are slightly varying from 
the results obtained from the first set of experiment.
In cytotoxicity experiment 2, for lOpM KDA treatment a 
survival rate of 91 and 69% compared to 57 and 45% was observed at 48 hrs and 72 
hrs. However, the survival rate of HUF cells incubated with lOpM KDA is 54 and 
59% at 96 and 144hrs. The survival rate of cells treated with 20pM KDA treatments 
are 53 and 34% at 48 and 72hrs dropping to 18% by 96 hrs. The survival rates of cells 
incubated with lpM and 5pM KDA is almost 100% up to 72hrs there after dropping 
down to 86 and 78% by 96hrs. In other words the sensitivity of HUF cells was 
increased by 9, 31 and 46-fold in test 2 compared to 43, 56 and 70- fold in test 1, 
following incubation with lOpM KDA for 48, 72 and 96 hrs. Whereas, cells treated 
with 20pM KDA showed 47, 66 and 92-fold increase in sensitivity at 48, 72 and 
96hrs. Cells treated with 1 and 5 pM KDA showed 14 and 24-fold sensitivity after 
96hrs with respect to control [Table 5.2(a) and 5.2(b)].
Even though toxicity test 2 indicated cells incubated with 20pM 
KDA showed better toxicity profiles than cells treated with lOpM KDA by 48hrs, the 
percentage cell survival of cells incubated with 20pM was drastically dropped down
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to 34 and 18% compared to 69 and 54% of cells incubated with lOpM KDA by 72 
and 96hrs. The toxic effects observed with lOpM KDA concentrations from both sets 
of experiments are progressive rather than sudden drastic changes observed with cells 
treated 20pM KDA concentrations. In other words, toxic effects of 20 pM KDA 
concentration that were monitored by increase in cell sensitivity and decrease in 
percentage cell survival were severe compared to 10pM KDA concentrations. The 
cell sensitivity and percentage cell survival of cells incubated with lOpM KDA were 
moderate enough to obtain mutant clones. Hence, subsequent experiments were 
carried out with lOpM KDA treatments to obtain mutants for p53 analysis.
5.1.3 Results of p53 Mutation Analysis
Primary embryonic fibroblasts from Hupki embryos (Trp53tml/Ho11, homozygous for 
the Knock-in p53 allele harbouring human p53 sequences) were distributed at 2xl05 
cells/per well into 6-well plates and grown in DMEM medium supplemented with 
10% FCS. Two independent experiments were carried out of which one experiment 
consisted of totally 48 clones exposed to lOpM of KDA and the other experiment 
consisted of 24 clones exposed to lOOpM of KDA at described in section 2.4.2. 36 
clones of HUF cells that were not subjected to any treatment were used as positive 
controls. Initially cultures incubated with 10pM KDA did not show enough signs of 
toxicity. Due to the highly unstable nature of KDA, the toxicity profiles of this 
compound are varying from experiment to experiment. It is assumed that KDA might 
be decomposing very fast when mixed with the culture medium. Hence, another 
experiment was set up with clones treated with KDA concentration increased by 10- 
fold. This experiment was set up as a backup, just in case, that if any chance to obtain 
mutant clones from cultures treated with lOpM KDA were hampered. Cultures were
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passaged at ratios ranging from 1:2 to 1:4 dilutions until clones survived the stress 
period to form morphologically homogenous clones. Genomic DNA was then 
extracted from these morphologically homogenous clones as described in section
2.4.5. DNA binding domain (DBD) sequence of the p53 gene were examined by PCR 
amplification of p53 exons 4-9 using fluorescent dideoxynucleotide cycle sequencing 
using agents, primers, standard protocols, and equipment (Model 310 Genetic 
analyser) from Applied Biosciences International (ABI, Salt Lake City, UT), 
essentially as described previously [Section 2.4.4]. The genomic DNA of some of the 
mutant clones that were obtained from cultures incubated with lOpM KDA was 
sequenced to detect the presence of any functional mutations in the DBD region of 
p53 gene. The results did not show the presence of any functional mutations in the 
DNA binding region of p53 gene (exon 4 -  9). It was assumed that KDA treated 
clones might have incurred spontaneous mutations by secondary mechanism at some 
other down stream targets of p53 gene, which lead to the formation of homogenous 
clones that survived the crisis period. Hence, further sequencing of the remaining 
clones was not carried out.
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5.2 Discussion
Several studies have pinpointed the fact that p53 plays a central role in tumorigenesis 
both in humans and in experimental systems. Since 1989, about 570 different p53 
mutations have been identified in more than 8000 human cancers. The prevalence of 
p53 mutations varies among tumour types ranging from 0 to 60% in major cancers 
and is over 80% in some histological subtypes [Appendix 6] (Greenblatt et al., 1994). 
M. Hollstein and C.C.Harris initiated a database of these mutations in 1990. This 
database originally considered of a list of somatic point mutations in the p53 gene of 
human tumours and cell lines compiled from published literature and made available 
in a standard electronic form. The database is maintained at the International Agency 
for Research on Cancer (IARC) and updated versions are released twice every year 
(January and July) (Hainut et al., 1998). To date as per R10 released in July 2005 
from IARC the database contains 21,587 somatic mutations [appendix 7] reported in 
1,876 original publications, 283 germ-line mutations [appendix 8] reported in 129 
publications (published between 1989 and December 2004) and functional 
information on more than 425 mutant proteins. The database is available in different 
electronic formats at IARC (http://www.iarc.fr/p53/homepage.htm) or from the 
European Bioinformatics Institute (EBI) server (http://www.ebi.ac.uk) (Hainut et al., 
1998). A large and diverse collection of human tumour mutations at a specific locus 
of p53 provides information of mutation spectra of environmental or endogenous 
biological factors that elicit genetic damage and development of cancer (Hainut and 
Hollstein et al., 2000). P53 gene is well suited to mutations spectrum analysis for 
several reasons, (1) since p53 mutations are common in many human cancers (2) Its 
modest size (11 exons, 393 amino acids permits study of the entire coding region. (3) 
Point mutations that alter p53 function are distributed over a large region of the
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molecule (Greenblatt et al., 1994). Mutations appear because of endogenous processes 
or of the action of exogenous, physical or chemical carcinogens. Endogenous 
processes include methylation and deamination of cytosine at CpG residues, injury by 
free radicals generated by biological processes and errors in DNA-repair and 
synthesis. Mutations do not form at an equal rate at all base positions. For example, 
formation of adducts in p53 DNA by metabolites of benzo(a)pyrene occurs 
preferentially on guanines adjacent to methylated cytosine. DNA repair is also 
thought to be more efficient in actively transcribed genes than in silent DNA regions, 
and to be faster on the DNA strand used as a template for transcription than on the 
coding strand. Thus strand bias in the distribution of mutations indicate, involvement 
of the exogenous carcinogens. However, experimental evidence for the role of 
transcription-coupled repair in such bias is still inconclusive (Hainut et al., 1998). 
Individual mutagens generate characteristic changes, which are known as fingerprints 
of DNA damage at specific locations along a given DNA sequence. The analysis of 
p53 mutation database has revealed such examples of patterns of mutations consistent 
with fingerprints of DNA damage induced by defined exogenous carcinogens. These 
examples include G—>T transversion at codon 249 in hepatocellular carcinomas of 
patients with high dietary exposure to Aflatoxin B1 and tandem CC—»TT mutations, a 
typical signature of UV-Induced mutagenesis. However, in most cancers, the patterns 
of mutations are complex. Cancers associated with tobacco smoking is a good 
example for this complexity. Smoking is a risk factor for several cancers, including 
cancers of the oral cavity, oesophagus, lung and bladder. In all pathologies, the 
prevalence of p53 mutations is generally higher in smokers than in non-smokers. 
However, the spectrum of p53 mutations varies from one pathology to the other. For 
example, the typical signature mutations by benzo(a)pyrene in lung cancers are G—>T
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transversions. Experimental evidence shows that benzo(a)pyrene preferentially form 
adducts at codons 157, 248 and 273, which are all mutation hot spots in lung cancer. 
In squamous cell carcinoma of oral cavity and oesophagus, the predominant types of 
mutations are transitions or transversions at A:T base pairs and G —> A transitions. In 
these cancers the combined consumption of tobacco and alcohol is considered to be a 
cumulative risk factor and the observed spectrum is consistent with the role of N- 
nitrosamines (G:C transitions) and of metabolites of ethanol such as acetaldehyde 
(mutations at A:T bases) (Hainut et al., 1998). In principle, the p53 mutation spectrum 
data can be used to generate hypotheses regarding disease risk factors in a defined 
population (Hussain and Harris, 1999). In practice, however, interpretation of p53 
mutation patterns observed in human tumours from murine models has proved 
difficult. Although, there are yeast-based in-vitro methods to generate mutation 
spectra in human p53 sequences there have been no practical in vivo approaches 
(Fronza et al., 2000). The murine p53 gene is not an optimal target sequence to 
explore origins and modulators of p53 mutation patterns found in human tissues, 
because the mouse p53 gene differs from the human coding sequence at 15% of 
residues. However, human p53 knock-in mouse (HUPKI) mouse was engineered to 
replace core domain of the endogenous murine p53 allele with the homologous 
normal human p53 gene sequence (Luo et al., 2000). Hence, this model offers an in 
vivo approach for such investigations and comparison with human data. It is already 
known that methylating agents such as MNNG and MNU have been shown to 
produce gastric cancer (Preussmann et al., 1984) and dimethyhydrazine is associated 
with colorectal cancer (Druckrey et al., 1967). These agents generate methylating 
agents after metabolic activation and result in DNA adducts in target organs (Herron 
and Shank, 1980; Preussmann and Stewart, 1984). The levels of 0 6-MedG adduct
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were also found to be increased in individuals with intragestinal tract tumours (Hall et 
al., 1991; Jackson et al., 1996; Krytopoulos et al., 1984; The Eurogast Study Group, 
1994; Umbenhauer et al., 1985). All these data suggests that methylating agents may 
be involved in the etiology of these cancers. Therefore, intragastric nitrosation and 
intraintestinal nitrosation were thought to be major sources of alkylating agents. 
Further evidence for this hypothesis is the observation in human volunteers that 
increased protein intake results in elevated levels of intra-intestinal total NOC and a 
number of epidemiological studies have linked high protein intake with increased risk 
for GI tract, particularly colorectal cancers (UK department of health, 1998). 
However, it is unlikely that MNNG and MNU occur naturally in the GI tract 
indicating that major targets of nitrosation are amino acids and dietary proteins 
(Mirvish, 1995; Sheperd and Lutz, 1989). The nitrosation products of glycine would 
probably constitute a major source of alkylatings agents, as glycine is one of the most 
abundant amino acids in nature (Sedgwick, 1997). It has already been reported that
0 6-CMdG, the major 0 6-guanine adduct of nitrosated glycine derivatives, is not 
repaired by 0 6-alkylguanine-DNA-alkyltransferase, so could accumulate in the DNA 
of GI tissues as promutagenic lesion (Shuker and Margison, 1997). Further evidence 
of the likely human exposure of nitrosated glycine is based on the fact that 0 6-CMdG 
is indeed detectable in gastric biopsies and human blood DNA samples using a 
sensitive immunoslot blot (ISB) assay (Cupid et al, 2004; Singh et al., 2000). 
Potassium diazoacetate (KDA) is particularly interesting because it is a stable 
nitrosated derivative of glycine which decomposes or rearrange to give 
carboxymethylating agents resulting in the formation of 0 6-carboxymethyl-2'- 
deoxyguanosine and 0 6-methyl-2'-deoxyguanosine. It was also reported that KDA is 
a powerful alkylating agent than APNG. It produced 8-fold increase in O6-
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carboxymethyl-2'-deoxyguanosine and 11 fold increase in <96-methyl-2'- 
deoxyguanosine (Harrison et al., 1999). Although KDA was initially synthesised in 
1908 its genetic effects have been never investigated. In the wake of the recent 
findings that linked high dietary protein consumption with colorectal cancers, it would 
be interesting to investigate the role of KDA via carboxymethylating adducts in 
colorectal cancers. The highly evolved genetically engineered Hupki mice with human 
p53 gene sequence means that we can generate KDA p53 gene mutation spectra 
experimentally. Thus, information regarding mutational specificity of KDA such as 
types, locations, hotspots and frequency of mutations can be obtained. This will allow 
us to compare the experimental p53 mutation data to human p53 mutation data of 
colorectal cancers from IARC database that will further help us to understand the 
mechanisms of mutation induction and carcinogenesis by nitrosoglycine derivatives. 
KDA was synthesised according to reported synthetic route (Kreevoy and 
Konasewich, 1970). The potassium diazoacetate was freeze-dried to obtain a fine 
yellowish powder and was characterised using LC-MS. (M+H+) found at 123.96 
observed with positive ion mode confirmed that the product obtained was potassium 
diazoacetate. Two independent cytotoxicity tests were performed twice to determine 
optimal mutagenic dose (IC50) of potassium diazoacetate by monitoring cell growth 
and calculating percentage viability of cells. The results of cytotoxicity tests showed 
us a trend of decreasing number of cells with increasing concentrations of KDA. Cell 
growth was monitored by counting the cells present in KDA incubated samples with 
respect to controls at regular intervals. Percentage viability was calculated by dividing 
the total number of cells in KDA treated sample by number of cells present in controls 
at that respective time point. The results of the cytotoxicity tests indicated that 10pM 
KDA dose is the optimal mutagenic dose (IC50) to obtain mutant clones. Previous
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cytotoxic studies on nitrosoglycine derivatives have reported to observe similar trend 
of decreasing percentage of viability on increasing dose. Previous studies on 
genotoxic effects of KDA were investigated by monitoring DNA damage in a comet 
assay. KDA showed dose related responses in the comet assay in vitro in the different 
cell types, over the dose range of 0 - 4nM (Anderson et al., 1999). Another study also 
reported dose dependent decrease in survival and mutation frequency in E.coli cells 
transfected with plasmid DNA treated with KDA over the dose range of 0 -  lOmM 
(Gottschalg et al., 2006). Two independent mutagenesis experiments were carried out 
of which one experiment consisted of totally 48 clones exposed to lOpM of KDA and 
the other experiment consisted of 24 clones exposed to lOOpM of KDA. The clones 
were passaged until mutant selection and clonal expansion process is completed. The 
fluorescent dideoxynucleotide cycle sequencing results of DNA binding domain 
(DBD) sequence of the p53 gene of seven of the clones treated with lOpM KDA did 
not show the presence of any functional mutations. The results suggested that KDA 
treated clones might have incurred spontaneous mutations by secondary mechanisms 
at some other down stream targets of p53 gene, which had lead to the formation of 
homogenous clones that survived the crisis period. Since, KDA is quiet unstable, it 
was assumed that as soon as KDA is mixed with DMEM media, it started 
decomposing. Therefore, the toxic effects of KDA to which cells were exposed might 
be low. Hence, further sequencing of the remaining clones was not carried out. 
Previous mutation studies of KDA on p53 gene using p53 yeast expression assay has 
indicated that most common mutations induced by KDA were base pair substitutions 
(Gottschalg et al., 2006). The mutations were obtained by treating plasmid, pLS76 
with KDA mixed either in IX Tris-EDTA (TE) or Phosphate Buffered Saline (PBS 
Buffer). Approximately 57% of all mutations induced by KDA treatments in IX TE
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buffer were targeted at GC base pairs, where as 29% were directed against AT base 
pairs. Of these substitutions 53% were transitions, most of which were GC—>AT 
(74%) base pairs. Transversions accounted for 47% of the base pair substitutions and 
were comprised largely of GC—>TA (42%) and AT—>TA (32%). The remaining 
mutations (14%) were identified to be mainly base pair deletions (Gottschalg et al., 
2006). In contrast to treatments carried out in TE buffer, the percentage of mutations 
directed against AT base pairs is elevated to 43% with KDA treatment in IX PBS 
buffer. 49% were transitions, most of which were GC—»AT (74%) base pairs. 
Transversions accounted for 51% of the base pair substitutions and encompassed 
mainly AT—>TA (32%) [Appendix 9] (Gottschalg et al., 2006). KDA mutation 
spectrum obtained from yeast-based p53 functional assay was compared with stomach 
p53 mutation spectra data from IARC database. One of the most common base pair 
substitutions in stomach cancer is the AT—>GC transition at codon 220. KDA was 
shown to be able to induce this mutation in vitro. One of the gastric mutational 
hotspot, a GC transversion at codon 176 was also seen in the KDA- induced p53 
spectrum in vitro. GC—>AT mutations at codons 146, 151, 192, 277 and 278 were 
observed in the yeast based assay as with p53 database. However, other hotspots in 
the gastric tumour spectrum such as GC—>AT transitions at codons 138, 159, 173 and 
289 were not observed (Gottschalg et al., 2006). KDA was able to induce GC—>AT 
transition at codon 241 that is an abundant hotspot in colon cancer according to IARC 
p53 database. Similar observations were made at codons 146, 238, 272 and 278. The 
statistical comparison of in vitro p53 mutation spectra data with IARC gastric p53 
mutation data using Cariello’s software indicated that that the two spectra were 
different (Gottschalg et al., 2006). Hence, it would be more interesting to repeat this 
experiment with HupJci mouse model that has several advantages over other in vivo
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and in vitro models. It will enable us to obtain information regarding the mutagenic 
specificity of KDA that is quite closer to the data of human p53 mutation spectrum 
that will enable better understanding of the mechanisms of mutagenesis by 
nitrosoglycine derivatives. DNA was extracted from HUF embryonic fibroblasts 
incubated with increasing KDA concentrations for adduct analysis. These samples 
were supposed to be analysed using immunoslot-blot (ISB) procedure to detect and 
measure the amount of 0 6-alkylguanine adducts present in the KDA treated DNA 
samples. The idea was to observe a trend of increase in the number of adducts with an 
increase in the concentrations of KDA. Since the project has reached its final stage 
and so funding and time allotted to his project, this analysis has not been carried out.
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6.0 Introduction
The carcinogenic activity of many chemicals is found to depend upon their ability to 
act as electrophiles. Some carcinogens are inherently electrophilic and some 
spontaneously hydrolyse to active species in solution or are activated by cellular 
enzymes. The resultant reactive intermediates modify the constituents of DNA, 
forming covalent adducts in which the carcinogen residue is joined to nucleophilic 
atoms of the constituent nucleotides. DNA adducts have the potential to force 
replication errors and repairs and thus be chemical progenitors of heritable genetic 
alterations. 0 6-carboxymethyl-2'-deoxyguanosine is one of those DNA adducts, 
which has interesting features like 0 6-methyl-2'-deoxyguanosine is also not repaired 
by repair enzyme <96-alkylgaunine-DNA-alkyltransferase. Several different aspects of 
DNA adduct, 0 6-carboxymethyl-2'-deoxyguanosine have been investigated as a part 
of this project. Areas of research include synthesis and characterization of DNA 
adduct, 0 6-carboxymethyl-2'-deoxyguanosine. Synthesis and characterization of 
oligonucleotides containing 0 6-alkylguanine adducts using nucleoside composition 
analysis and fluorescence assays. Base-pairing stability of 0 6-alkylguanine adducts 
were investigated using meting curve studies. The mutagenic properties of O6- 
carboxymethyl-2'-deoxyguanosine adduct (Oe-CMdG) was investigated using ARMS 
PCR assay technique. Mutation spectrum of potassium diazoacetate was also 
investigated using mouse embryonic fibroblast cell lines as a part of this research 
project. The main findings and conclusions are summarised in the following sections, 
along with some indications of future directions.
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6.1 Conclusions
6.1.1 Synthesis of 0 6-carboxymethyI-2’-deoxyguanosine phosphoramidite
Chemical alkylation of DNA bases is believed to play an important role in the 
induction of mutagenesis and carcinogenesis. For example, formation of O6- 
methylguanine and 0 4-methylthymine has a causative role in carcinogenesis. 
Interestingly, bile acid derivative such as TV-nitrosoglycocholic acid reacts with DNA 
to give rise to 0 6-MedG and 0 6-CMdG adducts (Shuker et al., 1997). The mutagenic 
potential of (/-MedG adduct has already been well established. However, physical, 
chemical and biological properties of 0 6-CMdG adduct have never been reported 
before. In addition, another interesting feature of 0 6-CMdG adduct is that it is not 
repaired by repair enzyme 0 6-alkylguanine-DNA-alkyltransferase. One of the 
central problems in the field of carcinogenesis was lack of an experimental system to 
identify which DNA lesion gave rise to which types of mutations. Hence, it is difficult 
to implicate the specificity and true mutagenic potential of 0 6-carboxymethyl-2'- 
deoxyguanosine adduct with random mutagenesis studies. As a result, it is necessary 
to chemically synthesise 0 6-carboxymethyl-2'-deoxyguanosine adduct and then 
incorporate site-specifically in to oligonucleotides to study physical, chemical and 
biological properties of this adduct in isolation. The reported method of synthesis is 
primarily based on the preparation of (/-sulfonated derivative, which is quite reactive 
and can be easily displaced by amine and then alkoxide ions. (/-carboxymethyl-2'- 
deoxyguanosine adduct is chemically synthesised by introducing alkyl group 
modification by displacing an arylsulphonate present group at (/-position of 2'- 
deoxyguanosine. The reactive 3'-OH and 5-OH groups of the 2’-deoxyguanosine 
were protected with acetyl groups instead of methoxyacetyl groups previously used 
for the protection (Harrison et al., 1997). The acetylation procedure used in the
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reported method is a very slow reaction. However, when catalyst 
dimethylaminopyridine was used, it hastened the process much faster than original 
method. It has been documented that acyl groups at N  - position of O -substituted 
guanines are much more resistant to removal by ammonia than those at O6- 
unmodified guanine. Therefore, a more base-labile group such as phenylacetyl group 
was chosen to protect exocyclic N  -position of guanine instead of isobutyryl group. 
This allowed selective removal of acetyl groups at 3' and 5 -OH position with out 
removing phenylacetyl group at N  -position of guanine. Reagent phenylacetyl 
chloride, which was used for this reaction is highly reactive forming many side 
products. This caused not only the process of purifying desired compound difficult 
but also reduced the yield of the product. Better yields and purity can be achieved 
using phenylacetic anhydride reagent. However, the highly unstable characteristic of 
phenylacetic anhydride is a limiting factor. The 3',5'-diacetyl-N2-phenylacetyl-2'- 
deoxyguanosine was first converted in to arylsulphonate derivative, 3',5'-diacetyl-N2- 
phenylacetyl-6-mesitylenesulphonyl-2'-deoxyguanosine. The arylsulphonate 
derivative is very sensitive and it was found that any attempts to purify this compound 
on silica column cause degradation of the compound. Hence, it was straight away 
converted in to quinuclidinium salt, which in turn was replaced by methylglycolate 
moiety. The acetyl groups protecting the hydroxyl groups of the sugar were 
selectively removed using triethylamine in methanol instead of using aqueous NaOH. 
This is because the later procedure is less specific and there is always a high risk of 
losing N2-phenylacetyl protecting group. However, it was observed that often it is not 
possible to crystallise deacetylated product from methanol. Addition of 4',4- 
dimethoxytrityl group to 5'-OH group and its purification is a bit tricky process. In our 
findings, it was observed that after certain time point, equilibrium of the reaction do
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not shift in either directions. When the reaction was monitored on TLC, it appears that 
the amount of the starting material is equivalent in proportion to the final product. The 
equilibrium of reaction does not shift towards forward direction even after adding 
increasing amounts of DMT-chloride. Since, silica has acidic properties and DMT 
group is vulnerable to hydrolysis in acidic environment, basic conditions were 
maintained by adding few drops of pyridine to every fraction of eluting solvent to 
purify the compound. Dimethoxytritylation of the 5'-OH to give compound 6 was 
accomplished in acceptable yield (65% after chromatography). Finally, reaction with 
2-cyanoethyl- N  , N  -diisopropyl chlorophosphoramidite for 30 min at ambient 
temperature followed by a methanol quench gave the desired O6 phosphoramidite 7 in 
46% yield after chromatography. Chemical characterisation data, final yields and 
purity of all intermediates and final compound is in accordance with earlier reported 
data.
6.1.2 Automated Synthesis of Oligonucleotides containing 0 6-alkylguanine 
Adducts
Synthetically modified nucleic acids can serve as powerful probes for studies on types 
of confirmations assumed my modified adducts in helix structure of DNA, protein- 
nucleic acid interactions and of course to study the biological properties of a DNA 
adduct in a cellular environment. Modified synthetic phosphoramidites are 
particularly useful, since they allow site-specific incorporation of modifications in to 
DNA or RNA oligonucleotides. Automatic DNA synthesis is based on the principle of 
solid phase synthesis. Heterogeneous reactions involved in the DNA synthesis are 
standardised, and these procedures were easily automated, p-cyanoethyl 
phosphoramidite chemistry is chosen for internal incorporation of phosphoramidite
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analogues in to a series of oligonucleotides using automated DNA synthesis. The 
conditions of oligonucleotide synthesis via phosphoramidite chemistry had to be 
adjusted to take in to account the altered structure and reactivity of monomers 
compared to standard phosphoramidites. As part of this project, a method is 
developed particularly for convenient synthesis of oligonucleotides containing O6-  
alkylguanine phosphoramidites. It was observed that using this method, modified O6-  
alkylguanine adducts can be efficiently incorporated in to a DNA sequence. The 
method developed to synthesise modified oligonucleotides is called as “Push” and 
“Pull” method, which involves interruption of automated DNA synthesis at adduct 
site and addition of modified DNA adducts on to support manually. The advantage of 
this method is that it uses less amount of modified adduct to synthesise modified 
oligonucleotides at reasonable yields. Significant differences in overall synthetic 
yields were not observed between oligonucleotides made with normal 
deoxynucleotide phosphoramidites and those which containing the analogues (O6- 
MedG and 0 6-CMdG) indicating that the modified 0 6-alkylguanine phosphoramidite 
is a suitable reagent for automated oligonucleotide synthesis. Normal oligonucleotides 
were finally deprotected by treating with ammonium hydroxide solution overnight at 
room temperature followed by incubation at 55° C for 2hrs. The similar conditions if
used for deprotection of oligonucleotides containing 0 6-MedG adduct causes not only
2 6 stabilisation of the exocyclic amino protecting N  -isobutyryl group of O -MedG, but
also O6- alkyl groups become vulnerable to displacement by ammonia leading to the
production of oligomers containing 2',6,-diaminopurine. Therefore, oligonucleotides
containing 0 6-MedG adducts were deprotected by treating with 10% DBU in
methanol solution and left in dark for 5days. It was already reported that 0 6-CMdG
adduct when deprotected with ammonia produced mainly an oligonucleotide
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containing amide at O6 position of guanine. Hence, these oligomers were deprotected 
by treating with 0.5M NaOH solution overnight. This method of deprotection will 
only just hydrolyse the ester group at O6- position of guanine and will not remove the 
0 6-carboxymethyl group. This was explained by the fact that the alkaline solution 
initially hydrolyses the ester group and the resultant negatively charged carboxylate 
anion prevents further nucleophilic attack by hydroxide ion on the Opposition of the 
guanine. All synthetic oligonucleotides are subjected to some level of contamination 
depending upon the method of preparation. The purity requirement is not very 
stringent for oligonucleotides used for structural determination studies. However, if 
the oligonucleotides were to be used for genetic studies, the levels of tolerable 
impurities are very low. Hence the oligonucleotide that were used in our studies are 
initially purified with Nensorb Prep cartridges to remove all reaction intermediates 
salts and incomplete short sequences. These are further purified using fast protein 
liquid chromatography (FPLC). All the oligonucleotide sequences were analysed on 
both HPLC and FPLC and found that they are in excess of 98% pure and contained 
modified O6 -  alkylguanine adducts.
6.1.3 Characterization of Oligonucleotides using Nucleoside Composition 
Analysis and Fluorescence Assays 
It is very important to characterise oligonucleotides to verify the presence of 
modified adducts. It is particularly important because, it is necessary to determine that 
alkylation modification introduced at O6 position of 2'-deoxyguanosine is stable to the 
conditions of automated DNA synthesis, deprotection, purification conditions of 
FPLC and of course to avoid false positive results from adduct specific mutagenesis 
studies. This analysis is an enzymatic reaction in which the pentamers were
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hydrolysed to individual nucleosides, which will be monitored on HPLC using either 
UV or fluorescence detector. Since, pentamers are short sequences, it is easy to detect 
signal from modified base with out any disturbance from background produced by 
normal nucleosides. Initially, all the pentamers were characterised on FPLC by 
observing the individual retention times. From the results of FPLC analysis on 
pentamers, it was confirmed that all three pentamers have different retention times. 
The results were confirmed not only by observing the differences in retention times 
for each pentamer separately but also by co-injection of all three pentamers together. 
Additionally, it was also confirmed that modified oligonucleotides were eluting later 
than normal pentamer due to presence of extra negative charge on 0 6-alkylguanine 
adducts. The enzymatic degradation of both normal and modified pentamers provided 
the correct ratios of unmodified and modified nucleosides. Chemically synthesised 
0 6-MedG and 0 6-CMdG nucleosides were used as standards. Both the chemically 
synthesised and enzymatically obtained 0 6-MedG and 0 6-CMdG nucleosides were 
confirmed to have similar retention times from the nucleoside composition analysis 
results. The UV spectrum of both 0 6-MedG and 0 6-CMdG nucleosides have Xmax at 
247, which confirms the fact that both 0 6-MedG and 0 6-CMdG nucleosides were 
made from starting material 2-deoxyguanosine and A,max 280 is associated with the 
alkyl modification introduction at O6 position of 2'-deoxyguanosine. The main 
drawback of this assay is that it cannot be applied effectively on longer 
oligonuclotides that were used for adduct specific mutagenesis studies. It is 
practically difficult, if not impossible to detect the presence of modified nucleoside 
from normal nucleosides due to strong background. However, this technique is 
utilised to confirm the presence of modified adducts in longer oligonucleotides by 
taking advantage of the fact that 0 6-alkylguanines are slightly more fluorescent than
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the corresponding deoxynucleosides. Single peak was observed for all the sequences 
when monitored on HPLC confirmed that all sequences used for adduct specific 
mutagenesis studies were in excess of 98% pure. The modified nucleosides from 
enzymatic reaction were monitored using fluorescence detector instead of UV 
detector. The enzymatically obtained modified nucleosides at excitation wavelength 
286nm and emission wavelength 378nm were observed to have similar retention 
times as chemically synthesised standards. Additionally when co-monitored with UV 
detector, the fluorescent peaks observed for 0 6-MedG and 0 6-CMdG nucleosides 
obtained from enzymatic digestion were observed to have similar UV absorption 
profile (A/max at 247nm and 280nm) as their chemical standards.
6.1.4 Melting curve analysis on Self-Complementary Oligomers containing O6- 
Alkylguanine Adducts
Our Melting curve studies fairly indicated that O6 -  alkylguanine adducts if formed, 
would effect base pairing property and probably induce mutations. Qualitatively, the 
differences in base pair stabilities appear to be sufficient. The melting curves obtained 
were not ideal S-shaped curves. The midpoint of the raising portion of these S -  
shaped curves defines the melting temperature Tm, a rough indicator of the stability 
of the oligonucleotide complexes. Hence, exact melting temperatures were not 
determined. However, the data obtained from melting temperature profiles and the 
first derivative curves of melting profiles have given estimate about the 
thermodynamic properties and stabilities of base pairs of O6 -  MedG, and O6 -  CMdG 
adducts. The O6 -  alkylguanine adducts were incorporated in to self-complementary 
sequences of the types 5' CGC XAG CTT GCG 3' and 5' CGC XAG CTC GCG 3' at 
position X. The melting curve profiles and derivative curve data confirmed that
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introduction of G:T mismatch pair in normal sequence 4 caused reduction in melting 
temperature causing destabilisation effect on hairpin structure, with respect to normal 
sequence 5 containing G:C base-pair. Our studies have also confirmed that O6- 
MedG:T base pair formed in sequence 6 is relatively much more stable than O6- 
MedG:C base pair formed in sequence 7. <96-MedG:T base pair has induced increase 
in melting temperature with respect to normal sequence 4 containing G:T mismatch 
base pair. In other words, it was understood that 0 6-MedG:T base pair caused little 
destabilisation of hairpin structure than it could be caused by introducing G:T 
mismatch base pair. In addition, it was also observed that sequence 7 containing 06- 
MedG: C base pair caused marginal reduction in melting temperature with respect to 
normal sequence 5 containing G:C base pair. However, 0 6-MedG:C base pair 
containing sequence 7 denaturises earlier than 0 6-MedG:T base pair containing 
sequence 6 suggesting that the later is much more stable base pair. In addition the 
melting temperature at the point of maximum absorption is estimated to be in the 
range 70 - 80°C for sequence 6 containing 0 6-MedG:T base pair, whereas it is around 
60 °C, for sequence 7 containing 0 6-MedG:C base pair. The exact melting 
temperatures for self-complementary sequences containing 0 6-CMdG adducts were 
not determined due to technical constraints of the instrumentation. Sequence 8 and 9 
containing 0 6-CMdG:T and 0 6-CMdG:C base pairs induced increase in melting 
temperatures with respect to normal sequences 4 and 5 containing G:T and G:C base 
pairs. It is understood from the above data that 0 6-CMdG:T base pair do not have 
strong destabilising effect on the hairpin with respect to sequence 4 containing 
mismatch base pair G:T. In addition, the data from derivative curve indicated that 
sequence 8 containing 0 6-CMdG:T base pair denaturises later than sequence 9 
containing <96-CMdG:C base pair. This suggests that 0 6-CMdG:T base pair might be
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having less destabilising effect on hairpin structure indicating that 0 6-CMdG adduct 
might preferentially base pair with T, there by inducing GC —> AT transition 
mutations. Clearly further experimentation and effort is needed to substantiate the 
validity of the above data.
6.1.5 Characterization of Mutations Induced by 0 6-alkylguanine adducts
Due to the diversity of adducts produced by certain mutagens, it is desirable to relate 
the mutations produced to the structure and position of a given lesion. In conducting 
such experiments, it is essential to establish the degree of homogeneity and purity of 
the mutagenic species so that experimental results are not confounded by the presence 
of minor components. For example, previous mutagenesis studies on KDA, a 
carcinogen of our particular interest that predominantly forms O6- CMdG adduct, was 
found to induce mainly GC -  AT and other transition mutations in p53 cDNA. It is 
also known that KDA reacted with DNA to form O6- MedG adduct. Hence, it is 
practically difficult, if not impossible to determine which adduct causes which 
mutation and why. Hence as a part of this research project, a site-specific plasmid 
based mutagenesis approach was designed, in which a single DNA adduct was 
uniquely placed in either strand of plasmid vector to study the genotoxic effects of the 
DNA adduct, 0 6-carboxymethyl-2'-deoxyguanosine. 0 6-CMdG adduct was 
synthesised according to reported synthetic route (Xu, 2000). The complementary 
oligonucleotide sequences 25 and 26mer used to form adduct containing duplex were 
designed from the p53 cDNA sequence of E.coli plasmid, pLS76. 0 6-alkylguanine 
adducts were incorporated in to codon 196 of p53 gene at nucleotide position 587 for 
duplexes containing adduct on sense strand and at nucleotide position 586 for 
duplexes containing adduct on anti-sense strand. The normal and adduct containing
223
Chapter 6: Conclusions and Future Work
duplexes were successfully prepared by annealing complementary sequences 25 and 
26mer. The duplexes were purified from unannealed single strands on nondenaturing 
polyacrylamide gel, removing all other impurities to construct a pure adduct 
containing plasmid. However, the restriction site BbvC 1, formed at 5-end by these 
duplexes with which they ligate with gapped plasmid was found to have poor 
religation efficiency. In addition, other restriction site Apol, formed at 3'-end by the 
duplexes was found to be a unique restriction site in p53 cDNA, but not in whole 
plasmid DNA sequence. Nevertheless, a brilliant strategy was designed overcoming 
these limitations to construct the intact plasmids containing (/-alkylguanine adducts.
The duplexes were successfully incorporated in to E.coli based plasmid, pLS76 to
6 6form a double stranded DNA shuttle vector containing either a single O -MedG or O - 
CMdG adduct. Plasmids incorporated with adducts were characterised by PCR 
reaction. PCR results showed that all plasmids incorporated with (/-alkylguanine 
adducts when amplified with p53 specific primers produced 800bp p53 cDNA. These 
results indicated that adduct containing duplex DNA was efficiently incorporated to 
form intact adduct containing shuttle vectors. The advantage of studying the 
mutations induced by a lesion in double stranded vector is that the system comes as 
close as possible to resembling genomic replication. Amplification Refractory 
Mutation System (ARMS) technique was used to study the type of mutations that can 
be induced by (/-alkylguanine adducts. This technique is designed to discriminate 
between target DNA sequences that differ by a single nucleotide in the region of 
interest, codon 196. Complementary primers that amplify the region of interest were 
site specifically designed to differ at the nucleotide that occurs at the extreme 3' 
terminus. Since the DNA synthesis step in a PCR reaction is dependent on correct 
base pairing at 3’-end, this method is particularly useful in detecting any pathogenic
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mutations. This principle behind this technique is similar to primer extension reaction 
except that nucleotide that is going to base pair with DNA adduct is already present at 
the 3* terminus of primer. The results of ARMS-PCR assays have indicated that O6- 
CMdG adduct is substantially mutagenic and force translesion synthesis in in vitro 
system. PCR assay have shown that positive control plasmids have normal GC base 
pair present at adducted site i.e., nucleotide position 587. The results obtained from 
plasmid pLS76 - 2 containing 0 6-MedG adduct were different from plasmid, pLS76 - 
4 containing 0 6-CMdG adduct. When both plasmids, pLS76 -  2 and pLS76 - 4 
containing adduct on sense strand at nucleotide position 587 in codon 196 were 
compared, 0 6-MedG adduct was preferably inducing GC - AT transition and O6- 
CMdG adduct induced GC - TA transversion mutation. However, results obtained 
from plasmids, pLS76 - 3 and pLS76 - 5 containing adducts on anti-sense strand i.e., 
at nucleotide position 586 in codon 196 indicated that both 0 6-MedG and 0 6-CMdG 
adducts induced GC -  TA transition mutation. The results from positive control 
plasmids confirmed the presence of normal GC base pair at nucleotide position 586 
on anti-sense strand. Nevertheless, of its location on either strand, 0 6-MedG adduct 
predominantly induced GC-AT transition mutations. The results supports the 
following explanations offered to support the true mutagenic potential of 0 6-MedG 
adduct. Firstly, DNA polymerase might mistake Oe-methylguanine for adenine 
because of the physical similarity of these bases. Both, 0 6-methylguanine and adenine 
are similarly lipophilic and the X-ray crystallographic studies on the nucleosides have 
shown a close similarity in bond angles and lengths between 0 6-methylguanine and 
adenine. Secondly, the important factor in the miscoding is that the alkylG.T 
mismatch pair retains the Watson-Crick alignment with N1 of the purine juxtaposed 
to N3 of the pyrimidine. However, results obtained from 0 6-CMdG adduct were quiet
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surprising. Because the 0 6-CMdG is a guanine adduct modified at O6 position just 
like 0 6-MedG, was expected to induce GC-AT transitions preferably. Nevertheless, it 
has induced GC-TA transversion mutations when present on sense strand and GC-AT 
transition mutations when present on anti-sense strand. The qualitative data has 
clearly indicated that 0 6-CMdG adduct behaves more like a bulky adduct that can 
induce multiple mutations. However, quantitative data relating to mutation 
frequency, specificity, and relative effects of the DNA strand and flanking sequences 
on mutagenic potential have to be determined to further substantiate the reliability of 
the above data. Further experimentation and effort is also needed to probe the 
mutagenic mechanisms of 0 6-CMdG adduct in in vivo systems.
6.1.6 Characterisation of KDA p53 Mutation Spectra using Hupki mouse model
The Promutagenic potential of potassium diazoacetate is studied as a part of a 
collaborative project with Dr Monica Hollstein in German Cancer Research Centre, 
Heidelberg, Germany. Human p53 knock-in mouse (HUPKI) mouse in which core 
domain of the endogenous murine p53 allele has been replaced with the homologous 
normal human p53 gene sequence was treated with KDA to obtain mutant clones. The 
aim of this collaboration was to compare in vivo mutation spectrum with the p53 
mutation database at IARC and possibly identify KDA as risk factor in certain type of 
malignancies. Potassium diazoacetate (KDA) is particularly interesting because it is a 
stable nitrosated derivative of glycine. KDA will decompose or rearrange to give 
carboxymethylating agents resulting in the formation of 0 6-carboxymethyl-2 ’ - 
deoxyguanosine (O6- CMdG) and 0 6-methyl-2’-deoxyguanosine (0 6-MedG) adducts. 
KDA was synthesised according to reported synthetic route and characterised on LC- 
MS. Cytotoxicity tests were performed twice and the optimal mutagenic dose (IC50)
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of potassium diazoacetate was calculated from cell growth and percentage viability of 
cells. A trend of decreasing number of cells in samples incubated with increasing 
concentrations of KDA was observed. Cell growth was monitored by cell counting at 
regular intervals and percentage viability of cells was calculated by dividing the 
number of cells present in samples treated with KDA with number of cells present in 
respective controls. Two independent mutagenesis experiments were carried out of 
which one contain 48 clones incubated with lOpM of KDA and the other contained 
24 clones treated with lOOpM of KDA. Clones were passaged until selection process 
and clonal expansion is completed. The results of the sequencing of p53 gene of some 
of the clones obtained by treating with lOpM KDA indicated that KDA did not induce 
any functional mutations in the DNA binding region of p53 gene (exon 4 - 9 ) .  The 
results have indicated that KDA might have decomposed on mixing with DMEM, 
therefore subdued the toxic effects of the KDA to which cells were exposed. The 
results also suggested that spontaneous mutations by secondary mechanisms at some 
other down stream targets of p53 gene might be responsible for the formation of 
homogenous clones that survived the crisis period. Hence, further sequencing of the 
remaining clones was not carried out. Since time and funding allotted to this project 
have reached to their limitations, DNA adduct analysis using ISB technique was not 
carried out.
6.1.6.1 Further Mutagenesis Studies using p53 Yeast Expression System and 
Hupki Mouse
Endogenous nitrosation of dietary amino acids and peptides has been proposed as a 
major route of exposure to genotoxic agents in the gastrointestinal tract (Challis, 
1989; Shephard, 1989). Cupid et al. (Cupid, 2001) showed that diazoacetate was
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formed upon treatment of glycine with NO at conditions similar to those found in the 
GI tract in vivo. Moreover, incubation of the reaction mixture with 2.-dG and DNA 
resulted in the formation of 0 6-CMdG and 0 6-MedG DNA adducts. These findings 
suggested that diazoacetate was a key alkylating agent formed from the nitrosation of 
glycine under simulated physiological conditions. Potassium diazoacetate (KDA) is 
particularly interesting because it is a stable nitrosated derivative of glycine which 
decomposes or rearrange to give carboxymethylating agents resulting in the formation 
of 0 6-carboxymethyl-2'-deoxyguanosine and 0 6-methyl-2'-deoxyguanosine It was 
also reported that KDA is a powerful alkylating agent than APNG. It produced 8-fold 
increase in 0 6-carboxymethyl-2'-deoxyguanosine and 11 fold increase in 0 6-methyl- 
2'-deoxyguanosine (Harrison et al., 1999) 0 6-CMdG has also been detected in human 
gastric biopsies (Singh, 2000). Previous mutagenesis studies on KDA have reported 
that this compound induced some p53 mutations found in colon and stomach cancer. 
Hotspots such as the AT—»GC transition at codon 220 were found in both human 
spectra and the in vitro spectrum. One of the major hotspots found in colon cancer, a 
GC—»AT transition at codon 241 was also common to the KDA-induced p53 
spectrum (Gottschalg et al., 2006). Our experiments on KDA to study its mutation 
spectra in p53 gene using murine model HUPKI mouse did not showed the presence 
of any functional mutations. However, this is mostly due to the stability problems 
associated with KDA rather than the system. Surely better results can be expected 
with this, if we overcome the problem associated with KDA stability. The mutation 
spectrum data obtained for KDA from p53 yeast expression system means that similar 
data can be obtained from the above murine model. Also, as a part of this research 
project we have successfully synthesised 0 6-CMdG adduct and could incorporate it 
site specifically in to p53 cDNA. Although, our results obtained with ARMS-PCR
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assay technique which used this site specific sequences indicated that 0 6-CMdG 
adduct is qualitatively mutagenic. However, it would be more interesting to see 
whether 0 6-CMdG adduct can induce similar mutations in vivo system such as p53 
yeast expression system. This system could not only verify our data qualitatively but 
also can produce quantitative data relating to mutation specificity and frequency. 
Alternatively, incubation of KDA-treated yeast expression vector pLS76 using O6- 
alkylguanine-DNA alkyltransferases prior to transformation into yeast cells might 
allow the study of 0 6-CMdG specific mutagenesis. As this adduct was shown to be
a
not repaired by O -alkylguanine-DNA alkyltransferases (Shuker, 1997) it might not 
only be an important and possibly persistent biomarker but also a contributor to some 
types of human malignancies.
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6.2 Overall Conclusions
The main objectives set out at the beginning of this project could be achieved in the 
majority of cases. 0 6-carboxymethyl-2'-deoxyguanosine adduct was successfully 
synthesised and incorporated site specifically in to p53 sequences. The results from 
nucleoside composition analysis had confirmed that these site specifically modified 
sequences contain 0 6-CMdG adduct. Melting curve studies have shown qualitative 
differences in the stabilities of base pairs formed by 0 6-CMdG adduct with respect to 
controls containing 0 6-MedG adduct and 2’-dG. However, quantitative data was not 
obtained from the above meting curve studies due to the technical limitations of the 
instrumentation. Thus future studies need to focus on obtaining quantitative 
differences in the stabilities of the base pairs.
The important aspect relating to the mutagenic potential of 0 6-CMdG adduct had 
been investigated using Amplification Refractory Mutation Sytem (ARMS) PCR 
technique. Qualitative data from the above studies have suggested that 0 6-CMdG 
adduct is a potential mutagenic adduct and can induce multiple mutations like a bulky 
adduct. However, further studies are needed to investigate the mutagenic specificity 
and frequency of the 0 6-CMdG adduct
Results of the mutation spectrum studies on potassium diazoacetate, a stable 
nitrosoglycine derivative indicated that the above compound did not induce any 
functional mutations in the p53 gene of HUPKI mouse embryonic fibroblast cells. 
However, this is mainly due to problems associated with KDA stability. Previous 
studies on KDA mutagenic potential which used p53 yeast expression system have 
reported that this compound induced some p53 mutations found in colon and stomach 
cancer. Hence, further effort and experimentation is needed to overcome the problems
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associated with KDA stability to study the mutation spectrum of KDA using HUPKI 
mouse.
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Appendix 1:
Proton Chemical Shift Values of Compounds 1-6:
Group 1 2 3 4 5 6
Acetyl at 5’-OH, 3H, s 2.04 2.02 1.98 2.00 I
I CH3,3H , s  (4’-mesityI) 2.20
Acetyl a t 3’-OH, 3H, s 2.09 2.08 2.05 2.06
CH3, 6H, s  (2’& 6’-mesityl) 2.54
2*-H and 2” -H ,2H ,m 2.44-2.98
2.47-
3.02
2.89-
2.98
2.47-
2.95
2.23- i 2.30- 
2.74 1 2.85
5’-H ,2H ,m | 3.57 | 3.07
OCH3 of CH2COOCH3 3.64 | 3.64 | 3.65
OCH3 of DMT, 6H, s 3.69
CH2ofC 6H5CH2,2 H ,s 3.80 3.82 3.94 3.79 3.77
4’-H, 1H, d 3.84 3.94 |
4’-H and 5’-H, 3H, in 4.17-432
4.14-
4.27
4.24-
436
4.25-
4.41
5’-OH, 1H, t, ex 4.89
CH2 of 0 6-CH2,2H , s 4.98 5.17 5.18
3’-H, 1H, d 533 5.30 5.40 5.37 4.40 4.45
3*-OH, 1H, d, ex 5.30 5.30
Exocyclic -NH2 6.56
l ’-H, 1H, t 6.15 6.24 630 6.85 6.32 6.35
3’ & 5’- H of (mesityl)
............
638 ]
C6H5,5H , m 7.19-7.34
7.19-
736
7.19- 7.19- 
7.33 I 7.34 7.13-
7.32
Dimethoxytrityl, 13H, m 1
8’-H, 1H, s 7.93 8.24 8.02 7.92 | 8.48 | 8.36 |
N2-H, ex, 1H, s | 10.78 | 10.68 | 10.64 10.60
Compound 7 is characterised using p NMR
31P NMR chemical shifts from compound 7 were observed at 151.15 and 151.20 
using CDCI3 as solvent. The two peaks represent two stereo isomers of the 
phosphoramidite monomer.
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Appendix 2:
Characterisation of compounds 1-7 using LC-MC Mass spectrometer:
Compound -1:
MS m/z (positive ion mode)
[MH+] -351.32
[MH+- Sugar Fragment] -  151.40 
[2MFT1] -702.12
Compound-2:
MS m/z (positive ion mode)
[MH4] - 470.40
[MH4- Sugar Fragment] -  269.56 
[MH4- Sugar Fragment - PAC] -  151.53
Compound 3 - It is an unstable compound and undergoes hydrolysis very fast. Hence, 
it was not characterised using LC-MS.
Compound 4:
MS m/z (positive ion mode)
[MH4] - 542.44
[MH+- Sugar Fragment] -  342.24 
[MH4"- Sugar Fragment - PAC] -  224.03
Compound 5:
MS m/z (positive ion mode)
[MH4] - 458.30
[MH4- Sugar Fragment] -  342.61 
[MH+- Sugar Fragment - PAC] -  224.05
Compound 6:
MS m/z (positive ion mode)
[M H*]-759.54 
[MH+- DMT] -  302.24
All the LC-MS data was obtained using 50/50 acetonitrile/ammonium acetate 
(pH-5.4) solvent at the flow rate 0.2ml/min.
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Appendix 3:
p53 cDNA Sequence:
1 ATG GAG GAG CCG CAG TCA GAT CCT
1 6 CAG GAA ACA TTT TCA GAC CTA TGG
3 1 GTT CTG TCC CCC TTG CCG TCC CAA
4 6 TCC CCG GAC GAT ATT GAA CAA TGG
61 GAT GAA GCT CCC AGA ATG CCA GAG
7 6 GGA CCA GCA GCT CCT ACA CCG GCG
91 TGG CCC CTG TCA TCT TCT GTC CCT
1 0 6 AGC TAC GGT TTC CGT CTG GGC TTC
1 2 1 TCT GTG ACT TGC ACG TAC TCC CCT
1 3 6 CAA CTG GCC AAG ACC TGC CCT GTG
1 5 1 CCC CCG CCC GGC ACC CGC GTC CGC
1 6 6 TCA CAG CAC ATG ACG GAG GTT GTG
1 8 1 CGC TGC TCA GAT AGC GA.T GGT CTG
1 9 6 CGA GTG GAA GGA AAT TTG CGT GTG
2 1 1 ACT TTT CGA CAT AGT GTG GTG GTG
2 2 6 GGC TCT GAC TGT ACC ACC ATC CAC
2 4 1 TCC TGC ATG GGC GGC ATG AAC CGG
2 5 6 ACA CTG GAA GAC TCC AGT GGT AAT
2 7 1 GAG GTG CGT GTT TGT GCC TGT CCT
2 8 6 GAA GAG AAT CTC CGC AAG AAA GGG
3 0 1 CCA GGG AGC ACT AAG CGA GCA CTG
3 1 6 CCC CAG CCA AAG AAG AAA CCA CTG
3 3 1 CAG ATC CGT GGG CGT GAG CGC TTC
3 4 6 GAG GCC TTG GAA CTC AAG GAT GCC
3 6 1 GGG AGC AGG GCT CAC TCC AGC CAC
3 7 6 TCT ACC TCC CGC CAT AAA AAA CTC
3 9 1 GAC TCA GAC TGA
AGC GTC GAG CCC CCT CTG AGT 1 5
AAA CTA CTT CCT GAA AAC AAC 3 0
GCA ATG GAT GAT TTG ATG CTG 4 5
TTC ACT GAA GAC CCA GGT CCA 60
GCT GCT CCC CGC GTG GCC CCT 7 5
GCC CCT GCA CCA GCC CCC TCC 90
TCC CAG AAA ACC TAC CAG GGC 1 0 5
TTG CAT TCT GGG ACA GCC AAG 1 2 0
GCC CTC AAC AAG ATG TTT TGC 1 3 5
CAG CTG TGG GTT GAT TCC ACA 1 5 0
GCC ATG GCC ATC TAC AAG CAG 1 6 5
AGG CGC TGC CCC CAC CAT GAG 1 8 0
GCC CCT CCT CAG CAT CTT ATC 1 9 5
GAG TAT TTG GAT GAC AGA AAC 2 1 0
CCC TAT GAG CCG CCT GAG GTT 2 2 5
TAC AAC TAC ATG TGT AAC AGT 2 4 0
AGG CCC ATC CTC ACC ATC ATC 2 5 5
CTA CTG GGA CGG AAC AGC TTT 2 7 0
GGG AGA GAC CGG CGC ACA GAG 2 8 5
GAG CCT CAC CAC GAG CTG CCC 3 0 0
CCC AAC AAC ACC AGC TCC TCT 3 1 5
GAT GGA GAA TAT TTC ACC CTT 3 3 0
GAG ATG TTC CGA GAG CTG AAT 3 4 5
CAG GCT GGG AAG GAG CCA GGG 3 6 0
CTG AAG TCC AAA AAG GGT CAG 3 7 5
ATG TTC AAG ACA GAA GGG CCT 3 9 0
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Chapter 9: Appendices
Appendix 6:
Prevalence of p53 mutations in different Tumour types
COLORECTUM ( 2362) 
RESP .SYSTEM ( 2456 ) 
BREAST (2209 ) 
~  HEAD&NECK ( 2145 )tsV>
|  OTHER ( 2047 )3
j» FEM.GEN.ORG. ( 1670 )
|  ESOPHAGUS (1653 )
e
0  BRAS'! (1 4 3 6  )
1
|  HEMATQLOGtC AL (1206 ) 
TS
g  BLADDER (1030 )
v
LIVER (9 7 4 )  
STOMACH ( 907) 
MAC GEN.ORG. (3 6 9 )  
SOFT TISSUE5< 284) 
BONES (2 3 9 )
----------------- ----
—ftTTj________
v*«.
—14 ^  I
2 3 4 5 6 7 8 9
%
(C) !ARC TP53 Mutation Database, R10 retease, July 2005
Prevalence of p53 Germ-line mutations in different Tumour types
BREAST( 18 4 )
SOFT TISSUES (104 )
BRAIN ( 91 )
BONES ( 88 )
ADRENAL GLAND ( 64 )
~  OTHER £ 55 )
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§HEMATOLOG*CAL ( 26 )
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g  COLORECTUM ( 1 2 )  
§
OVARY ( 1 1 )  
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KIDNE Y < 3 ) 
LIVER ( 2 ) 
HEAD8NECK (  2 ) 
PROSTATE ( 2 )
s- ]''
12 14 16 18
% of «4 tumors (ri*679)
(C) (ARC TP53 Mutation Database. R10 release, July 2005
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Appendix 7:
Somatic Mutations -  Mutation Effect / 21587 Mutations
E o a  623 ins * 623 (2.88%)
■ 1 1,899 m  -1899 (8 .79%)
C H 3160 tandem -160 (0.74%)
C Z 3 169 CC tandem -169 (0.73%)
■ 1  92 complex - 92 (0 42%)
CZD 827 A:T>C:G - 827 (3.33%)
H Z ] 2,383 A T*G C - 2383 (11.0%)
E m  1,103 A T > T :A -1103 (5 10%) 
c m  4,246 G:C»A T - 4246 (19 6%)
Hi 5,350 G:C>A:T at CpG - 5350 (24 7%) 
Hi 1,597 G:C>C:G -1597 (7.39%) 
wm 3,137 G :O T,A  - 3137 (14 5%)
1 NA - 1 (0.00%)
(C) I ARC TP53 Mutation Database. R1Q release. Jut/ '2005
Somatic Mutations -  Mutations Pattern / 21587 Mutations
wm 15,921 msser.se -15921 (73.7%) 
C m  1,605 nonsense -1605 (7.43%) 
Hi 956 silent - 956 (4 42%)
□  1,930 6 5 -1 9 3 0  (8.94%)
H i 399 splice - 399 (1 84%)
CZ3 740 other - 740 (3.42%)
C m  36 NA - 36 (016% )
(O IARC TP53 Mutation Database, R10 release. July 2005
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Appendix 8:
Germ-line Mutations -  Mutations Effect / 283 Mutations
M i  210 mis sense - 210 (74 2%) 
O  21 nonsense - 21 (7 42%) 
W M  4 silent - 4 (1.41 %)
0 2 1  FS-21 (7.42%)
M i 11 splice-11 (3.88%) 
0 1 6  other -1 6  (5.65%)
(Q1ARC TP53 Mutation Database, R10 release, July 2005
Germ-line Mutations -  Mutations Pattern / 283 Mutations
(C) IARC 7P53 Mutation Database, RIO release, July 2005
r a  8 ins - 8 (2.82%)
S i  23 del - 23 (8.12%)
MM 1 complex -1 (0.35%)
[~ 17 A:T>€:G - 7 (2 47%)
E O  24 A:T>0;C - 24 (8.48%)
MM 16 A:T>T:A -16 (5.65%)
C O  33 GiOAiT - 33 (11.8%)
MM 137 G O A :T  at CpG - 137 (48.4%) 
MM 16 G:OC:G -16  (5.65%)
MM 18 0 :O T ;A  -18 (6.36%)
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Appendix 9:
Comparison of classes of between p53 mutations in human colon and stomach 
tumours. Data presented in above figure were adapted from p53 1ARC database. 
GC to AT at CpG sites were not included fElke Gottschaig nee Griech (20021.
to  AT
<;{ loC’G
t o  AT
Comparison of classes of between p53 mutations induced by KDA treatments in 
lx TE and PBS Buffer fElke Gottschaig nee Griech (20021.
<»( to C i  >
fA in iXl
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